Packages | Rate |
---|---|
CM0076 : INGUINAL BLOCK DISSECTION ONE SIDE | 13275 |
CM0077 : ABDOMNO PERINEAL RESECTION (APR) + SACRECTOMY | 41040 |
CM0078-A : LAPROSCOPIC APR | 46440 |
CM0078-B : EXTRALEVATOR APR | 34740 |
CM0078-C : TRANS ABDOMINAL | 34740 |
CM0078-D : TRANS ANAL | 34740 |
CM0078-E : INTERSPHINCTERIC RESECTION | 34740 |
CM0078-F : LOW ANTERIOR RESECTION | 39240 |
CM0079 : ABDOMINAL WALL TUMORS RESECTION WITH RECONSTRUCTION | 40050 |
CM0080 : ABDOMINAL WALL TUMORS RESECTION WITHOUT RECONSTRUCTION | 28800 |
CM0081 : BILATERAL PELVIC LYMPH NODE DISSECTION(BPLND) ANY SITE | 19800 |
CM0082-A : RADICAL VAGINECTOMY WITHOUT RECONSTRUCION a) WITH LND | 25425 |
CM0082-B : RADICAL VAGINECTOMY WITHOUT RECONSTRUCION b) WITHout LND | 23175 |
CM0083-A : RADICAL VAGINECTOMY WITH RECONSTRUCION a) WITH LND | 37125 |
CM0083-B : RADICAL VAGINECTOMY WITH RECONSTRUCION b) WITHOUT LND | 32625 |
CM0084-A : RADICAL HYSTERECOMY+BILATERAL PELVIC LYMPH NODE DISSECTION+BILATERAL SALPHINGO OOPHERECTOMY | 33525 |
CM0084-B : OVARIAN TRANSPOSITION | 39825 |
CM0085-A : ANTERIOR EXENTRATION - ANY SITE | 51975 |
CM0085-B : POSTERIOR EXENTRATION- ANY SITE | 37575 |
CM0086 : TOTAL PELVIC EXENTRATION - ANY SITE | 63675 |
CM0087 : EXTRALEVATOR EXENTRATION - ANY SITE | 36225 |
CM0088 : SUPRALEVATOR EXENTRATION - ANY SITE | 36225 |
CM0089 : TOTAL ABDOMINAL HYSTERECTOMY+BILATERAL SALPHINGO OOPHERECTOMY+BILATERAL PELVIC LYMPH NODE DISSECTION+OMENTECTOMY | 31230 |
CM0090-A : RETRO PERITONEAL LYMPH NODE DISSECTION(RPLND) (FOR RESIDUAL DISEASES /STAGING | 19125 |
CM0090-B : RETRO PERITONEAL LYMPH NODE DISSECTION(RPLND) (FOR RESIDUAL DISEASES /WITH VASCULAR RECONSTRUCTION | 28350 |
CM0091-A : OESOPHAGECTOMY WITH TWO FIELD LYMPADENECTOMY | 54225 |
CM0091-B : OESOPHAGECTOMY WITH THREE FIELD LYMPADENECTOMY | 65475 |
CM0092-A : VERMILIONECTOMY WITHOUT WEDGE EXCISION | 15075 |
CM0092-B : VERMILIONECTOMY WITH WEDGE EXCISION | 16875 |
CM0093 : EMASCULATION | 22230 |
CM0094 : PALATECTOMY ANY TYPE | 22725 |
CM0095 : RADICAL TRACHELECTOMY | 30825 |
CM0096 : SUBSTERNAL BYPASS | 24525 |
CM0097 : ABBE OPERATION | 16875 |
CM0098 : CYTOREDUCTIVE SURGERY | 20925 |
CM0099 : VULVECTOMY | 13725 |
CM0100-a-I : BREAST CANCER - Dose Dense AC (Adriamycin/Cyclophosphamide) ; (Day 1: Doxorubicin 60mg/m2 IV, Cyclophosphamide 600mg/m2 IV) ; Repeat cycle - every 14 days for 4 cycles; Followed by Paclitaxel for 4 cycles | 3000 |
CM0100-a-II : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 14 days for 4 cycles | 7000 |
CM0100-b : BREAST CANCER - TC (Doectaxel & Cyclophosphamide) ; Day 1: Docetaxel 75mg/m2 IV, Cyclophosphamide 600mg/m2 IV ; Repeat cycle - every 21 days for 4 cycles | 6000 |
CM0100-c : BREAST CANCER - CMF (Cyclophosphamide/Methotrexate/Fluorouracil) - (includes day 1 & day 8) ; Days 1-14: Cyclophosphamide 100mg/m2 orally ; Days 1 and 8: Methotrexate 40mg/m2 IV ; Days 1 and 8: 5-fluorouracil 600mg/m2 IV. ; Repeat cycle - every 28 days for 6 cycles | 2700 |
CM0100-d : BREAST CANCER - EC (Epirubicin/Cyclophosphamide) ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 830mg/m2 IV. ; Repeat cycle - every 21 days for 8 cycles | 5100 |
CM0100-e-I : BREAST CANCER - FEC/CEF followed by T (Fluorouracil/Epirubicin/Cyclophosphamide) - followed by Docetaxel or followed by weekly Paclitaxel) ; Day 1: 5-fluorouracil 500mg/m2 IV ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle every 21 days for 3 cycles | 5100 |
CM0100-e-II : BREAST CANCER - Docetaxel - (Preceeded by FEC/CEF ) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle - every 21 days for 3 cycles | 5500 |
CM0100-e-III : BREAST CANCER - Paclitaxel - weekly - (Preceeded by FEC/CEF ) ; Paclitaxel 100mg/m2 IV ; Repeat cycle - once weekly for 8 weeks | 3500 |
CM0100-f-I : BREAST CANCER - FAC followed by T (Fluorouracil/Adriamycin/Cyclophosphamide) - followed by weekly Paclitaxel ; 5-fluorouracil 500mg/m2 IV Days 1 and 8 OR 1 and 4: ; Day 1: Doxorubicin 50mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle - every 21 days for 6 cycles | 3200 |
CM0100-f-II : BREAST CANCER - Paclitaxel - weekly - Preceeded by FAC ; Paclitaxel 80mg/m2 IV ; Repeat Cycle weekly for 12 weeks. | 3500 |
CM0100-g : BREAST CANCER - TAC (Docetaxel/Adriamycin/Cyclophosphamide) ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, | 5600 |
CM0100-h-I : BREAST CANCER - AC - followed by Paclitaxel + Trastuzumab +/- Pertuzumab ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle - every 21 days for 4 cycle | 3000 |
CM0100-h-II : BREAST CANCER - Paclitaxel (Preceeded by AC) ; (To be choosen along with Trastuzumab package - CM0100-h-III or CM0100-h-IV or CM0100-h-V) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. | 3500 |
CM0100-h-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with Paclitaxel Cycle 1, 4, 7, 10 and standalone for the upto 1 year every 21 days) | 30500 |
CM0100-h-IV : BREAST CANCER - Trastuzumab 4mg (Followed by Trastuzumab 2mg subsequent weeks) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) | 30500 |
CM0100-h-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 2mg/kg IV weekly Till one year from Day 1 of AC. ; (to be approved with Paclitaxel Cycles 2 - 12 and standalone for the upto 1 year every week) | 11500 |
CM0100-i-I : BREAST CANCER - TC (Docetaxel/Carboplatin) ; (To be choosen along with Trastuzumab package - CM0100-i-II or CM0100-i-III or CM0100-i-IV) ; Day 1: Docetaxel 75mg/m2 IV; Carboplatin AUC 6mg per min/mL IV. ; every 21 days for 6 cycles | 7100 |
CM0100-i-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with TC package CM0100-i-I) ; Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with TC Cycle 1 to 6 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 18 weeks as standalone for the upto 1 year every 21 days) | 30500 |
CM0100-i-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with TC package CM0100-i-I) ; Day 1: Trastuzumab 4mg/kg IV ; (First dose - only to be approved with TC Cycle 1. Subsequent cycles - 2mg package only) | 30500 |
CM0100-i-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses - Weekly) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 17 weeeks may overlap with TC Cycles 2 - 6. To be followed by Trastuzumab (6mg) package upto 1 year | 11500 |
CM0100-j-I : BREAST CANCER - AC - followed by Docetaxel + Trastuzumab ; Day 1: Doxorubicin 60mg/m2 IV; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, | 3000 |
CM0100-j-II : BREAST CANCER - Docetaxel (preceeded by AC) + Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-j-III or CM0100-j-IV or CM0100-j-V) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles | 5400 |
CM0100-j-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel package CM0100-j-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat every 21 days till 1 year ; (to be approved with Docetaxel Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) or from 13 th week after completion of 12 weeks of weekly Trastuzumab - upto 1 year every 21 days) | 30500 |
CM0100-j-IV : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel package CM0100-j-II) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel Cycle 1. Subsequent cycles - 2mg package only) | 30500 |
CM0100-j-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) | 11500 |
CM0100-k-I : BREAST CANCER - Docetaxel + Cyclophosphamide - with Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-k-II or CM0100-k-III or CM0100-k-IV) ; Day 1: Docetaxel 75mg/m2 IV; Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, | 5000 |
CM0100-k-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Day 1: Trastuzumab 6mg/kg IV ; (to be approved with Docetaxel + Cyclophosphamide Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) | 30500 |
CM0100-k-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel + Cyclophosphamide Cycle 1. Subsequent cycles - 2mg package only) | 30500 |
CM0100-k-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel + Cyclophosphamide Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) | 11500 |
CM0100-L-I : BREAST CANCER - Paclitaxel - (with Trastuzumab) ; (To be choosen along with Trastuzumab package - CM0100-L-III or CM0100-L-IV) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. | 3000 |
CM0100-L-II : BREAST CANCER - Trastuzumab (6mg) ; trastuzumab 6mg/kg IV ; Repeat every 21 days ; (to be approved after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) | 30500 |
CM0100-L-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) | 30500 |
CM0100-L-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Day 1: Trastuzumab 2mg/kg IV weekly ; (to be approved with Paclitaxel Cycles 2 - 12. May be approved as standalone for the upto 1 year every week or Trastuzumab 6mg Package may be used once every 21 days upto 1 year) | 11500 |
CM0100-M : BREAST CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0101-a-I : BLADDER CANCER - DDMVAC ; Day 1: Methotrexate 30mg/m2 IV; Day 2: Vinblastine 3mg/m2 IV, doxorubicin 30mg/m2 IV, cisplatin 70mg/m2 IV; ; Repeat every 2 weeks for 3-4 cycles | 3800 |
CM0101-a-II : BLADDER CANCER - Gemcitabine + cisplatin ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV; Day 2: Cisplatin 70mg/m2. ; Repeat every 4 weeks for 4 cycles. | 6400 |
CM0101-a-III : BLADDER CANCER - Cisplatin + methotrexate + vinblastine (CMV) ; Day 1: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV; Day 2: Cisplatin 100mg/m2 IV, leucovorin 15mg oral or IV every 6 hours for 4 doses; Day 8: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV Day 9: Leucovorin 15mg oral every 6 hours for 4 doses ; Repeat every 3 weeks for 3 cycles. | 4800 |
CM0101-b : BLADDER CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0102-i-a : LUNG CANCER - Mesothelioma - Pemetrexed + cisplatin ; Day 1: Pemetrexed 500mg/m2 IV, cisplatin 75mg/m2 ; Repeat every 21 days up to 12 cycles. | 14500 |
CM0102-i-b : LUNG CANCER - Mesothelioma - Pemetrexed + carboplatin ; Day 1: Pemetrexed 500mg/m2 IV, carboplatin AUC 5mg/min/mL IV. ; Repeat every 21 days for a max of 9 cycles. | 16500 |
CM0102-i-c : LUNG CANCER - Mesothelioma - Cisplatin & Gemcitabine ; Day 1: Cisplatin 80-100mg/m2 IV ; Days 1, 8, and 15: Gemcitabine 1000-1250mg/m2 IV ; Repeat every 21 - 28 days for 6 cycles. | 7600 |
CM0102-i-d : LUNG CANCER - Mesothelioma - Vinorelbine ; Vinorelbine 25-30mg/m2 (max 60mg) IV ; Repeat every week for 12 weeks. | 9000 |
CM0102-i-e : LUNG CANCER - Mesothelioma - Pemetrexed ; Day 1: Pemetrexed 500mg/m2 IV. ; Repeat every 21 days for 4 cycles (If First line) or Repeat every 21 days for 8 cycles (If Second line) | 14500 |
CM0102-i-f : LUNG CANCER - Mesothelioma - Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1250mg/m2 IV. ; Repeat every 28 days for a max of 10 cycles. | 7600 |
CM0102-i-g : LUNG CANCER - Mesothelioma - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0102-ii-a : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (i) ; Days 1 and 8: Cisplatin 50mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 25mg/m2 IV ; (or) ; Day 1: Cisplatin 100mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 30mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. | 33600 |
CM0102-ii-b : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (ii) ; Day 1: Cisplatin 75-80mg/m2 ; Days 1 and 8: Vinorelbine 25-30mg/m2. ; Repeat every 3 weeks for 4 cycles | 17900 |
CM0102-ii-c : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 100mg/m2 IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles | 4900 |
CM0102-ii-d : LUNG CANCER - NSCLC - Cisplatin & Docetaxel ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. | 6300 |
CM0102-ii-e : LUNG CANCER - NSCLC - Cisplatin & Gemcitabine ; Day 1: Cisplatin 75mg/m2 IV ; Days 1 and 8: Gemcitabine 1,250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles | 6100 |
CM0102-ii-f : LUNG CANCER - NSCLC - Pemetrexed + cisplatin (for Non Squamous Cell CA) ; Day 1: Cisplatin 75mg/m2 IV, pemetrexed 500mg/m2 IV. ; Repeat every - 21 days for 4 cycles. | 14500 |
CM0102-ii-g : LUNG CANCER - NSCLC - Paclitaxel/Carboplatin ; Day 1: Paclitaxel 200mg/m2 IV, carboplatin AUC 6mg per min/mL IV. ; Repeat cycle every 3 weeks for 4 cycles. | 8100 |
CM0102-ii-h : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Days 1, 8, 29 and 36: Cisplatin 50mg/m2 IV ; Days 1-5 and 29-33: Etoposide 50mg/m2 IV ; Concurrent thoracic radiotherapy 1.8Gy/day for 5 days/week (total dose, 61Gy). | 8500 |
CM0102-ii-i : LUNG CANCER - NSCLC - Cisplatin & Vinblastine ; Days 1 and 29: Cisplatin 100mg/m2 IV ; Days 1, 8, 15, 22 and 29: Vinblastine 5mg/m2 IV ; concurrent thoracic radiotherapy (total dose, 60Gy). | 8200 |
CM0102-ii-j : LUNG CANCER - NSCLC - Carboplatin + Pemetrexed ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 4 cycles. | 16500 |
CM0102-ii-k : LUNG CANCER - NSCLC - Cisplatin + Pemetrexed ; Day 1: Cisplatin 75 mg/m2 IV. ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 3 cycles. | 14900 |
CM0102-ii-l : LUNG CANCER - NSCLC - Paclitaxel + Carboplatin ; Paclitaxel 45mg/m2 IV + carboplatin AUC 2mg per min/mL IV ; with concurrent thoracic radiotherapy (total dose, 60Gy) ; Repeat weekly for 6 weeks | 3300 |
CM0102-ii-m : LUNG CANCER - NSCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0102-iii-a : LUNG CANCER - SCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 60mg/m2 IV, Days 1-3: Etoposide 120mg/m2 IV. ; Repeat cycle every 3 weeks for at least 4 cycles. ;(OR) ; Day 1: Cisplatin 80mg/m2 IV, Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4-6 cycles. | 4900 |
CM0102-iii-b : LUNG CANCER - SCLC - Carboplatin & Etoposide ; Day 1: Carboplatin AUC 5-6mg per min/mL IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 21 days or 28 days for 4 - 6 cycles | 6500 |
CM0102-iii-c : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. | 5800 |
CM0102-iii-d : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1 and 8: Cisplatin 30mg/m2 IV, irinotecan 65mg/m2 IV. ; Repeat cycle every 3 weeks for 4-6 cycles. | 5700 |
CM0102-iii-e : LUNG CANCER - SCLC - Carboplatin & Irinotecan ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 50mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles | 7700 |
CM0102-iii-f : LUNG CANCER - SCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0103-i-a : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV + carboplatin AUC 2mg/min/mL IV. ; Repeat weekly for 5 weeks | 3300 |
CM0103-i-b : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV. | 12000 |
CM0103-i-c : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5 and Days 22-26: 5-FU 800 mg/m2 IV ; Repeat every 21 days for 2 cycles | 7100 |
CM0103-i-d : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil + Oxaliplatin + Leucovorin ; Day 1: Oxaliplatin 85mg/m2, leucovorin 200mg/m2 and 5-FU 400mg/m2 bolus, with 1,600mg/m2 infusion; ; Repeat every 14 days for 6 cycles | 4600 |
CM0103-i-e : ESOPHAGEAL CANCER - Neo Adjuvant - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks | 2500 |
CM0103-i-f : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV | 25800 |
CM0103-i-g : ESOPHAGEAL CANCER - Neo Adjuvant - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks. | 8900 |
CM0103-i-h : ESOPHAGEAL CANCER - Neo Adjuvant - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV, cisplatin 30mg/m2 IV. | 9700 |
CM0103-i-i : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV infusion. ; Repeat cycle weekly for 5 weeks. | 5500 |
CM0103-i-j : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. | 12200 |
CM0103-i-k : ESOPHAGEAL CANCER - Neo Adjuvant - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0103-ii-a : ESOPHAGEAL CANCER - Peri-Operative - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV continuous infusion once daily; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively | 16700 |
CM0103-ii-b : ESOPHAGEAL CANCER - Peri-Operative - EOF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. | 18700 |
CM0103-ii-c : ESOPHAGEAL CANCER - Peri-Operative - EOC (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. | 7800 |
CM0103-ii-d : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV ; Repeat cycle every 28 days for 2-4 cycles | 12000 |
CM0103-ii-e : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cyclesCycled every 21 days for 2 cycles | 7100 |
CM0103-ii-f : ESOPHAGEAL CANCER - Peri-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0103-iii-a : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (i) ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV, followed by 4 weeks break and CCRT ; RT Days 1-4 and 23-25: 5-FU 400mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV. | 25400 |
CM0103-iii-b : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 200mg/m2 IV, 5-FU 400mg/m2 IV push and 5-FU 600mg/m2 infusion | 9000 |
CM0103-iii-c : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily; ; Repeat every 28 days; 1 cycle before and 2 cycles after chemoradiation | 3100 |
CM0103-iii-d : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily, ; once weekly for 5 weeks. | 1600 |
CM0103-iii-e : ESOPHAGEAL CANCER - Post-Operative - FluorouracilDays 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV continuous infusion over 24 hours daily, ; once weekly for 5 weeks.once weekly for 5 weeks. | 6500 |
CM0103-iii-f : ESOPHAGEAL CANCER - Post-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0103-iv-a : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV | 12000 |
CM0103-iv-b : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cycles | 7100 |
CM0103-iv-c : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day continuous IV infusion. | 25800 |
CM0103-iv-d : ESOPHAGEAL CANCER - Definitive - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks | 2000 |
CM0103-iv-e : ESOPHAGEAL CANCER - Definitive - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks | 8900 |
CM0103-iv-f : ESOPHAGEAL CANCER - Definitive - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV and carboplatin 2mg/min/mL IV ; Repeat weekly for 5 weeks. | 3300 |
CM0103-iv-g : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (i) ; Days 1 and 22: Docetaxel 60mg/m2 IV ; Days 1 and 22: Cisplatin 60-80mg/m2 IV given for 1 cycle | 8900 |
CM0103-iv-h : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (ii) ; Day 1: Docetaxel 20-30mg/m2 IV ; Day 1: Cisplatin 20-30mg/m2 IV ; Repeat weekly for 5 weeks | 3000 |
CM0103-iv-i : ESOPHAGEAL CANCER - Definitive - Cisplatin with Paclitaxel ; Days 1, 8, 15, and 22: Paclitaxel 60mg/m2 IV ; Day 1: Cisplatin 75mg/m2 IV given for 1 cycle. | 13100 |
CM0103-iv-j : ESOPHAGEAL CANCER - Definitive - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV ; Days 1, 8, 22, and 29: Cisplatin 30mg/m2 IV. | 9700 |
CM0103-iv-k : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV ; Repeat cycle weekly for 5 weeks. | 5500 |
CM0103-iv-l : ESOPHAGEAL CANCER - Definitive - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 PO twice daily. ; Repeat cycle weekly for 5 weeks. | 12200 |
CM0103-iv-m : ESOPHAGEAL CANCER - Definitive - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0104-i-a : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV, carboplatin AUC 2mg/min/mL IV. ; Repeat cycle weekly for 5 weeks. | 3300 |
CM0104-i-b : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1000mg/m2/day IV | 12000 |
CM0104-i-c : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV once daily, 5-FU 800mg/m2/day IV ; Repeat cycle every 21 days for 2 cycles. | 7100 |
CM0104-i-d : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (i)Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV. | 25800 |
CM0104-i-e : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (ii)Day 1: Oxaliplatin 85mg/m2 and leucovorin 400mg/m2 followed by 5-FU 400mg/m2 bolus, then 800mg/m2 24-hour continuous infusion over days 1 and 2; the first 3 cycles were delivered during radiotherapy (RT), the other 3 after RT; 6 bimonthly (14 days) cycles. | 6100 |
CM0104-i-f : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. | 2000 |
CM0104-i-g : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks | 8900 |
CM0104-i-h : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45-50mg/m2 IV weekly ; Days 1-5: 5-FU 300mg/m2 IV ; Repeat cycle weekly for 5 weeks | 5500 |
CM0104-i-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. | 3100 |
CM0104-i-j : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0104-ii-a : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV, cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2/day IV ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively | 16700 |
CM0104-ii-b : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - EOF (Epirubicin/ oxaliplatin /Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. | 18700 |
CM0104-ii-c : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - epirubicin + cisplatin + capecitabine ; Day 1: Epirubicin 50mg/m2 IV + cisplatin 60mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. | 5900 |
CM0104-ii-d : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF modification (epirubicin + oxaliplatin + capecitabine) ; Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperativelyRepeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively | 7800 |
CM0104-ii-e : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Fluorouracil & Cisplatin ; Day 1: Cisplatin 75-80mg/m2 IV ; Days 1-5: 5-FU 800mg/m2 IV ; Repeat cycle every 28 days for 2-3 cycles preoperatively and 3-4 cycles postoperatively for a total of 6 cycles. | 6900 |
CM0104-ii-f : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0104-iii-a : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (i) ; Cycles 1, 3, and 4 (before and after radiation) Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2/day IV ; Repeat cycle every 28 days. ; Cycle 2 (with radiation) Days 1-4 and 31-33: Leucovorin 20mg/m2 IVP ; Days 1-4: 5-FU 400mg/m2/day IVP. ; Repeat cycle every 35 days | 25400 |
CM0104-iii-b : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 400mg/m2 IV, 5-FU 400mg/m2 IV and 5-FU 1200mg/m2 infusion; ; 1 cycle before and 2 cycles after chemoradiation. ; Repeat cycle every 28 daysRepeat cycle every 28 days | 14900 |
CM0104-iii-c : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily. ; Repeat cycle every 28 days; 1 cycle before and 2 cycles after chemoradiation. | 3100 |
CM0104-iii-d : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily; weekly for 5 weeks. | 1600 |
CM0104-iii-e : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil ; Days 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV; ; weekly for 5 weeks. | 6500 |
CM0104-iii-f : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Cisplatin + capecitabine ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 6 cycles. | 4000 |
CM0104-iii-h : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Oxaliplatin + capecitabine ; Day 1: Oxaliplatin 130mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 8 cycles.Repeat cycle every 21 days for 8 cycles. | 6000 |
CM0104-iii-i : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0105-i-a : COLORECTAL CARCINOMA - FOLFOX (Stage - III) - (Oxaliplatin, Leucovorin, 5-FU) ; Day 1: Oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV , 5-FU 400mg/m2 IV, followed by 5-FU 1,200mg/m2/day IV x 2 days (total 2,400mg/m2) over 46-48-hour continuous infusion. ; Repeat cycle every 2 weeks- upto 12 cycles | 8000 |
CM0105-i-b : COLORECTAL CARCINOMA - CAPEOX (Stage - III) (Oxaliplatin, Capecitabine) ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Days 1-14: Capecitabine 1,000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 6 months | 6500 |
CM0105-i-c : COLORECTAL CARCINOMA - FLOX (Stage - III) (5-FU, leucovorin, oxaliplatin) ; 5-FU 500mg/m2 IV bolus weekly x 6, leucovorin 500mg/m2 IV weekly x 6, each ; oxaliplatin 85mg/m2 IV on weeks 1, 3, and 5 ; 8-week cycle x 3 cycles ; | 30000 |
CM0105-i-d : COLORECTAL CARCINOMA - Capecitabine ; Capecitabine 1,250mg/m2 - BD / TDS D 1-14 ; every 3 weeks * 24 weeks | 4300 |
CM0105-i-e : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (i) ; Leucovorin 500mg/m2 weekly x 6 weeks, ; 5-FU 500mg/m2 weekly x 6 weeks. ; Repeat cycle every 8 weeks for 4 cycles. | 23700 |
CM0105-i-f : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (ii)Simplified biweekly infusion. ; Leucovorin 400mg/m2 IV, 5-FU bolus 400mg/m2 and then 1,200mg/m2/day x 2 days (total 2,400mg/m2 over 46-48 hours) ; Repeat cycle every 2 weeks for 6 cycles. | 5200 |
CM0105-i-g : COLORECTAL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0105-ii-a : COLORECTAL CARCINOMA - Concurrent - 5FU - with XRT ; Days 1-5 OR 1-7: 5-FU 225mg/m2 IV ; with External beam radiotherapy | 3800 |
CM0105-ii-b : COLORECTAL CARCINOMA - Concurrent - Fluorouracil + Leucovorin - with XRT ; Days 1-4: 5-FU 400mg/m2 IV + leucovorin 20mg/m2 IV. ; Repeat cycle during weeks 1 and 5 of XRT. | 6100 |
CM0105-ii-c : COLORECTAL CARCINOMA - Concurrent - Capecitabine - with XRT ; Capecitabine Tablet 825mg / m2 twice daily on Days 1-5 ; Repeat cycle weekly for 5 weeks. | 1300 |
CM0105-ii-d : COLORECTAL CARCINOMA - Concurrent - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0106-i-a : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Cisplatin + doxorubicin ; Days 1-3: Doxorubicin 25mg/m2/day IV, ; Day 1: Cisplatin 100mg/m2 IV ; Repeat cycle every 3 weeks for 6 cycles | 5600 |
CM0106-i-b-1 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - PRE OPERATIVE ; Days 1 and 28: Methotrexate 8g/m2 IV ; Days 7-9 and 34-36: Cisplatin 120mg/m2 by infusion for 72 hours. ; Days 9 and 36: Doxorubicin 60mg/m2 IV | 24200 |
CM0106-i-b-2 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS < 90% ; Days 1, 48, 96, and 144: Doxorubicin 45mg/m2/day for 2 consecutive days ; Days 21, 69, and 117: Methotrexate 8g/m2 IV ; Days 27, 75, and 123: Cisplatin 120mg/m2 by infusion for 72 hours. | 40100 |
CM0106-i-b-3 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS > 90%Postoperative Chemotherapy (Necrosis | 59100 |
CM0106-i-c : Doxorubicin + cisplatin + ifosfamide + high-dose methotrexate (surgery to be done also) | 111505 |
CM0106-i-d : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Ifosfamide + cisplatin + epirubicin ; Day 1: Epirubicin 90mg/m2 IV, cisplatin 100mg/m2 IV ; Days 2-4: Ifosfamide 2.0g/m2 with mesna ; Repeat cycle every 21 days. (3 cycles preoperatively and 3 cycles postoperatively). | 8300 |
CM0106-ii-a : Other bone tumors - Chordroma - Imatinib ; Imatinib 800 mg once daily | 4500 |
CM0106-ii-b : Other bone tumors - Chordroma - Imatinib + cisplatin ; Imatinib 400mg OD + cisplatin 25mg/m2 weekly. | 4500 |
CM0106-ii-c : Other bone tumors - Chordroma - Imatinib + sirolimus ; Imatinib 400mg OD + sirolimus 2mg OD | 6000 |
CM0106-ii-d : Other bone tumors - Chordroma - Erlotinib ; Erlotinib 150mg OD | 2200 |
CM0106-ii-e : Other bone tumors - Chordroma - Sunitinib ; Sunitinib 37.5mg OD | 28500 |
CM0106-iii-a :Other bone tumors - Giant Cell Tumor of Bone - Denosumab ; Denosumab 120mg subcutaneous on Week 1,2 and 3 of a 4 week cycle | 56000 |
CM0106-iii-b :Other bone tumors - Giant Cell Tumor of Bone - Interferon alfa ; interferon alfa- 2a thrice weekly | 4600 |
CM0106-iii-c :Other bone tumors - Giant Cell Tumor of Bone - Peginterferon ; Peginterferon alfa-2a 1.0mcg/kg SQ injection weekly. | 3500 |
CM0106-iv-a : VAC and IE cycles | 6420 |
CM0106-iv-b : Other bone tumors - Mesenchymal Chordosarcoma VAIA ; Day 1: Vincristine 1.5mg/m2 IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 3 weeks. | 7600 |
CM0106-v : Other bone tumors - Mesenchymal Chordosarcoma Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0107-a : WILMS TUMOR - Vincristine & Actinomycin D ; Dactinomycin 45mcg/kg - week - 0, 3, 6,9,12,15,18 ; Vincristine 1.5 mg/m2 - week - 1,2,3,4,5,6,7,8,9,10,12,15,18 | 19400 |
CM0107-b : WILMS TUMOR - Dactinomycin, Vincristine & Adriamycin ; Dactinomycin 1.35 mg /m2 - week - 0, 6, 12, 18,24 ; Adriyamycin 30-45 mg /m2- week - 3, 9, 15, 21 ; Vincristine 2mg max- week - 1,2,3,4,5,6,7,8,9,10,12,15,18,21,24 | 23200 |
CM0107-c : WILMS TUMOR - Adriamycin, Cyclophosphamide, Etoposide, Vincristine ; Cyclophosphamide 440mg/m2/day - week 3, 9, 15, 21 for 5 days, week - 6,12,18,24 for 3 days ; Adriyamycin 30-45mg /m2- week -0, 6, 12, 18,24 ; Vincristine 2mg (max)- week - 1,2,4,5,6,7,8,10,11, 12,13,18,24 ; Etoposide 100mg /m2- week - 3,9,15,21 | 53700 |
CM0107-d : WILMS TUMOR - Cyclophosphamide, Etoposide, Carboplatin ; Cyclophosphamide 440mg/m2/day - week 6,15,24 *5 days / week ; Carboplatin 500mg/m2 - week - 0,3,9,12,18,21 *2 days / week ; Etoposide 100mg/m2 - week - 0,3,9,12,18,21 *5 days / week | 84500 |
CM0107-e : WILMS TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0108-a : HEPATOBLASTOMA- OPERABLE - PLADO - Cisplatin + Doxorubicin ; cisplatin (PLA) (80mg/m2 / iv), doxorubicin (DO) (30 mg/m2 IV ; Every 21 days for 6 cycles | 2800 |
CM0108-b : HEPATOBLASTOMA- OPERABLE - Cisplatin + Vincristine +5FU ; cisplatin (90 mg/m2), vincristine (1.5mg/m2), 5-FU(5-Flurouracil- 600 mg/m2) ; Every 21 days for 6 cycles | 2400 |
CM0108-c : HEPATOBLASTOMA- OPERABLE - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0109-a : HEPATOCELLULAR CARCINOMA - Sorafenib ; Sorafenib 400 mg PO BID | 5800 |
CM0109-b : HEPATOCELLULAR CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0110A : Neuroblastoma ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN | 8000 |
CM0110B : Neuroblastoma ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300mg/m2 ; ADRIAMYCIN 60mg/m2 ; VINCRISTINE 1.5mg/m2 | 7100 |
CM0110C : Neuroblastoma ALL STAGES - Cisplatin & Etoposide ; Days 1-5 : Cisplatin - 20mg/m2 ; Days 1-5 : Etoposide - 70 mg/m2 | 4900 |
CM0110D : Neuroblastoma ALL STAGES - Carboplatin & Etoposide ; Days 1-2 : Carboplatin - 500mg/m2 ; Days 1-5: Etoposide 100mg/m2 | 6500 |
CM0110E : Neuroblastoma ALL STAGES - For Stage IV Palliative Chemotherapy only | 10000 |
CM0110F : Neuroblastoma ALL STAGES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0111-a : RETINOBLASTOMA - Melphalan - Intra-arterial ; Melphalan - 3-7.5mg - Intra-arterial | 9700 |
CM0111-b : RETINOBLASTOMA - Carboplatin - Intra-arterial ; Carboplatin 15-30 mg - Intra-arterial | 8900 |
CM0111-c : RETINOBLASTOMA - Topotecan - Intra-arterial ; Topotecan 0.15-1.5 mg - Intra-arterial | 9900 |
CM0111-d : RETINOBLASTOMA - Methotrexate - Intra-arterial ; Methotrexate 6-12 mg - Intra-arterial | 8600 |
CM0111-e : RETINOBLASTOMA - Carboplatin - Peri Ocular ; Carboplatin 20mg/m2 - Peri Ocular | 1900 |
CM0111-f : RETINOBLASTOMA - Topotecan - Peri Ocular ; Topotecan 0.09 - 0.27 - Peri Ocular | 4300 |
CM0111-g : RETINOBLASTOMA - Melphalan - Intra-vitreal ; Melphalan 20-30 mcg / 0.1cc - Intra-vitreal | 270 |
CM0111-h : RETINOBLASTOMA - Carboplatin - Intra-vitreal ; Carboplatin 3-6mcg / 0.05cc - Intra-vitreal | 1900 |
CM0111-i : RETINOBLASTOMA - Methotrexate - Intra-vitreal ; Methotrexate 400mcg/0.1cc - Intra-vitreal | 1600 |
CM0111-j : RETINOBLASTOMA - Carboplatin + Etoposide + Vincristine ; Carboplatin 560mg/m2 ; Etoposide 150mg/m2 ; Vincristine 1.5mg/m2 | 6800 |
CM0111-k : RETINOBLASTOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0112-a : HISTIOCYTOSIS - Prednisolone and Vinblastine - 1; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 | 6100 |
CM0112-b : HISTIOCYTOSIS - Prednisolone and Vinblastine - 2; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 | 6800 |
CM0112-c : HISTIOCYTOSIS - Prednisolone and Vinblastine - continuation; Prednisolone and Vinblastine - continuation after either course 1 or both 1 & 2 ; Prednisolone - 5 days a week oral ; Vinblastine -IV ; repeat every 3 weeks till 1 year | 1800 |
CM0112-d : HISTIOCYTOSIS - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0113-a : RHABDOMYOSARCOMA - VAC (Vincristine + Dactinomycin + Cyclophosphamide + Mesna ) ; Day -1 - Vincristine 1.5 mg /m2 IV (2 mg max), Doxorubicin 75 mg /m2 IV , cyclophosphamide 1200 mg /m2 IV + mesna ; Repeat at 21 day intervals for 4-6 cycles | 3800 |
CM0113-b : RHABDOMYOSARCOMA - IVA (Vincristine + Dactinomycin + Ifosfamide + Mesna ) ; Day 1,2 - Ifosfamide IV 3 g/m2 + mesna ; Day 1 - Vincristine IV 1.5 mg/m2 (max 2 mg), Actinomycin-D IV 1.5 mg/m2 (max 2 mg) ; Repeat at 21 day intervals for 6 cycles | 5600 |
CM0113-c : RHABDOMYOSARCOMA - IVAD (Vincristine + Doxorubicin + Ifosfamide + Mesna ) ; Days 1 and 2 - Ifosfamide 3 g/m2 + Mesna, Doxorubicin 30mg/m2 ; Day 1 - vincristine 1.5 mg/m2, Actinomycin-D 1.5 mg/m2 ; Repeat at 21 day intervals for 6 cycles | 5500 |
CM0113-d : RHABDOMYOSARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0114-i-a : EWINGS SARCOMA - Induction Treatment - VIDE ; Day 1:Vincristine 1.5mg/m2(max 2mg) IV ; Days 1-3:Doxorubicin 20mg/m2 IV, ifosfamide 3g/m2IV, mesna continuous IV, etoposide 150mg/m2 IV ; Repeat cycle every 3 weeks for up to 6 cycles | 8300 |
CM0114-i-c : EWINGS SARCOMA - Induction Treatment - VAIA - 4 day Regimen ; Day 1:Vincristine 1.5mg/m2IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, then local therapy, followed by 10 additional cycles of VAIA for High risk and ; 10 additional cycles of VAIA or 10 cycles of VACA for standard-risk patients | 7600 |
CM0114-i-d : EWINGS SARCOMA - Induction Treatment - VAIA - 24 day Regimen ; Days 1, 8, 15, and 22: Vincristine 1.5mg/m2 IV ; Days 1, 2, 22, 23, 43, and 44 : Ifosfamide 3,000mg/m2 IV + mesna ; Days 1, 2, 43, and 44 : Doxorubicin 30mg/m2 IV ; Days 22, 23, and 24: Dactinomycin 0.5mg/m2 IV ; After completion of one 9-week cycle, local therapy followed by 3 additional cycles. | 17700 |
CM0114-ii-a : EWINGS SARCOMA - Maintenance Treatment - Etoposide/Ifosfamide ; Days 1-5: Ifosfamide 1,800mg/m2/day IV + mesna ; Days 1-5: Etoposide 100mg/m2/day IV. | 8200 |
CM0114-iii : EWINGS SARCOMA - Maintenance Treatment - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0115 : PALLIATIVE CHEMOTHERAPY (Any Regimen)- Maximum Payable | 10000 |
CM0116-a : CERVICAL CANCER - CISPLATIN ; Cisplatin 40mg/m2 IV once weekly for up to 6 cycles | 1800 |
CM0116-b : CERVICAL CANCER - Cisplatin & 5FU with RT ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 IV over 96 hours ; Repeat cycle every 3 weeks for 3 | 9200 |
CM0116-c : CERVICAL CANCER - Cisplatin & 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV | 8900 |
CM0116-d : CERVICAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0117-a : VULVAL CANCER - Cisplatin ; Day 1 : 40 mg/m 2 IV | 1800 |
CM0117-b : VULVAL CANCER - Cisplatin + 5FU ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 ; Repeat cycle every 3 weeks - total 3 cycles | 4700 |
CM0117-c : VULVAL CANCER - 5-FU + Mitomycin ; 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day continuous IV infusion ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), | 11400 |
CM0117-d : VULVAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0118-a : VAGINAL CANCER - Cisplatin ; Cisplatin 75mg/m2 ; once weekly for up to 6 doses | 1800 |
CM0118-b : VAGINAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0119-a : OVARIAN CANCER - Paclitaxel + Cisplatin ; Day 1: Paclitaxel 135mg/m2 continuous IV ; Day 2: Cisplatin 75-100mg/m2 ; Day 8: Paclitaxel 60mg/m2 ; Repeat every 3 weeks for 6 cycles. | 8800 |
CM0119-b : OVARIAN CANCER - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 175mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL IV ; Repeat every 3 weeks for 6 cycles | 7000 |
CM0119-c : OVARIAN CANCER - Docetaxel + Carboplatin ; Day 1: Docetaxel 60-75mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL ; Repeat every 3 weeks for 6 cycles | 8700 |
CM0119-d : OVARIAN CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0120 : ENDOMETRIAL CANCER (Palliative Chemotherapy only) | 10000 |
CM0121-a : OVARY- GERM CELL TUMOR - BEP (Bleomycin + Etoposide + Cisplatin) ; Days 1,8,15 : Bleomycin 30 units/wk IV, Etoposide 100 mg/m 2/day IV ; Days 1-5 : Cisplatin 20 mg/m 2/day IV ; Repeat every 21 days 3-4 cycles | 10800 |
CM0121-b : OVARY- GERM CELL TUMOR - EP ( Etoposide + Carboplatin) ; Day 1 : Carboplatin 400 mg/m 2 IV on days 1-3 ; Repeat every 28 days for three cycles | 6500 |
CM0121-c : OVARY- GERM CELL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0122-a : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (5 days regimen) ; Days 1-5: MTX 0.4 mg/kg/day IV or IM for 5 days, not to exceed 25 mg/day ; Repeat cycle every 14 days | 2100 |
CM0122-b : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (8-day alternating regimen) ; Days 1, 3, 5, and 7 : MTX 1 mg/kg IM, ; Days 2, 4, 6, and 8 : Folinic acid 15 mg ; Repeat cycle every 14 days | 2900 |
CM0122-c : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate + Folinic Acid ; Day 1 : MTX 100 mg/m 2 IVP, then 200 mg/m 2 infusion ; Day 2 : Folinic acid 15 mg IM/PO q12h for 4 doses ; Repeat cycle every 18 days | 2000 |
CM0122-d : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate - Weekly ; MTX 30-50 mg/m 2 IM weekly | 1300 |
CM0122-e : GESTATIONAL TROPHOBLAST DISEASES - Act-D ; Act-D 10-13 mcg/kg or 0.5-mg flat dose IV qd for 5d ; Repeat cycle every 14 days | 7800 |
CM0122-f : GESTATIONAL TROPHOBLAST DISEASES - Actinomycin ; Actinomycin 1.25 mg/m 2 IV ; Repeat every 2 weeks | 2200 |
CM0122-g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (complete) ; Day 1 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, MTX - 300 mg/m2 IV ; Day 2 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, Leucovorin - 15 mg PO/IM q12h 4 doses ; Day 8 : Vincristine - 0.8 mg/m2 IV, Cyclophosphamide - 600 mg/m2 IV ; Repeat cycle every 14 days | 6400 |
CM0122-h : GESTATIONAL TROPHOBLAST DISEASES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0123-a : TESTICULAR CANCER - EP ; Days 1-5: Etoposide 100mg/m2, cisplatin 20mg/m2 ; Repeat cycle every 3 weeks for 4 cycles. | 5400 |
CM0123-b : TESTICULAR CANCER - BEP ; Days 1-5: Cisplatin 20mg/m2, etoposide 100mg/m2 ; Days 1, 8, and 15 OR Days 2, 9, or 16: Bleomycin 30 units IV ; Repeat cycle every 3 weeks for 3 cycles. | 10000 |
CM0123-c : TESTICULAR CANCER - VIP ; Day 1 (before ifosfamide): Mesna 120mg/m2 IV ; Days 1-5: Etoposide 75mg/m2 IV, mesna 1,200mg/m2 IV, ifosfamide 1,200mg/m2 IV + cisplatin 20mg/m2. ; Repeat cycle every 3 weeks for 4 cycles. | 6300 |
CM0123-d : TESTICULAR CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0124-a : PROSTATE CANCER - Docetaxel + prednisone ; Day 1: Docetaxel 75mg/m2 IV, prednisone 5mg orally twice daily. ; once every 3 weeks, Repeat for up to 10 cycles if tolerated | 3600 |
CM0124-b : PROSTATE CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0125-a : FEBRILE NEUTROPENIA - First-line monotherapy ; Piperacillin-tazobactam 4.5 g ; Cefepime 2 g ; Meropenem 1 g ; Imipenem-cilastatin 500 mg | 13500 |
CM0125-b : FEBRILE NEUTROPENIA - Second-line dual therapy ; Piperacillin-tazobactam 4.5 g IV plus an aminoglycoside ; Meropenem 1 g IV plus an aminoglycoside ; Imipenem-cilastatin 500 mg IV plus an aminoglycoside | 19500 |
CM0125-c : Other Regimen | 10000 |
CM0126-a : THYROID CANCER - sorafenib ; sorafenib 400 mg PO BID | 2900 |
CM0126-b : THYROID CANCER - sunitinib ; sunitinib 50 mg | 28500 |
CM0126-c : THYROID CANCER - pazopanib | 9500 |
CM0126-d : THYROID CANCER - Doxorubicin ; Doxorubicin 60 mg/m2 as monotherapy or in combination with cisplatin 40 mg/m2 | 4400 |
CM0126-e : THYROID CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0127-a : THYMOMA - CAP ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 50mg/m2 IV, cyclophosphamide 500mg/m2 IV. ; Repeat every 21 days for a max of 8 cycles. | 4600 |
CM0127-b : THYMOMA - CAPP ; Day 1: Cyclophosphamide 500mg/m2 IV ; Days 1-3: Cisplatin 30mg/m2 IV ; Days 1-3: Doxorubicin 20mg/m2 ; Days 1-5: Prednisone 100mg. ; Repeat every 3 weeks for 3 cycles. | 6800 |
CM0127-c : THYMOMA - ADOC ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 40mg/m2 IV ; Day 3: Vincristine 0.6mg/m2 IV ; Day 4: Cyclophosphamide 700mg/m2 IV. ; Repeat every 3 weeks for 5 cycles. | 5900 |
CM0127-d : THYMOMA - PE ; Day 1: Cisplatin 60mg/m2 IV ; Days 1-3: Etoposide 120mg/m2 IV ; Repeat every 3 weeks for a max of 8 cycles. | 5100 |
CM0127-e : THYMOMA - VIP ; Days 1-4: Etoposide 75mg/m2 IV, ifosfamide 1.2g/m2 IV, cisplatin 20mg/m2 IV. ; Repeat every 3 weeks for 4 cycles | 7600 |
CM0127-f : THYMOMA - Carboplatin+paclitaxel ; Day 1: Paclitaxel 225mg/m2 IV, carboplatin AUC = 6 IV ; Repeat every 3 weeks for a max of 6 cycles. | 9300 |
CM0127-g : THYMOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0128-i-a : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Combination PCV (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally. ; Days 8-21: Procarbazine 60mg/m2 orally once daily. ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. | 3800 |
CM0128-i-b : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (7 weeks) ; Days 1-49: Temozolomide 75mg/m2 orally. ; Repeat cycle every 11 weeks (7 weeks on/4 weeks off) for 6 cycles. | 6500 |
CM0128-i-c : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide monthly 5-day course ; Temozolomide monthly 5-day courses at doses of 180 - 200mg/m2/day | 2100 |
CM0128-i-d : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (3 weeks) ; Days 1-21: Temozolomide 75mg/m2/day orally. ; Repeat cycle every 28 days. | 3400 |
CM0128-ii-a : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Temozolomide monthly 5-day course ; Days 1-5: Temozolomide 200mg/m2/day orally. ; Repeat cycle every 4 weeks until disease progression or for up to 24 cycles. | 2100 |
CM0128-ii-b : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV with deferred RT (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks | 3800 |
CM0128-ii-d : Adjuvant Temozolomide | 2100 |
CM0128-ii-e : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV for 1p19q co-deleted (with Radiotherapy) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. for 6 cycles | 3800 |
CM0128-iii-a : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) | 7200 |
CM0128-iii-b : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Adjuvant Temozolomide (preceeded by Concurrent temozolzmide) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days for 6 cycles. | 2100 |
CM0128-iii-c : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (post RT) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days | 2100 |
CM0128-iii-d : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (200mg) with standard RT ; Days 1-5: Temozolomide 200mg/m2, orally | 2100 |
CM0128-iv-a : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + lomustine ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; ; During Cranio-spinal RT | 4400 |
CM0128-iv-b : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV. | 5500 |
CM0128-v-a-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + Cytarabine ; Day 1: MTX 3.5g/m2 ; Days 2-3: Cytarabine 2g/m2 IV twice a day. | 6600 |
CM0128-v-a-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + leucovorin + Ifosfamide + mesna ; Day 1: MTX 4gm/m2 IV, ; Days 2-5: leucovorin 20-25mg IV (upto 40mg) ; Days 3-5: Ifosfamide 1.5gm/m2 IV + mesna 400mg IV | 9500 |
CM0128-v-b-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + MTX + vincristine +procarbazine ; Day 1: Rituximab 500mg/m2 IV ; Day 2: MTX 3.5mg/m2 IV plus vincristine 1.4mg/m2 ; Procarbazine 100mg/m2/day administered for 7 days with odd-numbered cycles | 41900 |
CM0128-v-c-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Induction ; MTX 8g/m2 IV ; Repeat every 2 weeks until complete response achieved or max of 8 cycles reached. ; | 7900 |
CM0128-v-c-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Consolidation ; MTX 8g/m2 IV administered ; Repeat every 2 weeks for 2 cycles. | 7900 |
CM0128-v-c-3-i : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (Cycles 1-4) ; Day 1: MTX 8g/m2 IV, Rituximab 375mg/m2 IV. ; Repeat every 4 weeks for 4 cycles | 32400 |
CM0128-v-c-3-ii : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (cycles 5-11) ; MTX 8g/m2 IV administered every 4 weeks for 11 cycles. ; Repeat cycle every 4 weeks for 4 cycles | 7900 |
CM0128-v-d-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - Induction ; Day 1: Rituximab 375mg/m2 IV, followed by ; Days 1-5: Temozolomide 150-200mg/m2 orally daily, after rituximab infusion. ; Repeat cycle every 4 weeks for 4 cycles. | 26600 |
CM0128-v-d-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - MaintananceDays 1-5: Temozolomide 150-200mg/m2 orally daily. ; Repeat cycle every 4 weeks for 8 cycles. | 1600 |
CM0128-v-e-1 : BRAIN CARCINOMA - Meningioma - Interferon-alfaInterferon-alfa ; alpha-IFN 106 units/m2 SC every other day for 4 weeks. ; Repeat cycle every 4 weeks. ; | 6000 |
CM0128-v-e-2 : BRAIN CARCINOMA - Meningioma -Somatostatin analog ; Sandostatin LAR Depot 10-30mg IM ; Repeat every 4 weeks. ; | 5400 |
CM0128-v-e-3 : BRAIN CARCINOMA - Meningioma - Sunitinib ; Days 1-28: Sunitinib 50mg orally daily. ; Repeat cycle every 42 days. | 2900 |
CM0129-i-a : HEAD AND NECK CANCER - HIgh Dose Cisplatin ; Cisplatin 100mg/m2 IV + concurrent radiotherapy; Repeat cycle every 3 weeks for 3 cycles | 2000 |
CM0129-i-b : HEAD AND NECK CANCER - Carboplatin + infusional 5-FU ; Days 1-4: 5-FU 600mg/m2/day as continuous IV I, carboplatin 70mg/m2/day IV ; Repeat every 3 weeks for 3 cycles (given concurrently with radiotherapy). | 4700 |
CM0129-i-c : HEAD AND NECK CANCER - 5-FU + hydroxyurea ; Day 1: Hydroxyurea 1,000mg orally every 12 hours (11 doses/cycle), 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy | 2300 |
CM0129-i-d : HEAD AND NECK CANCER - Cisplatin + paclitaxel ; Day 1: Paclitaxel 30mg/m2 IV (every Monday), ; Day 2: Cisplatin 20mg/m2 IV (every Tuesday). ; Repeat cycle every week for 7 cycles, with Concurrent radiotherapy | 3400 |
CM0129-i-e : HEAD AND NECK CANCER - Cisplatin + infusional 5-FU ; Day 1: Cisplatin 60mg/m2 over ; Days 1-5: 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy | 5300 |
CM0129-i-f : HEAD AND NECK CANCER - Carboplatin + paclitaxel ; Day 1: Paclitaxel 40-45mg/m2, carboplatin 100mg/m2 ; Repeat cycle every week for 8 cycles, with Concurrent radiotherapy | 3500 |
CM0129-i-g : HEAD AND NECK CANCER - Weekly cisplatin ; Cisplatin 40mg/m2 IV per week | 1800 |
CM0129-i-h : HEAD AND NECK CANCER - Cisplatin (For high risk oropharyngeal carcinoma) ; Days 1, 22, and 43: Cisplatin 100mg/m2 IV + radiotherapy. | 5300 |
CM0129-i-i : HEAD AND NECK CANCER - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV, ; Days 1-5: 5-FU 750mg/m2/day IV. ; Repeat every 3 weeks for up to 4 cycles. | 6700 |
CM0129-i-j : HEAD AND NECK CANCER - Paclitaxel + cisplatin+ infusional 5-FU ; Day 1: Paclitaxel 175mg/m2 ; Day 2: Cisplatin 100mg/m2 ; Day 2-6: 5-FU 500mg/m2/day IV ; Repeat every 3 weeks for 3 cycles. | 7900 |
CM0129-ii-a-1 : Nasopharynx Cancer - Concurrent Cisplatin (followed by concurrent Cisplatin +5FU) ; Day 1: Cisplatin 100mg/m2 IV; plus radiotherapy. ; Repeat cycle every 3 weeks for 3 cycles; followed by concurrent Cisplatin +5FU | 2000 |
CM0129-ii-a-2 : Nasopharynx Cancer - concurrent Cisplatin +5FU - Preceeded by (Concurrent Cisplatin 3 cycles) ; Days 1-4: Cisplatin 80mg/m2/day, 5-FU 1,000mg/m2/day IV ; Repeat cycle every 4 weeks for 3 cycles | 6700 |
CM0129-ii-b-1 : Nasopharynx Cancer - Concurrent Carboplatin - (followed by concurrent Carboplatin +5FU) ; Day 1: Carboplatin AUC 6mg/min/mL IV. ; Repeat cycle every 3 weeks for 3 cycles; | 4300 |
CM0129-ii-b-2 : Nasopharynx Cancer - concurrent Carboplatin +5FU - Preceeded by (Concurrent Carboplatin ) ; Day 1: Carboplatin AUC 5mg/min/mL IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. | 13500 |
CM0129-ii-c : Nasopharynx Cancer - Concurrent Cisplatin ; Cisplatin 40mg/m2 ; Repeat weekly for 7 cycles | 1800 |
CM0129-ii-d-1 : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU - followed by Cisplatin after 3 cycles ; Day 1: Docetaxel 70mg/m2 IV, cisplatin 75mg/m2 IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat every week for 3 cycles | 6200 |
CM0129-ii-d-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 3 cycles of Docetaxel + 5-FU ; Day 1: Cisplatin 100mg/m2; ; Repeat every 3 weeks, Till radiation | 2800 |
CM0129-ii-e-1 : Nasopharynx Cancer - Docetaxel + cisplatin - followed by Cisplatin after 2 cycles ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV ; Repeat every 3 weeks for two cycles | 3900 |
CM0129-ii-e-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 2 cycles of Docetaxel + cisplatin ; Cisplatin 40mg/m2 IV ; weekly concurrent with radiotherapy. | 2300 |
CM0129-ii-f : Nasopharynx Cancer - Cisplatin + 5-FU ; Day 1: Cisplatin 100mg/m2/day IV. ; Days 1-4: 5-FU 1,000mg/m2/day continuous IV infusion for 4 days. ; Repeat cycle every 3 weeks for a minimum of 6 cycles | 5100 |
CM0129-iii : HEAD AND NECK CANCER (or) Nasopharynx Cancer - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0130-a : Pazopanib | 19000 |
CM0130-b : Sunitinib | 29000 |
CM0130-c : Sorafenib | 5800 |
CM0130-d : Other Regimen | 10000 |
CM0131-i-a : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin + etoposide ; Day 1: Paclitaxel 200 mg/m 2 IV, carboplatin AUC 6 ; Days 1-10: etoposide 50 mg PO alternating with 100 mg daily ; Repeat every 21days for 2-3 cycles; restage, can be treated upto 8 cycles | 8000 |
CM0131-i-b : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin ; Day 1: Paclitaxel 200 mg/m 2, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles | 7200 |
CM0131-i-c : UNKNOWN PRIMARY - Adenocarcinoma - Docetaxel + carboplatin ; Day 1: Docetaxel 65mg/m2 IV, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles. | 3800 |
CM0131-i-d : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + cisplatin ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat cycle every 3 weeks for 4 cycles. | 5300 |
CM0131-i-e : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + docetaxel ; Day 1 and 8: Gemcitabine 1000mg/m2 IV over 30 minutes ; Day 8: Docetaxel 75mg/m2 IV ; Repeat cycle every 3 weeks for a maximum of 6 cycles | 5800 |
CM0131-i-f : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + irinotecan ; Days 1 and 8: Irinotecan 100mg/m2 IV, gemcitabine 1000mg/m2 IV. ; Repeat cycle every 3 weeks for 6 cycles.restage every 2-3 cycles | 5600 |
CM0131-ii-a : UNKNOWN PRIMARY - Squamous cell carcinoma - Paclitaxel + cisplatin + 5-FU ; Paclitaxel 175 mg/m 2 IV, ; Day 2: cisplatin 100 mg/m 2 IV, ; Day 5-FU (5-fluorouracil) 500 mg/m 2/day IV ; Repeat every 21d | 6200 |
CM0131-ii-b : UNKNOWN PRIMARY - Squamous cell carcinoma - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Days 1-5: 5-FU 750mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. | 6800 |
CM0131-iii-b : UNKNOWN PRIMARY - Neuroendocrine tumors - Etoposide + cisplatin ; Days 1-3: Etoposide 100 mg/m 2 ; Days 2-3: cisplatin 45 mg/m 2 IV ; Repeat every 28 days | 5000 |
CM0131-iv : UNKNOWN PRIMARY - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0132-a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Gemcitabine + cisplatin ; Days 1 and 8: Cisplatin 25mg/m2 IV, gemcitabine 1,000mg/m2 IV ; Repeat every 21 days for 4 cycles, re-evaluate and continue an additional 4 cycles if warranted | 3700 |
CM0132-b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV | 4100 |
CM0132-c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Capecitabine ; Capecitabine oral ; Repeat every 21 days | 3600 |
CM0132-d : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0133-i-a : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV ; Repeat every 4 weeks for six cycles | 6600 |
CM0133-ii-a : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - 5-FU + Leucovorin ; Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2 IV ; Repeat cycle every 4 weeks | 5000 |
CM0133-ii-b : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Gemcitabine & 5FU ; Prior to chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 4 weeks for 3 months. | 6700 |
CM0133-ii-c : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Continuous infusion 5-FU (with Radiation) ; Prior to chemoradiation: ; Days 1-21: 5-FU 250mg/m2/day continuous IV infusion; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1-28: 5-FU 250mg/m2/day continuous IV infusion; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 6 weeks for 3 months. | 20700 |
CM0133-iii-a : PANCREAS CARCINOMA - Neoadjuvant therapy - CapecitabineCapecitabine ; Capecitabine ; Repeat cycle every 3 weeks for up to 52 weeks. | 3600 |
CM0133-iv : PANCREAS CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0134-a : PERI AMPULLARY CARCINOMA - 5-FU ; Fluorouracil 425 mg/m2 administered on days 1 to 5 and 29-33 | 5300 |
CM0134-b : PERI AMPULLARY CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0135-b : NEURO ENDOCRINE CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0136-i-a : SARCOMA - Gastrointestinal Stromal Tumor - GIST - Imatinib ; Imatinib 400mg orally once daily to twice daily | 3000 |
CM0136-ii-a : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + dacarbazine (AD) ; Days 1-4: Doxorubicin 60mg/m2 + dacarbazine 750mg/m2 ; Repeat cycle every 3 weeks | 11500 |
CM0136-ii-b : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + ifosfamide + mesna ; Days 1 and 2: Doxorubicin 30mg/m2/day IV, ifosfamide 3,750mg/m2/day IV, mesna 750mg/m2 IV ; Repeat cycle every 3 weeks | 9200 |
CM0136-ii-c : SARCOMA - SOFT TISSUE SARCOMA - Mesna + doxorubicin + ifosfamide + dacarbazine (MAID) ; Days 1-3: Doxorubicin 20mg/m2/day, ifosfamide 2,500mg/m2/day, dacarbazine 300mg/m2/day IV ; Days 1-4: Mesna 2,500mg/m2/day IV for 84 to 96 hours. ; Repeat cycle every 3 weeks. | 10700 |
CM0136-ii-d : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide + epirubicin + mesna ; Days 1 and 2: Epirubicin 60mg/m2/day IV ; Days 1-5: Ifosfamide 1.8g/m2/day IV + mesna. ; Repeat cycle every 3 weeks for 5 cycles. | 12800 |
CM0136-ii-e : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + docetaxel ; Days 1 and 8: Gemcitabine 900mg/m2 IV ; Day 8: Docetaxel 100mg/m2 IV. ; Repeat cycle every 3 weeks | 5100 |
CM0136-ii-f : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + vinorelbine ; Days 1 and 8: Vinorelbine 25mg/m2 IV, gemcitabine 800mg/m2 IV ; Repeat cycle every 3 weeks | 14700 |
CM0136-ii-g : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + dacarbazine ; Day 1: Gemcitabine 1,800mg/m2 IV + dacarbazine 500mg/m2 IV. ; Repeat cycle ever 2 weeks for a total of 12 cycles; | 3300 |
CM0136-ii-h : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin ; Doxorubicin 60-75mg/m2 IV ; once every 3 weeks | 2900 |
CM0136-ii-i : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Days 1-3: Ifosfamide 2,000-3,000mg/m2/day IV for 3 to 4 days + mesna ; Repeat every 3 weeks. | 10000 |
CM0136-ii-j : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Day 1: Ifosfamide 5,000mg/m2 + mesna 5,000mg/m2 IV ; Day 2: mesna 400-600mg/m2 IV ; Ifosfamide, mesna ; Repeat every 3 weeks | 1900 |
CM0136-ii-k : SARCOMA - SOFT TISSUE SARCOMA - Epirubicin ; Epirubicin 160mg/m2 IV ; Repeat every 3 weeks | 5900 |
CM0136-ii-l : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine ; Days 1 and 8: Gemcitabine 1,200mg/m2 IV ; Repeat cycle every 3 weeks. | 3600 |
CM0136-ii-m : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (i) ; Dacarbazine 250mg/m2/day IV for 5 days ; Repeat every 3 weeks. | 6200 |
CM0136-ii-n : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (ii) ; Dacarbazine 800-1,000mg/m2 IV ; Repeat every 3 weeks. | 2400 |
CM0136-ii-o : SARCOMA - SOFT TISSUE SARCOMA - Liposomal doxorubicin ; Liposomal doxorubicin 30-50mg/m2 IV ; Repeat every 4 weeks. | 7900 |
CM0136-ii-p : SARCOMA - SOFT TISSUE SARCOMA - Temozolomide ; Temozolomide 200mg/m2 orally twice daily for 5 days, followed by 9 doses of 90mg/m2 orally ; Repeat every 4 weeks | 4200 |
CM0136-iii : SARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0137-a : PRIMITIVE NEURO ECTODERMAL TUMOR - Weekly vincristine ; vincristine 1.5mg/m2 IV, max 2mg ; for 5 to 6 weeks | 1700 |
CM0137-b : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + lomustine ; During craniospinal radiotherapy (RT) ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; up to max 8 doses | 4400 |
CM0137-c : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV, max 2mg ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV | 7600 |
CM0137-d : PRIMITIVE NEURO ECTODERMAL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0137-vi : Other Regimen | 10000 |
CM0138 : MELANOMA - No primary regimens only RT. For advanced unresectable and metastatic disease - Pallitive Chemotherapy | 10000 |
CM0139-a : ANAL CANAL CANCER - 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day IV ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), with Concurrent radiotherapy | 11400 |
CM0139-b : ANAL CANAL CANCER - Capecitabine + Mitomycin (i) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus, with Concurrent radiotherapy. | 8100 |
CM0139-c : ANAL CANAL CANCER - Capecitabine + Mitomycin (ii) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Day 1: Mitomycin 12mg/m2 IV bolus, with Concurrent radiotherapy | 6800 |
CM0139-d : ANAL CANAL CANCER - Cisplatin + 5-FU ; Days 1-5: 5-FU 1,000mg/m2/day IV ; Day 2: Cisplatin 100mg/m2 IV ; Repeat cycle every 4 weeks, with Concurrent radiotherapy | 6700 |
CM0139-e : ANAL CANAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0158 : UPTO-40% WITH SCALDS (CONSERVATIVE) | 25200 |
CM0159 : UPTO-40% MIXED BURNS (WITH SURGERIES) | 36000 |
CM0160 : UPTO-50% WITH SCALDS (CONSERVATIVE) | 44820 |
CM0161 : UPTO-50% MIXED BURNS ( WITH SURGERIES) | 54900 |
CM0162 : UPTO-60% WITH SCALDS (CONSERVATIVE) | 67320 |
CM0163 : UP TO-60% MIXED BURNS (WITH SURGERIES) | 72900 |
CM0164 : ABOVE 60% MIXED BURNS (WITH SURGERIES) | 90900 |
CM0165 : POST BURN CONTRACTURE FOR FUNCTIONAL IMPROVEMENT (INCLUDING SPLINT / PRESSURE GARMENT / PHYSIOTHERAPY) - MILD | 18900 |
CM0166 : POST BURN CONTRACTURE FOR FUNCTIONAL IMPROVEMENT (INCLUDING SPLINT / PRESSURE GARMENT / PHYSIOTHERAPY) - MODERATE | 27900 |
CM0167 : POST BURN CONTRACTURE FOR FUNCTIONAL IMPROVEMENT (INCLUDING SPLINT / PRESSURE GARMENT / PHYSIOTHERAPY) - SEVERE | 35100 |
CM0168 : PTOSIS | 22050 |
CM0169 : CUP AND BAT EARS | 22050 |
CM0170A : FILARIAL LYMPHOEDEMA -NV SHUNT | 12510 |
CM0170B : FILARIAL LYMPHOEDEMA -REDUCTION SURGERY | 22050 |
CM0171 : HEMIFACIAL ATROPHY | 31140 |
CM0172 : HEMIFACIAL MICROSMIA | 44640 |
CM0173 : LEPROSY RECONSTRUCTIVE SURGERY | 26010 |
CM0174 : TUMOR OF MANDIBLE AND MAXILLA | 36090 |
CM0175 : CORRECTIVE SURGERY FOR CONGENITAL DEFORMITY OF HAND (PER HAND) | 23940 |
CM0176 : PRESSURE SORE RECONSTRUCTIVE SURGERY | 39510 |
CM0177 : ABDOMINAL WALL RECONSTRUCTION INCLUDING POST CANCER EXCISION | 39420 |
CM0178 : LID DEFORMITY CORRECTION (FOLLOWING TRAUMA/BURNS/CONGENITAL) | 15120 |
CM0183 : SURGICAL CORRECTION OF LONGBONE FRACTURE-FRACTURE NECK/ SHAFT OF FEMUR/FRACTURE SHAFT OF OTHER LONG BONES (HUMERUS,BOTH BONES OF FOREARM, BOTH BONES OF LEG) | 20025 |
CM0184 : CORRECTION OF NON-UNION FRACTURES - NON-UNION OF FRACTURE OF FEMUR/BOTH BONE OF LEG/ NON-UNION OF OTHER LONG BONES -HUMERUS/ BOTH BONES OF FOREARM WITH OR WITHOUT BONE GRAFTING | 20025 |
CM0185 : SKELETAL SKULL TRACTION | 27315 |
CM0186A : IMPLANT EXIT- K-WIRES /SCREWS/OTHER MINOR IMPLANTS | 6975 |
CM0186B : IMPLANT EXIT- PLATES (SPINE IMPLANTS/OTHER MAJOR IMPLANT) | 18450 |
CM0187 : ARTHRODESIS OF JOINTS -SHOULDER/ HIP / KNEE /ELBOW/ ANKLE / WRIST / HAND / FOOT | 24300 |
CM0192 : ILIZAROV RING FIXATOR APPLICATION-FEMUR - DEFORMITY CORRECTION / LIMB LENGTHENING/TIBIA - DEFORMITY CORRECTION / LIMB LENGTHENING /PLATING/EXTERNAL FIXATOR/K WIRES | 35775 |
CM0193 : SURGERY FOR NEGLECTED CTEV/RECURRENT CTEV-CTEV CORRECTIVE SURGERY /CTEV PONSETTI CORRECTION (FOLLOW UP PROCEDURES)/CTEV ILIZAROV | 40275 |
CM0195 : KNEE LIGAMENT RECONSTRUCTION-ACL RECONSTRUCTION/PCL RECONSTRUCTION/MPFL RECONSTRUCTION | 27000 |
CM0203 : SURGICAL CORRECTION FOR PELVIC BONE FRACTURES | 29025 |
CM0204 : CORRECTION SACRO ILLIAC JOINT / ACETABULAR FRACTURES | 26550 |
CM0205 : TOTAL KNEE REPLACEMENT | 65000 |
CM0206A : TOTAL HIP REPLACEMENT- CEMENTED | 60075 |
CM0206B : TOTAL HIP REPLACEMENT-UNCEMETED | 69075 |
CM0291 : CRANIOTOMY AND EVACUATION OF HAEMATOMA | 52425 |
CM0292A : EXCISION OF BRAIN TUMORS - [PRIMARY /BENIGN ) ( SUPRATENTORIAL- FRONTAL/PARIETAL/TEMPORAL/SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) | 56925 |
CM0292B : EXCISION OF BRAIN TUMORS - [PRIMARY /BENIGN ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDES SUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR) | 61425 |
CM0293A : EXCISION OF BRAIN TUMORS - [MALIGNANT ) ( SUPRATENTORIAL- FRONTAL/PARIETAL/TEMPORAL/SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) | 56925 |
CM0293B : EXCISION OF BRAIN TUMORS - [MALIGNANT ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDES SUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR) | 61425 |
CM0294A : EXCISION OF BRAIN TUMORS - [SECONDARIES ) ( SUPRATENTORIAL- FRONTAL/PARIETAL/TEMPORAL/SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) | 56925 |
CM0294B : EXCISION OF BRAIN TUMORS - [SECONDARIES ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDES SUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR) | 61425 |
CM0295A : SHUNT SURGERIES-VENTRICULOATRIAL / VENTRICULOPERITONEAL SHUNT/ VENTRICULOPLEURAL SHUNT | 24255 |
CM0295B : LUMBAR PERITONEAL/SYRINGO SUBARACHANOID /CYSTO PERITONEAL | 26055 |
CM0296A : SHUNT SURGERIES-SHUNT DYSFUNTION - SHUNT SURGERIES-VENTRICULOATRIAL / VENTRICULOPERITONEAL SHUNT/ VENTRICULOPLEURAL SHUNT-REVISION | 24255 |
CM0296B : SHUNT SURGERIES-SHUNT DYSFUNTION - SHUNT SURGERIES-VENTRICULOATRIAL / VENTRICULOPERITONEAL SHUNT/ VENTRICULOPLEURAL SHUNT- REPLACEMENT | 26955 |
CM0296C : SHUNT SURGERIES-SHUNT DYSFUNTION - FAILURE/REVISION OF SHUNT ;LUMBAR PERITONEAL/SYRINGO SUBARACHANOID /CYSTO PERITONEAL - REVISION | 26055 |
CM0296D : SHUNT SURGERIES-SHUNT DYSFUNTION - FAILURE/REVISION OF SHUNT ;LUMBAR PERITONEAL/SYRINGO SUBARACHANOID /CYSTO PERITONEAL - REPLACEMENT | 28755 |
CM0297 : SHUNT SURGERIES - VP SHUNT WITH PROGRAMMABLE SHUNT | 36855 |
CM0298 : TWIST DRILL CRANIOSTOMY | 17955 |
CM0299 : SUBDURAL TAPPING | 17955 |
CM0300 : VENTRICULAR TAPPING | 17956 |
CM0301 : BRAIN ABSCESS & OTHER INFECTIVE LESION - BURR HOLE /TAPPING | 17957 |
CM0302 : CRANIOTOMY / EXCISION OF ABSCESS & OTHER INFECTIVE LESION | 24528 |
CM0303 : C.S.F. RHINORRHOEA & ACF REPAIR | 47925 |
CM0304 : CRANIOPLASTY | 36225 |
CM0305 : EXTERNAL VENTRICULAR DRAINAGE (EVD) | 24795 |
CM0306 : EXCISION OF LOBE (FRONTAL, TEMPORAL, PARIETAL , CEREBELLUM ETC) | 50625 |
CM0307 : PARASAGITAL LESION (INCLUDES VENTRICULAR LESIONS & CYSTS ) | 47925 |
CM0308 : BASAL LESION | 54225 |
CM0309 : BRAIN STEM LESION | 65925 |
CM0310 : C P ANGLE LESION | 65925 |
CM0311 : STEREOTACTIC PROCEDURES- SURGICAL PROCEDURE | 44775 |
CM0312 : STEREOTACTIC PROCEDURES- ABLATION | 95175 |
CM0313 : STEREOTACTIC PROCEDURES- BIOPSY | 44775 |
CM0314 : DE-COMPRESSIVE CRANIECTOMY (NON TRAUMATIC / CVA INFARCT) | 52425 |
CM0315 : INTRA-CEREBRAL HEMATOMA EVACUATION | 52425 |
CM0316 : SUBDURAL HEMORRHAGE/ DECOMPRESSION FOR CONTUSION & ICH | 52425 |
CM0317A : DECOMPRESSION - OPTIC NERVE LESION (INCLUDES PROPTOSIS) | 59175 |
CM0317B : EXCISION - OPTIC NERVE LESION (INCLUDES PROPTOSIS) | 58275 |
CM0317C : DECOMPRESSION - ORBITAL TUMOR (INCLUDES PROPTOSIS) | 42795 |
CM0317D : EXCISION - ORBITAL TUMOR (INCLUDES PROPTOSIS) | 42795 |
CM0318 : TEMPORAL LOBECTOMY | 38925 |
CM0319 : LESIONECTOMY | 110025 |
CM0320 : TEMPORAL LOBECTOMY PLUS DEPTH ELECTRODES | 44235 |
CM0321 : MICROVASCULAR DECOMPRESSION FOR TRIGEMINAL NEURALGIA | 48645 |
CM0322 : MENINGO ENCEPHALOCELE /MENINGO MYELOCELE /MENINGOCELE EXCISION/LIPOMENINGOCELE (AT ANY LEVEL REPAIR) | 29295 |
CM0323 : DERMAL SINUS WITH INTRADURAL EXTENSION/TETHERED CORD /RELEASE OF TIGHT FILUM | 28395 |
CM0324 : ARNOLD CHIARI MALFORMATION - FORAMEN MAGNUM DECOMPRESSION | 55395 |
CM0325 : INTRACRANIAL FOREIGN BODY REMOVAL | 52425 |
CM0326A : DEPRESSED FRACTURE ( WITH HEMATOMA) - EXCISION- TRAUMA /OTHER THAN TRAUMA FOR 3 CM SQ | 21555 |
CM0326B : DEPRESSED FRACTURE ( WITH HEMATOMA) - ELEVATION /SCREW & FIXATION -TRAUMA /OTHER THAN TRAUMA FOR 3 CM SQ | 29745 |
CM0326C : DEPRESSED FRACTURE ( WITH HEMATOMA) - BONE FLAP REMOVAL POST CRANIOPLASTY TRAUMA /OTHER THAN TRAUMA | 45045 |
CM0326D : DEPRESSED FRACTURE ( WITH HEMATOMA) - ELEVATION /SCREW & FIXATION -TRAUMA /OTHER THAN TRAUMA FOR MORE THAN 3 CM SQ | 37845 |
CM0326E : DEPRESSED FRACTURE ( WITHOUT HEMATOMA) - EXCISION- TRAUMA /OTHER THAN TRAUMA | 17595 |
CM0326F : DEPRESSED FRACTURE ( WITHOUT HEMATOMA) - ELEVATION /SCREW & FIXATION -TRAUMA /OTHER THAN TRAUMA FOR 3 CM SQ | 26145 |
CM0326G : DEPRESSED FRACTURE ( WITHOUT HEMATOMA) - BONE FLAP REMOVAL POST CRANIOPLASTY TRAUMA /OTHER THAN TRAUMA | 34245 |
CM0326H : DEPRESSED FRACTURE ( WITHOUT HEMATOMA) - ELEVATION /SCREW & FIXATION -TRAUMA /OTHER THAN TRAUMA MORE THAN FOR 3 CM SQ | 34245 |
CM0327A : BONY LESION OF SKULL (PRIMARY BENIGN /MALIGNANT, SECONDARIES) FOR 3 CM SQ | 40923 |
CM0327B : BONY LESION OF SKULL (PRIMARY BENIGN /MALIGNANT, SECONDARIES) FOR MORE THAN 3 CM SQ | 42723 |
CM0328A : SPONTANEOUS ICH - CRANIOTOMY & EVACUATION | 53775 |
CM0328B : SPONTANEOUS ICH - DECOMPRESSIVE CRANIECTOMY | 47475 |
CM0329A : DEEP BRAIN STIMULATION E-COG with Brain mapping (MRI, FMRI with 3D- Mapping) | 83475 |
CM0329B : DEEP BRAIN STIMULATION with E-COG, Brain mapping, intra-operative neuronavigation techniques & I-O CT/ MRI guided Stereotactic Stimulation | 105975 |
CM0330 : INTRATHECAL PUMP IMPLANT | 38925 |
CM0331 : NEURO ENDOSCOPY PROCEDURES-EXCISION OF INTRAVENTRICULAR LESION | 52695 |
CM0332 : NEURO ENDOSCOPY PROCEDURES-EXCISION OF SUPRATENTORIAL LESION | 55845 |
CM0333 : NEURO ENDOSCOPY PROCEDURES-SPINAL ENDOSCOPY FOR DISCECTOMY | 36495 |
CM0334 : NEURO ENDOSCOPY PROCEDURES-ENDOSCOPIC THIRD VENTRICULOSTOMY | 42345 |
CM0335 : CERVICAL / LUMBAR SYMPATHECTOMY | 29205 |
CM0471 : ECLAMPSIA WITH COMPLICATIONS REQUIRING VENTILATORY SUPPORT | 24975 |
CM0472 : ECLAMPSIA WITH COMPLICATIONS & HELLP SYNDROME | 20925 |
CM0473 : ABRUPTIO-PLACENTA WITH OUT COAGULATION DEFECTS (DIC) | 17595 |
CM0474 : ABRUPTIO-PLACENTA WITH COAGULATION DEFECTS (DIC) | 22995 |
CM0477 : SLINGS WITH MESH REPAIR FOR PROLAPSE | 16245 |
CM0478A : VAULT PROLAPSE ABDOMINAL REPAIR WITHOUT MESH | 14445 |
CM0478B : VAULT PROLAPSE ABDOMINAL REPAIR WITH MESH | 15345 |
CM0480 : LAPAROSCOPIC MYOMECTOMY | 18945 |
CM0481 A : RECANALISATION ANY TYPE- open | 13095 |
CM0481 B : RECANALISATION ANY TYPE- lap | 17145 |
CM0482 : STAGING LAPROTOMY FOR OVARIAN AND UTERINE CA | 24300 |
CM0484 : LAPAROSCOPIC SLING OPERATIONS | 21195 |
CM0485A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY | 17145 |
CM0485B : PPH SURGICAL MANAGEMENT -LIGATION/ EMBOLIZATION | 14445 |
CM0487 : ACUTE MI (CONSERVATIVE MANAGEMENT WITHOUT ANGIOGRAM) | 20000 |
CM0488 : ACUTE MI (CONSERVATIVE MANAGEMENT WITH ANGIOGRAM) | 30000 |
CM0489 : ACUTE MI WITH CARDIOGENIC SHOCK | 36000 |
CM0490 : ACUTE MI REQUIRING IABP PUMP | 54000 |
CM0491 : CONGESTIVE CARDIAC FAILURE | 50000 |
CM0492 : INFECTIVE ENDOCARDITIS | 30000 |
CM0493 : PULMONARY EMBOLISM | 40000 |
CM0494 : ARRYTHMIAS (SUPRAVENTRICULLAR / VENTRICULAR) - INVASIVE MANAGEMENT | 100000 |
CM0496 : PERICARDIAL EFFUSION/TAMPONADE | 30000 |
CM0497 : CARDIAC CATHETERISATION AND RIGHT & LEFT HEART STUDY | 15000 |
CM0498A : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - FOR SK | 24000 |
CM0498B : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - FOR RTPAS | 58000 |
CM0498-A : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - FOR SK | 14175 |
CM0498-B : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - FOR RTPAS | 44100 |
CM0499 : TENECTEPLASE/TPA ADDITIONAL FOR MI MANAGEMENT | 35000 |
CM0501 : ACUTE BRONCHITIS AND PNEUMONIA WITH RESPIRATORY FAILURE | 36000 |
CM0502 : REQUIRING VENTILATORY SUPPORT -OP POISIONING / METABOLIC COMA/SCORPION STING/ SNAKE BITE / BITES & STINGS - MAX 7 DAYS | 28350 |
CM0506 : CORROSIVE OESOPHAGEAL INJURY | 25335 |
CM0507 : ACUTE PANCREATITIS WITH PSEUDOCYST (INFECTED) | 27000 |
CM0508 : CHRONIC PANCREATITIS WITH SEVERE PAIN I) SEMS- SELF EXPANDABLE METALLIC STENT FOR BILIARY OBSTRUCTION (OBSTRUCTIVE JAUNDICE)- MALIGNANT/BENIGN | 63315 |
CM0509 : CHRONIC PANCREATITIS WITH SEVERE PAIN- II) ENDOSCOPIC PANCREATIC SPINCTEROTOMY AND /OR PANCREATIC DUCT STENTING | 15075 |
CM0510 : CHRONIC PANCREATITIS WITH SEVERE PAIN-PANCREATIC DUCT STENTING- PANCRETIC DUCT LEAKS, PSEUDOCYST OF PANCREAS, PANCREATIC STRICTURE, PANCREATIC STONE DISEASE | 15075 |
CM0511 : NON VARICEAL BLEED- HEATER PROBE (UPPER & LOWER GI BLEED) INCLUDES GAVE, ULCER, RADIATION PROCTITIS/COLITIS, POST POLYPECTOMY BLEED, DIEULAFOYS LESION, ANGIODYSPLASIA,MALLORY WEISS TEAR. | 14805 |
CM0515 : CHRONIC INFLAMMATORY DEMYELINATING POLY NEUROPATHY | 13095 |
CM0516A : HEMORRHAGIC STROKE | 27000 |
CM0516B : ISCHEMIC STROKE | 16200 |
CM0547A : RT. HEPATECTOMY. | 57150 |
CM0547B : NON ANATOMICAL RESECTION OF LIVER | 36000 |
CM0548A : LT. HEPATECTOMY | 57150 |
CM0548B : NON ANATOMICAL RESECTION OF LIVER | 36000 |
CM0549 : SPLENORENAL ANASTOMOSIS | 54000 |
CM0550 : SURGERY FOR BLEEDING ULCERS | 36000 |
CM0551 : I STAGE-SUB TOTAL COLECTOMY + ILEOSTOMY | 54000 |
CM0552 : II STAGE - J-POUCH | 31500 |
CM0553 : III STAGE-ILEOSTOMY CLOSURE | 19800 |
CM0554 A : HEPATICO JEJUNOSTOMY - BILIARY STRICTURE | 67500 |
CM0554 B : HEPATICO JEJUNOSTOMY - INJURY / EXTERNAL BILIARY FISTULA MANAGEMENT | 40500 |
CM0555A : BILIARY PANCREATITIS - CBD CALCULI - OTHER STENTS | 19800 |
CM0555B : BILIARY PANCREATITIS - CBD CALCULI - SEMS | 31500 |
CM0556 : REPAIR SURGERY FOR INJURIES DUE TO FB | 45000 |
CM0557A : SURGICAL REMOVAL OF FOREIGN BODY FROM GIT (INVASIVE) | 45000 |
CM0557B : SURGICAL REMOVAL OF FOREIGN BODY FROM GIT (NON INVASIVE ) | 18000 |
CM0558 : GASTRO STUDY FOLLOWED BY THORACOTOMY & SURGICAL MANAGEMENT FOR OESOPHAGEAL INJURY FOR CORROSIVE INJURIES/FB | 49950 |
CM0559 : HAEMANGIOMA SOL LIVER HEPATECTOMY + WEDGE RESECTION | 36000 |
CM0560 : LIENORENAL SHUNT | 54000 |
CM0563A : ANAL SPHINCTER RECONSTRUCTION | 31500 |
CM0563B : LEVATOROPLASTY | 36000 |
CM0564 : GRACILOPLASTY | 36000 |
CM0565 : BILIARY PERITONITIS -EMERGENCY LAPAROTOMY | 36000 |
CM0566 : SPLEEN SPARING DEVASCULARISATION | 36000 |
CM0567 : LIVER SEGMENTECTOMY | 40500 |
CM0568 : PORTOCAVAL ANASTOMOSIS | 72000 |
CM0569 : DEVASCULARISATION WITH OESOPHAGEAL TRANSECTION | 72000 |
CM0570 : WARREN SHUNT | 54000 |
CM0571 : PANCREAS DIVISUM | 27000 |
CM0573 A : CYSTOLITHOTRIPSY | 12600 |
CM0573 B : CYSTOLITHOTRIPSY - LASER LITHOTRIPSY | 15300 |
CM0573 C : RETROGRADE INTRARENAL SURGERY | 25200 |
CM0574 : PERCUTANEOUS NEPHROLITHOTOMY | 27900 |
CM0575 : EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY | 18000 |
CM0576 : URETERO RENOSCOPIC LITHOTRIPSY | 19800 |
CM0577 : SINGLE STAGE URETHROPLASTY FOR STRICTURE URETHRA | 41400 |
CM0578 : BUCCAL MUCOSAL GRAFT- URETHROPLASTY | 31500 |
CM0579 A : DOUBLE STAGE URETHROPLASTY FOR STRICTURE URETHRA - STAGE I | 22500 |
CM0579 B : DOUBLE STAGE URETHROPLASTY FOR STRICTURE URETHRA - STAGE II | 31500 |
CM0580 : DOUBLE STAGE URETHROPLASTY FOR STRICTURE URETHRA - RECONSTRUCTION PROCEDURE | 31500 |
CM0581 : ANATROPHIC PEYLOLITHOTOMY FOR STAGHORN CALCULUS | 40500 |
CM0582 A : RENAL CYST EXCISION - LAP | 22500 |
CM0582 B : RENAL CYST EXCISION - OPEN | 22500 |
CM0583 A : NEPHRECTOMY PYONEPHROSIS/XANTHO GRANULOMATOUS PYELONEPHRITIS - LAP | 36000 |
CM0583 B : NEPHRECTOMY PYONEPHROSIS/XANTHO GRANULOMATOUS PYELONEPHRITIS - OPEN | 36000 |
CM0584 : ENDOSCOPE REMOVAL OF STONE IN BLADDER | 12600 |
CM0585 : URETERIC INJURY REPAIR | 27000 |
CM0586 : BLADDER INJURY REPAIR | 27000 |
CM0587 : URETERIC REIMPLANTATION | 36000 |
CM0588 : VESICO VAGINAL FISTULA | 27000 |
CM0589 : CLOSURE OF URETHRAL FISTULA | 19800 |
CM0590 : OPTICAL URETHROTOMY | 22500 |
CM0591 : PERINEAL URETHROSTOMY | 18000 |
CM0592 : ANDERSON HYNES PYELOPLASTY | 31500 |
CM0593 A : CAECO CYSTOPLASTY / AUGMENTATION - CYSTOPLASTY | 28800 |
CM0593 B : BLADDER NECK INCISION (BNI) | 18000 |
CM0594 : SUPRA PUBLIC CYSTOSTOMY | 7200 |
CM0595 : DIVERTICULECTOMY /PERSISTENT URACHUS | 18000 |
CM0596 : URACHAL SINUS/TUMOR / EXCISION | 18000 |
CM0597 : INCONTINENCE URINE- (MALE)/ (FEMALE-INCLUDING CYSTOSCOPY OTIS URETHROTOMY) | 13500 |
CM0598 : TRANSURETHRAL RESECTION OF PROSTATE (TURP) | 24300 |
CM0599 : TURP WITH CYSTOLITHOTRIPSY | 25200 |
CM0600 : CHORDEE CORECTION | 13500 |
CM0601 : INFERIOR VENA CAVA STENTING SINGLE STENT | 110700 |
CM0602 : CORTICAL VENOUS SINUS THROMBOLYSIS | 67500 |
CM0603 : INTRA-ARTERIAL THROMBOLYSIS FOR ACUTE ISCHEMIC LIMBS | 66375 |
CM0604 : PERMANENT TUNNELED CATHETER PLACEMENT AS SUBSTITUTE FOR AV FISTULA IN LONG TERM DIALYSIS | 34650 |
CM0605 : STEREOTACTIC MAMMOGRAPHIC BIOPSY PROCEDURES | 11745 |
CM0606 : ENDOVASCULAR INTERVENTION FOR SALVAGING HEMODIALYSIS AV FISTULA | 91575 |
CM0607 : BALLOON RETROGRADE TRANSVENOUS OBLITERATION OF BLEEDING GASTRIC VARICES (BRTO) | 59625 |
CM0608 : PERCUTANEOUS VERTEBRO PLASTY/ CEMENTOPLASTY (FOR EACH LEVEL) | 42165 |
CM0609 : PTBD STENTING WITH OR WITHOUT DRAINAGE | 66600 |
CM0610 : TRANS JUGULAR LIVER BIOPSY | 37620 |
CM0611 : FLOW DIVERTOR FOR WIDE NECK ANEURYSM | 85725 |
CM0614-I : TRANSPLEURAL BPF CLOSURE | 38655 |
CM0615-I : CAROTID EMBOLECTOMY | 43965 |
CM0616-I : PULMONARY EMBOLECTOMY WITH IVC FILTER | 66150 |
CM0617-I : RENAL ANGIOPLASTY | 51075 |
CM0618-I : VERTERBRAL ANGIOPLASTY | 56475 |
CM0620-I : EXCISION OF TUMOR IN NASOPHARYNX( MALIGNANT) | 18810 |
CM0624-I : WERTHEIMS / RADICAL HYSTERECTOMY | 25695 |
CM0624-II : WERTHEIMS / RADICAL HYSTERECTOMY | 25695 |
CM0625-I : AMPUTATIONS - FORE QUARTER / HIND QUARTER WITH OR WITHOUT HEMIPELVECTOMY | 36000 |
CM0625-II : AMPUTATIONS - FORE QUARTER / HIND QUARTER WITH OR WITHOUT HEMIPELVECTOMY | 36000 |
CM0626 A : DENGUE SHOCK SYNDROME -(ADULT/PAEDIATRICS) | 19800 |
CM0626 B : DENGUE HEMORRHAGIC FEVER -(ADULT/PAEDIATRICS) | 16200 |
CM0628-I : NEPHROSTOMY | 7200 |
CM0628-II : NEPHROSTOMY | 7200 |
CM0629-I : OBSCURE/ NON VARICEAL BLEED- CLIPPING / ARGON PLASMA COAGULATION/ INJECTION/CONSERVATIVE | 41535 |
CM0629-II : OBSCURE/ NON VARICEAL BLEED- CLIPPING / ARGON PLASMA COAGULATION/ INJECTION/CONSERVATIVE | 41535 |
CM0630 A-II : MIXED CONNECTIVE TISSUE DISEASE-(METHOTREXATE OR AZATHIOPRINE OR HYDROXY CHLOROQUINE/ PULSE CYCLOPHOSPHAMIDE THERAPY | 14400 |
CM0631A-II : VASCULITIS (PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE/ PULSE CYCLOPHOSPHAMIDE THERAPY ) | 10800 |
CM0631B-II : VASCULITIS (PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE/ PULSE CYCLOPHOSPHAMIDE THERAPY / INTERNAL ORGAN INVOLVEMENT REQUIRING INTRAVENOUS IMMUNOGLOBULIN/ MYCOPHENOLATE MOFETIL INDUCTION/MYCOPHENOLATE MOFETIL MAINTENANCE/ PNEUMOCOCCAL VACCINATION) | 180000 |
CM0632-I : FULL THICKNESS BUCCAL MUCOSAL RESECTION & RECONSTRUCTION | 37665 |
CM0633-I : ORBITAL EXENTERATION/ EVISCERATION WITH IMPLANT | 21285 |
CM0635-I : OPEN PROSTATECTOMY | 27000 |
CM0635-II : OPEN PROSTATECTOMY | 27000 |
CM0636-I : RADICAL PROSTATECTOMY | 45000 |
CM0636-II : RADICAL PROSTATECTOMY | 45000 |
CM0637 : CT GUIDED MAJOR PROCEDURES (DRAINAGE PIGTAIL INSERTION) | 16605 |
CM0638-A : CT GUIDED MAJOR PROCEDURES ( RF - SOLID ORGANS) | 42750 |
CM0638-B : CT GUIDED MAJOR PROCEDURES ( RF - OTHER ORGANS) | 33750 |
CM0638-C : CT GUIDED MAJOR PROCEDURES (ETHANOL ABLATION - SOLID ORGANS) | 30150 |
CM0638-D : CT GUIDED MAJOR PROCEDURES (ETHANOL ABLATION - OTHER ORGANS) | 27000 |
CM0639-A : CT GUIDED MINOR PROCEDURES (FNAC, BIPOSY) | 6795 |
CM0639-B : CT GUIDED MINOR PROCEDURES (SINOGRAPHY) | 7695 |
CM0639-C : CT GUIDED MINOR PROCEDURES (TAPPING) | 9495 |
CM0640 : USG GUIDED MAJOR PROCEDURES ( EG. LIVER ABSCESS,POST OP COLLECTIONS)DRAINAGE PIGTAIL INSERTION | 8550 |
CM0641A-I : USG GUIDED MAJOR PROCEDURES (RF ABLATION Solid organs) | 26100 |
CM0641A-II : USG GUIDED MAJOR PROCEDURES (RF ABLATION Solid organs) | 26100 |
CM0641B-I : USG GUIDED MAJOR PROCEDURES (RF ABLATION other organs ) | 22500 |
CM0641B-II : USG GUIDED MAJOR PROCEDURES (RF ABLATION other organs ) | 22500 |
CM0641C-I : USG GUIDED MAJOR PROCEDURES (ETHANOL ABLATION Solid organs) | 19350 |
CM0641C-II : USG GUIDED MAJOR PROCEDURES (ETHANOL ABLATION Solid organs) | 19350 |
CM0641D-I : USG GUIDED MAJOR PROCEDURES (ETHANOL ABLATION other organs) | 35100 |
CM0641D-II : USG GUIDED MAJOR PROCEDURES (ETHANOL ABLATION other organs) | 35100 |
CM0642A-I : USG GUIDED MINOR PROCEDURES (FNAC & BIPOSY) | 1350 |
CM0642A-II : USG GUIDED MINOR PROCEDURES (FNAC & BIPOSY) | 1350 |
CM0642B-I : USG GUIDED MINOR PROCEDURES (SINOGRAPHY) | 1800 |
CM0642B-II : USG GUIDED MINOR PROCEDURES (SINOGRAPHY) | 1800 |
CM0642C-I : USG GUIDED MINOR PROCEDURES (TAPPING) | 1350 |
CM0642C-II : USG GUIDED MINOR PROCEDURES (TAPPING) | 1350 |
CM0643-I : RENAL ARTERY EMBOLIZATION WITH MULTIPLE COILS AND MICRO CATHETER | 85725 |
CM0644-I : EMBOLIZATION OF AV MALFORMATION OF PERIPHERAL EXTREMITY, CRANIOFACIAL AND VISCERAL PER SITTING | 60075 |
CM0645-I : GASTROINTESTINAL VISCERAL ARTERIAL EMBOLIZATION IN UPPER AND LOWER GASTROINTESTINAL BLEEDING WITH MICROCATHETER | 68625 |
CM0645-III : GASTROINTESTINAL VISCERAL ARTERIAL EMBOLIZATION IN UPPER AND LOWER GASTROINTESTINAL BLEEDING WITH MICROCATHETER | 68625 |
CM0646-I : BRONCHIAL ARTERY EMBOLIZATION IN HEMOPTYSIS USING PVA AND MICRO CATHETER | 50175 |
CM0647-I : EMBOLIZATION OF POSTOPERATIVE/ POST TRAUMATIC BLEEDING | 73575 |
CM0648-I : UTERINE ARTERY EMBOLIZATION IN SEVERE MENORRHAGIA SECONDARY TO PPH/UTERINE FIBROIDS / AVM | 47475 |
CM0649-I : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS | 63225 |
CM0649-III : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS | 63225 |
CM0650-I : EMBOLIZATION OF PULMONARY AV MALFORMATION | 65925 |
CM0651-I : EMBOLIZATION OF AV MALFORMATION OF BRAIN PER SITTING WITH ONYX | 68625 |
CM0651-II : EMBOLIZATION OF AV MALFORMATION OF BRAIN PER SITTING WITH ONYX | 68625 |
CM0652-I : EMBOLIZATION OF CARATICO-CAVERNOUS FISTULA | 83475 |
CM0652-III : EMBOLIZATION OF CARATICO-CAVERNOUS FISTULA | 83475 |
CM0653-I : PLAIN SIMPLE COILING OF ANEURYSM | 42975 |
CM0654-I : BRAIN AVM EMBOLIZATION | 87975 |
CM0654-III : BRAIN AVM EMBOLIZATION | 87975 |
CM0655-I : TUMOR EMBOLIZATION | 75375 |
CM0655-III : TUMOR EMBOLIZATION | 75375 |
CM0656-I : PERIPHERAL AVM EMBOLIZATION | 69075 |
CM0657-I : TRANS ARTERIAL CHEMOEMBOLIZATION | 82575 |
CM0658-I : HEAD AND NECK TUMOR EMBOLIZATION | 66375 |
CM0659-I : PSEUDOANEURYSM EMBOLIZATION | 41175 |
CM0660-I : PROSTATIC ARTERY EMBOLIZATION | 38925 |
CM0661-A-I : SPINAL AVM EMBOLIZATION | 43875 |
CM0661-A-II : SPINAL AVM EMBOLIZATION | 43875 |
CM0661-A-III : SPINAL AVM EMBOLIZATION | 43875 |
CM0661-B-I : SPINAL AVM EMBOLIZATION | 52875 |
CM0661-B-II : SPINAL AVM EMBOLIZATION | 52875 |
CM0661-B-III : SPINAL AVM EMBOLIZATION | 52875 |
CM0662-I : SPINAL DURAL FISTULA EMBOLIZATION | 55575 |
CM0662-II : SPINAL DURAL FISTULA EMBOLIZATION | 55575 |
CM0662-III : SPINAL DURAL FISTULA EMBOLIZATION | 55575 |
CM0663 : BALLOON RETERO GRADE VARICEAL EMBOLIZATION | 51075 |
CM0664-I : LIVER HEMANGIOMA EMBOLIZATION | 72675 |
CM0664-II : LIVER HEMANGIOMA EMBOLIZATION | 72675 |
CM0665-I : VEIN OF GALEN EMBOLIZATION | 59625 |
CM0665-II : VEIN OF GALEN EMBOLIZATION | 59625 |
CM0666-I : DURAL FISTULA EMBOLIZATION | 73125 |
CM0666-II : DURAL FISTULA EMBOLIZATION | 73125 |
CM0667 : RF ABLATION OF OSTEOID OSTEOMA | 48375 |
CM0668-I : SUPERFICIAL FEMORAL ARTERY ANGIOPLASTY ANY STENTING | 96525 |
CM0669-I : FISTULA SALVAGE ANGIOPLASTY | 65925 |
CM0670-I : CAROTID ARTERY STENTING WITH EMBOLIC PROTECTION DEVICE | 119475 |
CM0671-I : ILIAC / IVC STENTING / HIGH END VASCULAR REVASCULARISATION PROCEDURE | 99225 |
CM0672-I : VENOUS / POLY TETRA FLUORO ETHYLENE PATCH ANGIOPLASTY | 51525 |
CM0673-I : SUBCLAVIAN, ILIAC, SUPERFICIAL FEMORAL ARTERY STENTING EACH WITH ONE STENT | 94275 |
CM0674-I : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA | 83925 |
CM0675-I : MESENTERIC ARTERY ANGIOPLASTY & STENTING IN ACUTE & CHRONIC MESENTERIC ISCHEMIA - SINGLE STENT | 83925 |
CM0676-I : CENTRAL VENOUS STENTING FOR CENTRAL VENOUS OCCLUSION (BRACHIOCEPHALIC, SUBCLAVIAN VEIN AND SUP VENA CAVA) SINGLE METALLIC STENT | 88425 |
CM0677-I : INTRACRANIAL VENOUS STENTING | 110925 |
CM0677-II : INTRACRANIAL VENOUS STENTING | 110925 |
CM0678-I : INTRACRANIAL ARTERIAL STENTING | 110925 |
CM0678-II : INTRACRANIAL ARTERIAL STENTING | 110925 |
CM0679-I : PERIPHERAL STENT GRAFT FOR PERIPHERAL ANEURYSMS AND AV FISTULA | 110925 |
CM0680-I : PERIPHERAL ANGIOPLASTY | 52425 |
CM0681-I : PERIPHERAL ANGIOPLASTY AND STENTING | 56925 |
CM0682-I : SVC ANGIOPLASTY AND STENTING | 94950 |
CM0683-I : IVC ANGIOPLASTY | 57150 |
CM0684-I : IVC ANGIOPLASTY AND STENTING | 98550 |
CM0685-I : BELOW KNEE ANGIOPLASTY | 47925 |
CM0686-I : SUBCLAVIAN ANGIOPLASTY STENTING | 97875 |
CM0687-I : RENAL ANGIOPLASTY STENTING | 53775 |
CM0688-I : DURAL SINUS ANGIOPLASTY AND STENTING | 59175 |
CM0688-II : DURAL SINUS ANGIOPLASTY AND STENTING | 59175 |
CM0689-I : HEPATIC VEIN ANGIOPLASTY AND STENTING | 47475 |
CM0689-II : HEPATIC VEIN ANGIOPLASTY AND STENTING | 47475 |
CM0690-I : CENTRAL VEIN STENOSIS ANGIOPLASTY | 94500 |
CM0691-A : RF ABLATION OF TUMOR | 35325 |
CM0691-B : RF ABLATION OF TUMOR | 30825 |
CM0692-I : ACUTE STROKE THROMBOLYSIS (R TPA ) | 67725 |
CM0693-I : INFERIOR VENA CAVA FILTER PLACEMENT | 70650 |
CM0694-I : BILIARY DRAINAGE PROCEDURES/ERCP - EXTERNAL DRAINAGE AND STENT PLACEMENT - METALLIC BILIARY STENT / POST OP BILIARY STRICTURE/LEAK/CHOLANGITIS/BILIARY PANCREATITIS/CHOLEDOCHAL CYST/BILE DUCT STONES | 84105 |
CM0694-II : BILIARY DRAINAGE PROCEDURES/ERCP - EXTERNAL DRAINAGE AND STENT PLACEMENT - METALLIC BILIARY STENT / POST OP BILIARY STRICTURE/LEAK/CHOLANGITIS/BILIARY PANCREATITIS/CHOLEDOCHAL CYST/BILE DUCT STONES | 84105 |
CM0695-I : CAROTID STENTING SINGLE STENT WITH EMBOLIC PROTECTION DEVICE | 101475 |
CM0696 : CT GUIDED NERVE BLOCK (COELIAC PLEXUS, HYPOGASTRIC PLEXUS, STELLATE GANGLION, GASSERIAN GANGLION, MANDIBULAR NERVE, MAXILLARY NERVE, SELECTIVE NERVE ROOT, LUMBAR SYMPATHETIC PLEXUS, GANGLION IMPAR, SACRO ILIAC JOINT INFECTION, EPIDURAL STEROID, FACET JOINT, SPHENOPALATINE GANGLION, OCCIPITAL NERVE, GLOSSOPHARYNGEAL NERVE, THORACIC SYMPATHETIC, INTERCOSTAL NERVE, SPLANCHNIC NERVE, PIRIFORMIS INJECTION) | 22725 |
CM0697 : USG GUIDED NERVE BLOCK (COELIAC PLEXUS, HYPOGASTRIC PLEXUS, STELLATE GANGLION, GASSERIAN GANGLION, MANDIBULAR NERVE, MAXILLARY NERVE, SELECTIVE NERVE ROOT, LUMBAR SYMPATHETIC PLEXUS, GANGLION IMPAR, SACRO ILIAC JOINT INFECTION, EPIDURAL STEROID, FACET JOINT, SPHENOPALATINE GANGLION, OCCIPITAL NERVE, GLOSSOPHARYNGEAL NERVE, THORACIC SYMPATHETIC, INTERCOSTAL NERVE, SPLANCHNIC NERVE, PIRIFORMIS INJECTION) | 18225 |
CM0698 : C-ARM GUIDED NERVE BLOCK (COELIAC PLEXUS, HYPOGASTRIC PLEXUS, STELLATE GANGLION, GASSERIAN GANGLION, MANDIBULAR NERVE, MAXILLARY NERVE, SELECTIVE NERVE ROOT, LUMBAR SYMPATHETIC PLEXUS, GANGLION IMPAR, SACRO ILIAC JOINT INFECTION, EPIDURAL STEROID, FACET JOINT, SPHENOPALATINE GANGLION, OCCIPITAL NERVE, GLOSSOPHARYNGEAL NERVE, THORACIC SYMPATHETIC, INTERCOSTAL NERVE, SPLANCHNIC NERVE, PIRIFORMIS INJECTION) | 20475 |
CM0699 : CT GUIDED RF ABLATION (COELIAC PLEXUS, HYPOGASTRIC PLEXUS, STELLATE GANGLION, GASSERIAN GANGLION, MANDIBULAR NERVE, MAXILLARY NERVE, SELECTIVE NERVE ROOT, LUMBAR SYMPATHETIC PLEXUS, GANGLION IMPAR, SACRO ILIAC JOINT INFECTION, FACET JOINT, SPHENOPALATINE GANGLION, OCCIPITAL NERVE, GLOSSOPHARYNGEAL NERVE, THORACIC SYMPATHETIC, INTERCOSTAL NERVE, SPLANCHNIC NERVE)/ | 33525 |
CM0700 : USG GUIDED RF ABLATION (COELIAC PLEXUS, HYPOGASTRIC PLEXUS, STELLATE GANGLION, GASSERIAN GANGLION, MANDIBULAR NERVE, MAXILLARY NERVE, SELECTIVE NERVE ROOT, LUMBAR SYMPATHETIC PLEXUS, GANGLION IMPAR, SACRO ILIAC JOINT INFECTION, FACET JOINT, SPHENOPALATINE GANGLION, OCCIPITAL NERVE, GLOSSOPHARYNGEAL NERVE, THORACIC SYMPATHETIC, INTERCOSTAL NERVE, SPLANCHNIC NERVE)/ | 24525 |
CM0701 : C-ARM GUIDED RF ABLATION (COELIAC PLEXUS, HYPOGASTRIC PLEXUS, STELLATE GANGLION, GASSERIAN GANGLION, MANDIBULAR NERVE, MAXILLARY NERVE, SELECTIVE NERVE ROOT, LUMBAR SYMPATHETIC PLEXUS, GANGLION IMPAR, SACRO ILIAC JOINT INFECTION, FACET JOINT, SPHENOPALATINE GANGLION, OCCIPITAL NERVE, GLOSSOPHARYNGEAL NERVE, THORACIC SYMPATHETIC, INTERCOSTAL NERVE, SPLANCHNIC NERVE)/ | 24525 |
CM0702 : PREOPERATIVE PROPHYLACTIC TUMOR EMBOLISATION | 65925 |
CM0703 : IMMUNOGLOBULIN THERAPY - HEREDITARY MOTOR SENSORY NEUROPATHIES/HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY/PLEXOPATHY (LUMBOSACRAL/ BRACHIAL)/PERIPHERAL NEUROPATHY (WITH NERVE BIOPSY) (HANSEN, NUTRITIONAL, TOXIC, INFECTIVE, IMMUNE)/CARPAL TUNNEL SYNDROME/ACUTE ENTRAPMENT/ COMPRESSIVE NEUROPATHY / GBS/DOG BITE CATEGORY III/OTHERS | 200000 |
CM0704 : RECONSTRUCTIVE MICRO SURGERY - REPLANTATION OF HAND, FINGER, THUMB, ARM, SCALP ETC | 45720 |
CM0705 : RECONSTRUCTIVE MICRO SURGERY -FREE TISSUE TRANSFER | 61110 |
CM0706-I : EXCISION OF LINGUAL THYROID | 18495 |
CM0707-I : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS | 50355 |
CM0707-II : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS | 50355 |
CM0709 A-I : LAP NEPHRECTOMY SIMPLE/HEMI/PARTIAL. | 40500 |
CM0709 A-II : LAP NEPHRECTOMY SIMPLE/HEMI/PARTIAL. | 40500 |
CM0709 A-III : LAP NEPHRECTOMY SIMPLE/HEMI/PARTIAL. | 40500 |
CM0709 B-I : LAP NEPHRECTOMY-RADICAL | 40500 |
CM0709 B-II : LAP NEPHRECTOMY-RADICAL | 40500 |
CM0709 B-III : LAP NEPHRECTOMY-RADICAL | 40500 |
CM0710 A-I : NEPHROURETERECTOMY OPEN | 36000 |
CM0710 A-II : NEPHROURETERECTOMY OPEN | 36000 |
CM0710 B-I : NEPHROURETERECTOMY LAP | 36000 |
CM0710 B-II : NEPHROURETERECTOMY LAP | 36000 |
CM0713-I : TRACHEOSTOMY | 4545 |
CM0714-I : THOROCOSTOMY | 39060 |
CM0715 : CLEFT LIP | 14490 |
CM0716 : CLEFT PALATE | 18090 |
CM0717 : SYNDACTYLY OF HAND FOR EACH HAND | 23940 |
CM0718A : MICROTIA/ANOTIA - STAGE 1 | 22860 |
CM0718B : MICROTIA/ANOTIA - STAGE 2 | 15840 |
CM0719 : TM JOINT ANKYLOSIS | 36000 |
CM0720 : RECONSTRUCTIVE MICRO SURGERY -BRACHIAL PLEXUS SURGERY | 22500 |
CM0721 : RECONSTRUCTIVE BREAST SURGERY FOLLOWING CANCER EXCISION, REDUCTION, AUGMENTATION | 36360 |
CM0722-II : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE, MAXILLA | 18045 |
CM0722-III : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE, MAXILLA | 18045 |
CM0723-I : HEAD & NECK CANCER COMPOSITE RESECTION | 33615 |
CM0724-I : HEAD & NECK CANCER COMPOSITE RESECTION WITH RECONSTRUCTION | 42165 |
CM0725-I : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION | 22185 |
CM0725-II : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION | 22185 |
CM0725-III : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION | 22185 |
CM0725-IV : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION | 22185 |
CM0727-II : TRACHEO OESOPHAGEAL FISTULA - REPAIR / RECONSTRUCTION | 37665 |
CM0728-II : OESOPHAGEAL GROWTH / FISTULA / STRICTURE / PERFORATION / LUMINAL STENTING | 64665 |
CM0729-II : DIAPHRAGMATIC HERNIA | 36000 |
CM0730 A-I : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L OPEN | 36000 |
CM0730 A-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L OPEN | 36000 |
CM0730 A-III : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L OPEN | 36000 |
CM0730 B-I : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L LAP | 36000 |
CM0730 B-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L LAP | 36000 |
CM0730 B-III : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L LAP | 36000 |
CM0730 C-I : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L OPEN | 49500 |
CM0730 C-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L OPEN | 49500 |
CM0730 C-III : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L OPEN | 49500 |
CM0730 D-I : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L LAP | 49500 |
CM0730 D-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L LAP | 49500 |
CM0730 D-III : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L LAP | 49500 |
CM0731-I : HYPOSPADIAS | 27000 |
CM0731-II : HYPOSPADIAS | 27000 |
CM0732-I : EPISPADIAS | 37800 |
CM0732-II : EPISPADIAS | 37800 |
CM0733-I : TORSION TESTIS | 22500 |
CM0733-II : TORSION TESTIS | 22500 |
CM0734-I : URETEROCELE SURGERY | 27000 |
CM0734-II : URETEROCELE SURGERY | 27000 |
CM0735 A-I : OPEN CHOLECYSTECTOMY- RADICAL WITH OR WITHOUT CBD EXPLORATION | 45000 |
CM0735 A-II : OPEN CHOLECYSTECTOMY- RADICAL WITH OR WITHOUT CBD EXPLORATION | 45000 |
CM0735 B-I : OPEN CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION | 19800 |
CM0735 B-II : OPEN CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION | 19800 |
CM0736 A-I : LAP CHOLECYSTECTOMY- RADICAL WITH /WITHOUT CBD EXPLORATION | 45000 |
CM0736 A-II : LAP CHOLECYSTECTOMY- RADICAL WITH /WITHOUT CBD EXPLORATION | 45000 |
CM0736 B-I : LAP CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION | 19800 |
CM0736 B-II : LAP CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION | 19800 |
CM0737-I : LAP CHOLECYSTOSTOMY WITH /WITHOUT EXPLORATION CBD | 19800 |
CM0737-II : LAP CHOLECYSTOSTOMY WITH /WITHOUT EXPLORATION CBD | 19800 |
CM0738-I : OPEN CHOLECYSTOSTOMY | 18000 |
CM0738-II : OPEN CHOLECYSTOSTOMY | 18000 |
CM0739-I : GASTRECTOMY ANY TYPE - ANY CAUSE | 35865 |
CM0739-II : GASTRECTOMY ANY TYPE - ANY CAUSE | 35865 |
CM0739-III : GASTRECTOMY ANY TYPE - ANY CAUSE | 35865 |
CM0740-I : GASTRECTOMY ANY TYPE - ANY CAUSE WITH LYMPHADENECTOMY | 43965 |
CM0740-II : GASTRECTOMY ANY TYPE - ANY CAUSE WITH LYMPHADENECTOMY | 43965 |
CM0740-III : GASTRECTOMY ANY TYPE - ANY CAUSE WITH LYMPHADENECTOMY | 43965 |
CM0741-A : PENECTOMY- PARTIAL WITHOUT PERINEAL URETHEROSTOMY -CA | 14040 |
CM0741-B : PENECTOMY- Total WITHOUT PERINEAL URETHEROSTOMY -CA | 21915 |
CM0742A : PENECTOMY- PARTIAL WITH PERINEAL URETHEROSTOMY -CA | 26595 |
CM0742B : PENECTOMY- TOTAL WITH PERINEAL URETHEROSTOMY -CA | 35865 |
CM0743-I : ANTERIOR RESECTION | 45765 |
CM0743-II : ANTERIOR RESECTION | 45765 |
CM0743-III : ANTERIOR RESECTION | 45765 |
CM0744-A-I : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH | 22095 |
CM0744-A-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH | 22095 |
CM0744-A-III : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH | 22095 |
CM0744-B-I : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH /ILEOSTOMY | 44145 |
CM0744-B-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH /ILEOSTOMY | 44145 |
CM0744-B-III : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH /ILEOSTOMY | 44145 |
CM0744-C-I : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH/ WITH STAPLED ANASTOMOSIS | 67095 |
CM0744-C-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH/ WITH STAPLED ANASTOMOSIS | 67095 |
CM0744-C-III : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH/ WITH STAPLED ANASTOMOSIS | 67095 |
CM0745-I : ABDOMINOPERINIAL RESECTION | 35415 |
CM0745-II : ABDOMINOPERINIAL RESECTION | 35415 |
CM0745-III : ABDOMINOPERINIAL RESECTION | 35415 |
CM0746A-I : SPLENECTOMY WITHOUT DEVASCULARISATION -TRAUMATIC | 31500 |
CM0746A-II : SPLENECTOMY WITHOUT DEVASCULARISATION -TRAUMATIC | 31500 |
CM0749A-I : NECK DISSECTION ANY TYPE - WITH WIDE EXCISION (INCLUDING MALIGNANCY) | 27315 |
CM0749A-II : NECK DISSECTION ANY TYPE - WITH WIDE EXCISION (INCLUDING MALIGNANCY) | 27315 |
CM0749B-I : NECK DISSECTION ANY TYPE - WITHOUT WIDE EXCISION (INCLUDING MALIGNANCY) | 18315 |
CM0749B-II : NECK DISSECTION ANY TYPE - WITHOUT WIDE EXCISION (INCLUDING MALIGNANCY) | 18315 |
CM0750-A-I : NECK DISSECTION ANY TYPE - WITHOUT RECONSTRUCTION (INCLUDING MALIGNANCY) | 23265 |
CM0750-A-II : NECK DISSECTION ANY TYPE - WITHOUT RECONSTRUCTION (INCLUDING MALIGNANCY) | 23265 |
CM0750-B-I : NECK DISSECTION ANY TYPE - WITH RECONSTRUCTION (INCLUDING MALIGNANCY) | 31365 |
CM0750-B-II : NECK DISSECTION ANY TYPE - WITH RECONSTRUCTION (INCLUDING MALIGNANCY) | 31365 |
CM0751-I : HEMIMANDIBULECTOMY | 22635 |
CM0751-IV : HEMIMANDIBULECTOMY | 22635 |
CM0752-I : MARGINAL MANDIBULECTOMY | 20205 |
CM0752-IV : MARGINAL MANDIBULECTOMY | 20205 |
CM0753-I : SEGMENTAL MANDIBULECTOMY | 20205 |
CM0753-IV : SEGMENTAL MANDIBULECTOMY | 20205 |
CM0754 : LEIOMYOMA EXCISION | 10800 |
CM0755 : MULTI ORGAN RESECTION FOR ANY GI CANCERS | 60525 |
CM0756 : SURGERIES FOR ENTERO CUTANEOUS FISTULA | 36000 |
CM0757 : INCISIONAL HERNIA REPAIR WITHOUT MESH | 18000 |
CM0758 : INCISIONAL HERNIA REPAIR WITH MESH | 22500 |
CM0759A-i : CRANIOSYNOSTOSIS - STRIP CRANIECTOMY | 18000 |
CM0759A-ii : CRANIOSYNOSTOSIS - ORBITO FACIAL ADVANCEMENT | 13500 |
CM0759A-iii : CRANIOSYNOSTOSIS - PLASTIC SURGICAL CORRECTION | 13500 |
CM0759B-i : CRANIOSYNOSTOSIS - STRIP CRANIECTOMY | 18000 |
CM0759B-ii : CRANIOSYNOSTOSIS - ORBITO FACIAL ADVANCEMENT | 13500 |
CM0759B-iii : CRANIOSYNOSTOSIS - PLASTIC SURGICAL CORRECTION | 13500 |
CM0760-I : LIVER ABSCESS - OPEN DRAINAGE | 16200 |
CM0760-II : LIVER ABSCESS - OPEN DRAINAGE | 16200 |
CM0761 : BRAIN - ANY BIOPSY | 44973 |
CM0762 : SPINAL VASCULAR MALFORMATION (CONVENTIONAL/INTERVENTIONAL) | 40095 |
CM0763A-I : RECTAL PROLAPSE - THEIRSCH WIRING | 13500 |
CM0763A-II : RECTAL PROLAPSE - THEIRSCH WIRING | 13500 |
CM0763B-I : RECTAL PROLAPSE - DEBULKING | 23400 |
CM0763B-II : RECTAL PROLAPSE - DEBULKING | 23400 |
CM0763C-I : RECTAL PROLAPSE - LAPAROSCOPIC RECTOPEXY | 23400 |
CM0763C-II : RECTAL PROLAPSE - LAPAROSCOPIC RECTOPEXY | 23400 |
CM0764B : SPLENECTOMY WITH DEVASCULARISATION -TRAUMATIC | 34200 |
CM0764 : GLOSSECTOMY (TOTAL/HEMI/PARTIAL) FOR CANCER | 17550 |
CM0765 : GLOSSECTOMY (TOTAL/HEMI/PARTIAL) WITH RECONSTRUCTION- FOR CANCER | 35865 |
CM0766 : MAXILLECTOMY ANY TYPE -FOR CA | 22500 |
CM0767 : PAROTIDECTOMY ANY TYPE- FOR CA | 17550 |
CM0768 : LARYNGECTOMY ANY TYPE -FOR CA | 32625 |
CM0769-I : LARYNGO PHARYNGO OESOPHAGECTOMY | 66600 |
CM0770 A-I : TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE | 37800 |
CM0770 A-II : TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE | 37800 |
CM0770 A-III : TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE | 37800 |
CM0770 B-I : SUB TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE | 29700 |
CM0770 B-II : SUB TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE | 29700 |
CM0770 B-III : SUB TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE | 29700 |
CM0771-I : WHIPPLES ANY TYPE | 74250 |
CM0771-II : WHIPPLES ANY TYPE | 74250 |
CM0771-III : WHIPPLES ANY TYPE | 74250 |
CM0772A-I : OPEN CYSTECTOMY(/PARTIAL/ COMPLETE) WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE | 31500 |
CM0772A-II : OPEN CYSTECTOMY(/PARTIAL/ COMPLETE) WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE | 31500 |
CM0772A-III : OPEN CYSTECTOMY(/PARTIAL/ COMPLETE) WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE | 31500 |
CM0772B-I : OPEN CYSTECTOMY(RADICAL )WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE | 40500 |
CM0772B-II : OPEN CYSTECTOMY(RADICAL )WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE | 40500 |
CM0772B-III : OPEN CYSTECTOMY(RADICAL )WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE | 40500 |
CM0773 A-I : LAPAROSCOPIC CYSTECTOMY [PARTIAL / COMPLETE] WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE | 31500 |
CM0773 A-II : LAPAROSCOPIC CYSTECTOMY [PARTIAL / COMPLETE] WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE | 31500 |
CM0773 B-I : LAPAROSCOPIC CYSTECTOMY [RADICAL ]WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE | 40500 |
CM0773 B-II : LAPAROSCOPIC CYSTECTOMY [RADICAL ]WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE | 40500 |
CM0774 : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY | 18045 |
CM0775-I : SALPINGO OOPHORECTOMY U/L OR B/L- FOR CA | 22815 |
CM0775-II : SALPINGO OOPHORECTOMY U/L OR B/L- FOR CA | 22815 |
CM0776-I : MASTECTOMY ANY TYPE | 18000 |
CM0776-II : MASTECTOMY ANY TYPE | 18000 |
CM0777-A-I : MASTECTOMY ANY TYPE WITH AXILLARY DISSECTION | 22500 |
CM0777-A-II : MASTECTOMY ANY TYPE WITH AXILLARY DISSECTION | 22500 |
CM0777-B-I : MASTECTOMY ANY TYPE WITH SENTINAL NODE EXPLORATION | 22500 |
CM0777-B-II : MASTECTOMY ANY TYPE WITH SENTINAL NODE EXPLORATION | 22500 |
CM0778-A-I : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST -BENIGN | 4410 |
CM0778-A-II : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST -BENIGN | 4410 |
CM0778-B-I : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST (MALIGNANT) | 5850 |
CM0778-B-II : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST (MALIGNANT) | 5850 |
CM0785-I : METASTATECTOMY SOLITARY OR MULTIPLE - ANY CAUSE | 33615 |
CM0785-II : METASTATECTOMY SOLITARY OR MULTIPLE - ANY CAUSE | 33615 |
CM0786-A-I : OPERATIONS OF ADRENAL GLAND - U/L( ANY CAUSE) | 22455 |
CM0786-A-II : OPERATIONS OF ADRENAL GLAND - U/L( ANY CAUSE) | 22455 |
CM0786-B-I : OPERATIONS OF ADRENAL GLAND - B/L ( ANY CAUSE) | 40635 |
CM0786-B-II : OPERATIONS OF ADRENAL GLAND - B/L ( ANY CAUSE) | 40635 |
CM0787 : TEMPORAL BONE - EXCISION / RESECTION - ANY TYPE | 31500 |
CM0789-I : STERNOTOMY + MEDIASTINAL DISSECTION - CA / SOL | 37395 |
CM0795-I : PARATHYROIDECTOMY - ANY TYPE | 22500 |
CM0796-I : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - SMALL INTESTINE- ANY CAUSE | 36000 |
CM0796-II : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - SMALL INTESTINE- ANY CAUSE | 36000 |
CM0796-III : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - SMALL INTESTINE- ANY CAUSE | 36000 |
CM0797-I : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - LARGE INTESTINE- ANY CAUSE | 40500 |
CM0797-II : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - LARGE INTESTINE- ANY CAUSE | 40500 |
CM0797-III : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - LARGE INTESTINE- ANY CAUSE | 40500 |
CM0798-I : GASTROSTOMY/FEEDING GASTROSTOMY/PERCUTANEOUS ENDOSCOPIC GASTROSTOMY | 18000 |
CM0798-II : GASTROSTOMY/FEEDING GASTROSTOMY/PERCUTANEOUS ENDOSCOPIC GASTROSTOMY | 18000 |
CM0798-III : GASTROSTOMY/FEEDING GASTROSTOMY/PERCUTANEOUS ENDOSCOPIC GASTROSTOMY | 18000 |
CM0799-I : OESOPHAGOSTOMY | 22500 |
CM0799-II : OESOPHAGOSTOMY | 22500 |
CM0800-I : JEJUNOSTOMY / FEEDING JEJUNOSTOMY | 18000 |
CM0800-II : JEJUNOSTOMY / FEEDING JEJUNOSTOMY | 18000 |
CM0801-I : GASTROJEJUNOSTOMY | 22500 |
CM0801-II : GASTROJEJUNOSTOMY | 22500 |
CM0802-I : ILEOSTOMY | 18000 |
CM0802-II : ILEOSTOMY | 18000 |
CM0803 A-I : ILEOTRANSVERSE COLOSTOMY | 22500 |
CM0803 A-II : ILEOTRANSVERSE COLOSTOMY | 22500 |
CM0803 A-III : ILEOTRANSVERSE COLOSTOMY | 22500 |
CM0803 B-I : COLOSTOMY | 18000 |
CM0803 B-II : COLOSTOMY | 18000 |
CM0803 B-III : COLOSTOMY | 18000 |
CM0804-I : HARTMANNS PROCEDURE WITH COLOSTOMY- ANY CAUSE | 40500 |
CM0804-II : HARTMANNS PROCEDURE WITH COLOSTOMY- ANY CAUSE | 40500 |
CM0805-I : CLOSURE OF GASTROSTOMY/ILEOSTOMY/COLOSTOMY / JEJUNOSTOMY / GASTROJEJUNOSTOMY / ILEOTRANSVERSE COLOSTOMY / OESOPHAGOSTOMY | 18000 |
CM0805-II : CLOSURE OF GASTROSTOMY/ILEOSTOMY/COLOSTOMY / JEJUNOSTOMY / GASTROJEJUNOSTOMY / ILEOTRANSVERSE COLOSTOMY / OESOPHAGOSTOMY | 18000 |
CM0805-III : CLOSURE OF GASTROSTOMY/ILEOSTOMY/COLOSTOMY / JEJUNOSTOMY / GASTROJEJUNOSTOMY / ILEOTRANSVERSE COLOSTOMY / OESOPHAGOSTOMY | 18000 |
CM0806-I : RESECTION OF RETRO PERITONEAL TUMORS | 40095 |
CM0806-II : RESECTION OF RETRO PERITONEAL TUMORS | 40095 |
CM0807 : BONE RESECTION / CURRETTAGE/ CEMENTING- ANY CAUSE | 27000 |
CM0808A : URINARY DIVERSION PROCEDURES ( INCLUDING PERCUTANEOUS / ANTEGRADE/RETROGRADE URETERIC STENTING ) | 27000 |
CM0808B : URINARY DIVERSION PROCEDURES ( NEPHROSTOMY) | 7200 |
CM0809 : SUPRA PUBIC CYSTOSTOMY | 7200 |
CM0810-II : INTERCOSTAL DRAINAGE | 3690 |
CM0811 : CRYOTHERAPY FOR ALL LESIONS | 20475 |
CM0812A-i : NERVE RECONSTRUCTION ( WITH NERVE GRAFT ) | 31500 |
CM0812A-ii : NERVE REPAIR NEUROLYSIS | 18000 |
CM0812A-iii : NERVE REPAIR NERVE SUTURING | 18000 |
CM0812B-i : PERIPHERAL NERVE REPAIR | 18000 |
CM0812B-ii : PERIPHERAL NERVE RECONSTRUCTION ( WITH NERVE GRAFT ) | 31500 |
CM0812B-iii : TENDON REPAIR | 9000 |
CM0812B-iv : TENDON RECONSTRUCTION ( WITH TENDON GRAFT) | 18000 |
CM0813 : VAGINAL ATRESIA - (INCLUDING MC INDO-S REPAIR / PLASTIC SURGICAL REPAIR) | 26325 |
CM0814-II : VASCULAR MALFORMATIONS- (INCLUDING SCLEROTHERAPY/ REDUCTION SURGERY) | 23625 |
CM0815A : RECONSTRUCTIVE UPPER LIMB /HAND/LOWER LIMB/FOOT SURGERY FOLLOWING INFECTION, TRAUMA, BURNS, TUMORS/ MALIGNANCY, DEVELOPMENTAL INCLUDING DIABETIC FOOT - MILD | 23445 |
CM0815B : RECONSTRUCTIVE UPPER LIMB /HAND/LOWER LIMB/FOOT SURGERY FOLLOWING INFECTION, TRAUMA, BURNS, TUMORS/ MALIGNANCY, DEVELOPMENTAL INCLUDING DIABETIC FOOT - MODERATE | 31095 |
CM0815C : RECONSTRUCTIVE UPPER LIMB /HAND/LOWER LIMB/FOOT SURGERY FOLLOWING INFECTION, TRAUMA, BURNS, TUMORS/ MALIGNANCY, DEVELOPMENTAL INCLUDING DIABETIC FOOT - SEVERE | 34695 |
CM0816A : FLAP SURGERIES CUTANEOUS- FOR UPPER LIMB/HAND/LOWER LIMB/FOOT /AFTER FRACTURE FIXATION / ELETRICAL BURNS WITH OR WITHOUT VITALS EXPOSED/ ULCER/FOLLOWING TRAUMA/BURNS/ INFECTION/MALIGNANCY /DEVELOPMENTAL INCLUDING DIABETIC FOOT | 22500 |
CM0816B : MYOCUTANEOUS - FOR UPPER LIMB/HAND/LOWER LIMB/FOOT /AFTER FRACTURE FIXATION / ELETRICAL BURNS WITH OR WITHOUT VITALS EXPOSED/ ULCER/FOLLOWING TRAUMA/BURNS/ INFECTION/MALIGNANCY /DEVELOPMENTAL INCLUDING DIABETIC FOOT | 31950 |
CM0816C : OSTEOCUTANEOUS - FOR UPPER LIMB/HAND/LOWER LIMB/FOOT /AFTER FRACTURE FIXATION / ELETRICAL BURNS WITH OR WITHOUT VITALS EXPOSED/ ULCER/FOLLOWING TRAUMA/BURNS/ INFECTION/MALIGNANCY /DEVELOPMENTAL INCLUDING DIABETIC FOOT | 40950 |
CM0816D : MICROSURGICAL FREE FLAP SPLIT THICKNESS GRAFT - FOR UPPER LIMB/HAND/LOWER LIMB/FOOT /AFTER FRACTURE FIXATION / ELETRICAL BURNS WITH OR WITHOUT VITALS EXPOSED/ ULCER/FOLLOWING TRAUMA/BURNS/ INFECTION/MALIGNANCY /DEVELOPMENTAL INCLUDING DIABETIC FOOT | 61110 |
CM0817 : POST BURN HYPERTROPHY SURGERY/SCAR REVISION SURGERY | 22410 |
CM0818 : RECONSTRUCTION USING TISSUE EXPANDER (POST TRAUMATIC/POST BURNS) REQUIRES MULTIPLE SITTINGS | 50310 |
CM0819 : FLAP SURGERIES WITH BONE GRAFTING | 23400 |
CM0820-I : AMPUTATION OF ANY SITE / ANY CAUSE WITHOUT PROSTHESIS (except fingers, toes and small joints) | 22500 |
CM0820-II : AMPUTATION OF ANY SITE / ANY CAUSE WITHOUT PROSTHESIS (except fingers, toes and small joints) | 22500 |
CM0820-III : AMPUTATION OF ANY SITE / ANY CAUSE WITHOUT PROSTHESIS (fingers, toes and small joints) | 9000 |
CM0821-I : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS (except fingers, toes and small joints) | 100000 |
CM0821-II : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS (except fingers, toes and small joints) | 100000 |
CM0821-III : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS (fingers, toes and small joints) | 50000 |
CM0822 A-I : SOFT TISSUE INJURY - LACERATION (SUTURING) /WOUND DEBRIDEMENT | 540 |
CM0822 A-II : SOFT TISSUE INJURY - LACERATION (SUTURING) /WOUND DEBRIDEMENT | 540 |
CM0822 B-I : SOFT TISSUE INJURY - DEEP WOUND [NERVE/TENDON REPAIR] | 4500 |
CM0822 B-II : SOFT TISSUE INJURY - DEEP WOUND [NERVE/TENDON REPAIR] | 4500 |
CM0823 : OPERATIONS FOR BRACHIAL PLEXUS (multiple sitting - max 3) | 27000 |
CM0825A : POLYTRAUMA/HEAD INJURY MINOR (only lacerations less than 10 cm) | 2250 |
CM0825B : POLYTRAUMA/HEAD INJURY MINOR (deep / pitted wound exposing scalp/ bone requiring debridement and suturing) | 6300 |
CM0826 : POLYTRAUMA/HEAD INJURY MAJOR (with fractures, intracranial bleeding) | 22500 |
CM0827-I : SEVERE MYOCARDITIS/CONGENITAL HEART DISEASE PRESENTING WITH OR WITHOUT / INFECTION / FAILURE / CARDIOGENIC SHOCK / SEPTIC SHOCK / INFECTIVE ENDOCARDITIS/ CYANOTIC SPELL - NON VENTILATED | 36000 |
CM0827-II : SEVERE MYOCARDITIS/CONGENITAL HEART DISEASE PRESENTING WITH OR WITHOUT / INFECTION / FAILURE / CARDIOGENIC SHOCK / SEPTIC SHOCK / INFECTIVE ENDOCARDITIS/ CYANOTIC SPELL - NON VENTILATED | 36000 |
CM0828-I : SEVERE MYOCARDITIS/CONGENITAL HEART DISEASE PRESENTING WITH OR WITHOUT / INFECTION / FAILURE / CARDIOGENIC SHOCK / SEPTIC SHOCK / INFECTIVE ENDOCARDITIS/ CYANOTIC SPELL - VENTILATED | 45000 |
CM0828-II : SEVERE MYOCARDITIS/CONGENITAL HEART DISEASE PRESENTING WITH OR WITHOUT / INFECTION / FAILURE / CARDIOGENIC SHOCK / SEPTIC SHOCK / INFECTIVE ENDOCARDITIS/ CYANOTIC SPELL - VENTILATED | 45000 |
CM0829-I : STATUS EPILEPTICUS WITH MECHANICAL VENTILATION -(ADULT/PAEDIATRIC ) | 36000 |
CM0829-II : STATUS EPILEPTICUS WITH MECHANICAL VENTILATION -(ADULT/PAEDIATRIC ) | 36000 |
CM0830 : DIABETIC KETOACIDOSIS - TYPE I / TYPE II | 27000 |
CM0831-I : CHRONIC RENAL FAILURE WITH HEMODIALYSIS/ERYTHROPOIETIN / IRON | 15435 |
CM0832-I : ACUTE RENAL FAILURE WITHOUT HEMODIALYSIS/ERYTHROPOIETIN / IRON | 8730 |
CM0833-I : ACUTE RENAL FAILURE WITH HEMODIALYSIS/ ERYTHROPOIETIN / IRON | 10170 |
CM0834-I : ACUTE RENAL FAILURE / CRF WITH VENTILATOR CARE | 24030 |
CM0835A-I : ACUTE RENAL FAILURE / CRF - CONTINUOUS RENAL REPLACEMENT THERAPY-SCUF & SLED | 51300 |
CM0835B-I : ACUTE RENAL FAILURE / CRF - CONTINUOUS RENAL REPLACEMENT THERAPY - CVVH/CVVHD | 69300 |
CM0837-I : PYOGENIC /TB /VIRAL/ FUNGAL -MENINGITIS/ MENINGOENCEPHALITIS - NON VENTILATED | 27000 |
CM0837-II : PYOGENIC /TB /VIRAL/ FUNGAL -MENINGITIS/ MENINGOENCEPHALITIS - NON VENTILATED | 27000 |
CM0838-I : PYOGENIC /TB /VIRAL/ FUNGAL -MENINGITIS/ MENINGOENCEPHALITIS - WITH VENTILATORY SUPPORT | 45000 |
CM0839-I : NEURO TUBERCULOSIS/NEUROCYSTICERCOSIS/ TUBERCULOMA | 10800 |
CM0839-II : NEURO TUBERCULOSIS/NEUROCYSTICERCOSIS/ TUBERCULOMA | 10800 |
CM0840 A : IDIPOPATHIC THROMBOCYTOPENIC PURPURA | 36000 |
CM0840 B : TTP | 54000 |
CM0841 A : ANY COAGULATION DISORDERS | 45000 |
CM0841 B : DIC | 22500 |
CM0843A : MULTI SYSTEM ORGAN FAILURE- ARDS WITHOUT DIC(BLOOD PRODUCTS) | 66087 |
CM0843B : MULTI SYSTEM ORGAN FAILURE- ARDS WITH DIC(BLOOD PRODUCTS) | 90387 |
CM0844 : ENTERIC ENCEPHALOPATHY | 18198 |
CM0845 : LEPTOSPIROSIS WITH HEPATIC INVOLVEMENT | 17910 |
CM0846 : SUBMERSION INJURY WITH VENTILATORY SUPPORT | 24300 |
CM0847 : ARDS WITH VENTILATORY SUPPORT | 75645 |
CM0848-I : RESPIRATORY FAILURE OF ANY CAUSE REQUIRING HIGH FREQUENCY VENTILATION | 50580 |
CM0851A-II : CHEST WALL RESECTION WITHOUT RECONSTRUCTION | 35865 |
CM0851B-II : CHEST WALL RESECTION WITH RECONSTRUCTION | 47115 |
CM0854 A-I : ORCHIDECTOMY /HIGH ORCHIDECTOMY U/L | 10800 |
CM0854 A-II : ORCHIDECTOMY /HIGH ORCHIDECTOMY U/L | 10800 |
CM0854 A-III : ORCHIDECTOMY /HIGH ORCHIDECTOMY U/L | 10800 |
CM0855 B-II : ORCHIDECTOMY /HIGH ORCHIDECTOMY B/L | 13500 |
CM0856 : ANEURYSM CLIPPING | 87705 |
CM0857 : SURGERY OF CORD TUMORS - INTRA MEDULLARY TUMORS | 52893 |
CM0858 : SURGERY OF CORD TUMORS -INTRADURAL EXTRAMEDULLARY TUMOR | 41193 |
CM0859 : SURGERY OF CORD TUMORS - EXTRADURAL TUMOR | 41193 |
CM0860 : SPILT CORD MALFORMATIONS - ANY TYPE(INCLUDES SPINA BIFIDA MAJOR/MINOR) | 23445 |
CM0861-I : POSTERIOR DISCECTOMY WITH OR WITHOUT BONE GRAFT/SPACER/IMPLANT/VERTEBROPLASTY ( FOR CERVICAL COMPRESSIVE MYELOPATHY/ AT ANY LEVELS) | 38835 |
CM0861-II : POSTERIOR DISCECTOMY WITH OR WITHOUT BONE GRAFT/SPACER/IMPLANT/VERTEBROPLASTY ( FOR CERVICAL COMPRESSIVE MYELOPATHY/ AT ANY LEVELS) | 38835 |
CM0862 : ANTERIOR DISCECTOMY (WITH OR WITHOUT BONE GRAFTING/SPACER/IMPLANT/VETEBROPLASTY ) ANY LEVEL | 38835 |
CM0863 : ANTERIOR CERVICAL SPINE SURGERY WITH FUSION | 36045 |
CM0864 : ANTERIOR LATERAL DECOMPRESSION/STABILSIATION | 21645 |
CM0865-I : LAMINECTOMY AT ANY LEVEL - (INCLUDING LUMBAR LAMINECTOMY FOR LUMBAR CANAL STENOSIS)- MICROLUMBAR | 31545 |
CM0865-II : LAMINECTOMY AT ANY LEVEL - (INCLUDING LUMBAR LAMINECTOMY FOR LUMBAR CANAL STENOSIS)- MICROLUMBAR | 31545 |
CM0866-I : LAMINECTOMY AT ANY LEVEL - (INCLUDING LUMBAR LAMINECTOMY FOR LUMBAR CANAL STENOSIS)- CONVENTIONAL | 22545 |
CM0866-II : LAMINECTOMY AT ANY LEVEL - (INCLUDING LUMBAR LAMINECTOMY FOR LUMBAR CANAL STENOSIS)- CONVENTIONAL | 22545 |
CM0867 : SPINAL FUSION PROCEDURE | 38295 |
CM0868 : TRANS SPHENOIDAL SURGERY (SELLAR/SUPRASELLAR/SKULL BASAL LESION) | 71973 |
CM0869 : TRANS ORAL SURGERY | 22698 |
CM0870 : C.V. JUNCTION FUSION | 35775 |
CM0871 : SYRINGOMYELIA | 54675 |
CM0872 : CORPECTOMY (ANTERIOR /ANTEROLATERAL) AT ALL SPINAL LEVELS | 40545 |
CM0873 : SPINAL FIXATION RODS ,SCREWS,PLATES, ARTIFICIAL DISCS | 54045 |
CM0874 : RADIOFREQUENCY ABLATION FOR TRIGEMINAL NEURALGIA | 26775 |
CM0875 : EMBOLISATION OF ANEURYSM/ ANEURYSM COILING BALLOON ASSISTED | 39375 |
CM0876 : EMBOLISATION OF ANEURYSM / STENT ASSISTED COILING OF INTRACRANIAL ANEURYSM | 68625 |
CM0878-I : PELVIC FLOOR RECONSTRUCTION WITH MESH | 27675 |
CM0878-II : PELVIC FLOOR RECONSTRUCTION WITH MESH | 27675 |
CM0879-I : LAPAROSCOPIC / LAPROTOMY - ECTOPIC RESECTION | 19215 |
CM0879-II : LAPAROSCOPIC / LAPROTOMY - ECTOPIC RESECTION | 19215 |
CM0880 : LAPAROSCOPIC ADHESOLYSIS | 18045 |
CM0881 A-I : THALASSEMIA MAJOR /HAEMOGLOBINOPATHIES/ CHELATION THERAPY | 108000 |
CM0881 B-I : SICKLE CELL ANAEMIA | 4500 |
CM0882-I : INTERSTITAL LUNG DISEASE | 26370 |
CM0883-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - BANDING | 9180 |
CM0884-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - SCLEROTHERAPY | 6840 |
CM0884-II : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - SCLEROTHERAPY | 6840 |
CM0885-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - DEVASCULARISATION | 36000 |
CM0885-II : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - DEVASCULARISATION | 36000 |
CM0886-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - GLUE INJECTION | 6840 |
CM0886-II : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - GLUE INJECTION | 6840 |
CM0887-I : END STAGE RENAL DISEASE | 12735 |
CM0888-I : GULLAIN BARRE SYNDROME | 90000 |
CM0888-II : GULLAIN BARRE SYNDROME | 90000 |
CM0889-I : OPTIC NEURITIS | 9000 |
CM0889-II : OPTIC NEURITIS | 9000 |
CM0891-I : MYASTHENIA GRAVIS | 13500 |
CM0891-II : MYASTHENIA GRAVIS | 13500 |
CM0892 : MANAGEMENT OF COMA | 27072 |
CM0893 : CAVERNOUS SINUS THROMBOSIS | 22500 |
CM0894 : RHINOCEREBRAL MUCORMYCOSIS | 27000 |
CM0895 : HYPER OSMOLAR NON-KETOTIC COMA | 27000 |
CM0896 : OPERATION FOR HYDATID CYST OF LIVER | 31500 |
CM0897-I : HEPATO CELLULAR CARCINOMA (ADVANCED) RADIO FREQUENCY ABLATION | 26775 |
CM0897-III : HEPATO CELLULAR CARCINOMA (ADVANCED) RADIO FREQUENCY ABLATION | 26775 |
CM0898 : COLONIC PULL THOROUGH /COLOPLASTY/ ABDOMINAL RESECTION | 45000 |
CM0899-I : OESOPHAGECTOMY ANY TYPE INCLUDING (TRANS HIATAL / TRANS THORACIC WITH GASTRIC PULL UP) | 58500 |
CM0899-II : OESOPHAGECTOMY ANY TYPE INCLUDING (TRANS HIATAL / TRANS THORACIC WITH GASTRIC PULL UP) | 58500 |
CM0900 : OESOPHAGO- GASTRECTOMY | 72000 |
CM0901 : ACHALASIA CARDIA -SURGICAL CORRECTION | 27000 |
CM0902-I : ACHALASIA CARDIA - LAP SURGICAL CORRECTION ( INCLUDING HELLERS MYOTOMY) | 27000 |
CM0902-II : ACHALASIA CARDIA - LAP SURGICAL CORRECTION ( INCLUDING HELLERS MYOTOMY) | 27000 |
CM0903 : ACHALASIA CARDIA -PNEUMATIC DILATATION | 9405 |
CM0904 : LAP FUNDOPLICATIONS | 40500 |
CM0905-I : CYST EXCISION WITH OR WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE | 40500 |
CM0905-II : CYST EXCISION WITH OR WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE | 40500 |
CM0907 : ENUCLEATION OF CYST | 36000 |
CM0908A-I : OTHER BYPASS PANCREAS | 36000 |
CM0908A-II : OTHER BYPASS PANCREAS | 36000 |
CM0908B-I : TRIPLE BYPASS | 36000 |
CM0908B-II : TRIPLE BYPASS | 36000 |
CM0910 : PANCREATIC NECROSECTOMY OPEN | 37800 |
CM0911 : PANCREATIC NECROSECTOMY LAP | 37800 |
CM0913 : SCLEROSING CHOLANGITIS | 9000 |
CM0918 A : URETEROSCOPY AND DJ STENTING U/L | 5400 |
CM0918 B : URETEROSCOPY AND DJ STENTING B/L | 8100 |
CM0919 : URETEROSCOPY AND DJ STENT REMOVAL | 2700 |
CM0920 : TRANSURETHRAL RESECTION OF BLADDER TUMOR /RE-TURBT | 27000 |
CM0921A : EPIGASTRIC HERNIA / ABDOMINAL /UMBILICAL / FEMORAL HERNIA-WITHOUT MESH - OPEN | 13500 |
CM0921B : HIATUS HERNIA REPAIR ABDOMINAL - WITHOUT MESH - OPEN | 31500 |
CM0921C : VENTRAL AND SCAR /SPIGELIAN/OBTURATOR/SCIATIC- WITHOUT MESH - OPEN | 14400 |
CM0921D : EPIGASTRIC HERNIA/UMBILICAL HERNIA - WITH MESH - OPEN | 18000 |
CM0921E : HIATUS HERNIA REPAIR ABDOMINAL - WITH MESH - OPEN | 36000 |
CM0921F : VENTRAL AND SCAR / FEMORAL /SPIGELIAN/OBTURATOR/SCIATIC WITH MESH - OPEN | 18000 |
CM0922A : EPIGASTRIC HERNIA / ABDOMINAL /UMBILICAL / FEMORAL HERNIA-WITHOUT MESH - LAP | 13500 |
CM0922B : HIATUS HERNIA REPAIR ABDOMINAL - WITHOUT MESH - LAP | 31500 |
CM0922C : VENTRAL AND SCAR /SPIGELIAN/OBTURATOR/SCIATIC- WITHOUT MESH - LAP | 14400 |
CM0922D : EPIGASTRIC HERNIA/UMBILICAL HERNIA - WITH MESH - LAP | 18000 |
CM0922E : HIATUS HERNIA REPAIR ABDOMINAL - WITH MESH - LAP | 36000 |
CM0922F : VENTRAL AND SCAR / FEMORAL /SPIGELIAN/OBTURATOR/SCIATIC WITH MESH - LAP | 18000 |
CM0924 : APPENDICULAR PERFORATION | 13500 |
CM0925A : VAGOTOMY ANY TYPE WITHOUT DRAINAGE PROCEDURES | 22500 |
CM0925B : VAGOTOMY ANY TYPE WITH DRAINAGE PROCEDURES | 36000 |
CM0926 : OPERATION FOR BLEEDING PEPTIC ULCER | 36000 |
CM0927 : PYLOROMYOTOMY | 19800 |
CM0928 : OPERATIONS FOR RECURRENT INTESTINAL OBSTRUCTION (NOBLE PLICATION /OTHER) | 31500 |
CM0929 : OPERATION FOR ACUTE INTESTINAL PERFORATION / PERFORATION PERITONITIS (INTESTINAL/GASTRIC/BILIARY)/ DUODENAL PERFORATION | 27000 |
CM0930 : OPERATION FOR ACUTE INTESTINAL OBSTRUCTION (INCLUDING VOLVULUS / MALROTATION/INTUSUSCEPTION) | 36000 |
CM0931-I : INVESTIGATION AND MANAGEMENT CHRONIC HEPATITIS B / C | 158697 |
CM0932-I : CIRRHOSIS OF LIVER WITH COMPLICATIONS | 27072 |
CM0935 : STAY IN GENERAL WARD - OBSERVATION FOR TRAUMA - PER DAY | 630 |
CM0936 B : STAY IN ICU - MILD WITHOUT VENTILATION (FOR TRAUMA) | 900 |
CM0936 C : STAY IN ICU - MODERATE WITHOUT VENTILATION (FOR TRAUMA) | 13500 |
CM0936 D : STAY IN ICU - MODERATE WITH VENTILATION (FOR TRAUMA) | 22500 |
CM0936 E : STAY IN ICU - SEVERE WITHOUT VENTILATION (FOR TRAUMA / POST OP COMPLICATIONS - Sepsis / coma) | 22500 |
CM0936 F : STAY IN ICU - SEVERE WITH VENTILATION (FOR TRAUMA / POST OP COMPLICATIONS - Sepsis / Coma) | 45000 |
CM0937 A : PYELOLITHOTOMY - OPEN | 22500 |
CM0937 B : PYELOLITHOTOMY - LAP | 22500 |
CM0938 A : NEPHROLITHOTOMY - OPEN | 22500 |
CM0938 B : NEPHROLITHOTOMY - LAP | 22500 |
CM0939 : OPEN CYSTOLITHOTOMY | 12600 |
CM0940 A : URETEROLITHOTOMY - OPEN | 18000 |
CM0940 B : URETEROLITHOTOMY - LAP | 18000 |
CM0941 A : VESICOLITHOTOMY - OPEN | 12600 |
CM0941 B : VESICOLITHOTOMY - LAP | 12600 |
CM0942 : POSTERIOR FOSSA ENDOSCOPIC SURGERY | 72000 |
CM0943 : ENDOSCOPIC RESECTION OF ANTERIOR SKULL BASE LESIONS | 44973 |
CM0947 : SPINAL DEFORMITY STABILISATION/CORRECTION PROCEDURES /VERTERBROPLASTY | 68175 |
CM0948 : SPINAL EPIDURAL ABSCESS/HEMATOMA - LAMINECTOMY / EVACUATION | 24075 |
CM0951 A : TRANSVERSE MYELITIS WITH CENTRAL DEMYELINATION | 90000 |
CM0951 B : TRANSVERSE MYELITIS WITHOUT CENTRAL DEMYELINATION | 18000 |
CM0952A-I-i-a : Imatinib | 1525 |
CM0952A-I-i-b : Nilotinib | 17800 |
CM0952A-I-ii-a : Induction | 12840 |
CM0952A-I-ii-b : Imatinib | 1525 |
CM0952A-I-ii-c : Nilotinib | 17800 |
CM0952A-I-iii-a : Daunorubicin (90mg/m2)+ Cytarabine | 12320 |
CM0952A-I-iii-b : Daunorubicin + Cytarabine + Cladribine | 10365 |
CM0952A-I-iii-c : Daunorubicin + Cytarabine (High Dose) | 16725 |
CM0952A-I-iii-d : Daunorubicin (90mg) + Cytarabine | 12320 |
CM0952A-I-iii-e : Idarubicin + Cytarabine (High Dose) | 29600 |
CM0952A-I-iii-f : Idarubicin + Cytarabine | 23240 |
CM0952A-I-iii-g : mitoxantrone + Cytarabine | 10820 |
CM0952A-I-iii-h : Imatinib | 1525 |
CM0952A-I-iii-i : Nilotinib | 17800 |
CM0952A-I-iii-ii : Other Regimen | 10000 |
CM0952A-I-iii-iii : Other Regimen | 10000 |
CM0952A-II-a : Daunorubicin + Cytarabine 1 | 12320 |
CM0952A-II-b : Idarubicin + Cytarabine | 23240 |
CM0952A-II-c : Daunorubicin + Cytarabine 2 | 10365 |
CM0952A-II-d : Daunorubicin + Cytarabine (High Dose) | 16725 |
CM0952A-II-e : Idarubicin + Cytarabine (High Dose) | 29600 |
CM0952A-II-f : Daunorubicin (90mg) + Cytarabine | 12320 |
CM0952A-II-g : idarubicin + Cytarabine | 23240 |
CM0952A-II-h : mitoxantrone + Cytarabine | 10280 |
CM0952A-II-i : Cytarabine | 6800 |
CM0952A-II-j : Decitabine | 25000 |
CM0952A-II-k : azacytidine | 77500 |
CM0952A-II-l : Hydroxyurea | 1600 |
CM0952A-II-m : Cytarabine - High Dose | 9720 |
CM0952A-II-n : Cladribine + Cytarabine + Idarubicin + Gcsf | 85150 |
CM0952A-II-o : Cladribine + Cytarabine + Mitoxantrone + Gcsf | 40690 |
CM0952A-II-p : Fludarabine + Cytarabine + Idarubicin + Gcsf | 66710 |
CM0952A-II-q : Etoposide +Cytarabine+Mitoxantrone | 13260 |
CM0952A-II-r : Cytarabine SC | 2800 |
CM0952A-II-s : azacytidine | 77500 |
CM0952A-II-t : Decitabine | 25500 |
CM0952A-II-u : Other Regimen | 10000 |
CM0952A-III-a-i : Rituximab + chlorambucil Cycle 1 | 1084 |
CM0952A-III-a-ii : Rituximab + chlorambucil Cycle 3 | 25584 |
CM0952A-III-a-iii : Rituximab + chlorambucil Cycle 4-8 | 32984 |
CM0952A-III-a-iv : Maintanance - Rituximab | 25500 |
CM0952A-III-b : Rituximab Day 1, 8, 15, and 22: | 100500 |
CM0952A-III-c : Chlorambucil | 2344 |
CM0952A-III-d-i : Bendamustine + Rituximab (Cycle -1) | 36500 |
CM0952A-III-d-ii : Bendamustine + Rituximab (Cycles 2-6) | 37900 |
CM0952A-III-d-iii : Bendamustine (70mg) (Cycle -1) | 12500 |
CM0952A-III-d-iv : Bendamustine (90 mg) (Cycles 2-6) | 6500 |
CM0952A-III-e : Fludarabine + cyclophosphamide + rituximab (FCR) | 31898 |
CM0952A-III-f : Fludarabine + rituximab (FR) | 67930 |
CM0952A-III-g : Alemtuzumab + rituximab | 108950 |
CM0952A-III-h : Alemtuzumab without rituximab | 11450 |
CM0952A-III-i : High-dose methylprednisolone + rituximab | 103955 |
CM0952A-III-j : High-dose methylprednisolone | 6455 |
CM0952A-III-k : Other Regimen | 10000 |
CM0952A-IV-i-a-1 : Childrens Oncology Group (COG) AALL-0031 INDUCTION PHASE | 13340 |
CM0952A-IV-i-a-2 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 | 17095 |
CM0952A-IV-i-a-3 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 | 19175 |
CM0952A-IV-i-a-4 : Childrens Oncology Group (COG) AALL-0031 REINDUCTION | 25291 |
CM0952A-IV-i-a-5 : Childrens Oncology Group (COG) AALL-0031 INTENSIFICATION | 41425 |
CM0952A-IV-i-a-6 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 1-4 (8 weeks) | 35621 |
CM0952A-IV-i-a-7 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 5-12 (8 weeks) | 12836 |
CM0952A-IV-i-b-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | 59429 |
CM0952A-IV-i-b-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | 62380 |
CM0952A-IV-i-b-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | 11469 |
CM0952A-IV-i-b-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | 13420 |
CM0952A-IV-i-b-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II | 15133 |
CM0952A-IV-i-b-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III | 5535 |
CM0952A-IV-i-b-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance | 9923 |
CM0952A-IV-i-c-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE | 15133 |
CM0952A-IV-i-c-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I | 8460 |
CM0952A-IV-i-c-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II | 3700 |
CM0952A-IV-i-c-4 : Multiagent Chemotherapy + TKIs MAINTENANCE | 3410 |
CM0952A-IV-i-c-5 : Imatinib | 1525 |
CM0952A-IV-i-c-6 : Nilotinib | 17800 |
CM0952A-IV-i-d : Other Regimen | 10000 |
CM0952A-IV-ii-a-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | 59429 |
CM0952A-IV-ii-a-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | 62380 |
CM0952A-IV-ii-a-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | 11469 |
CM0952A-IV-ii-a-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | 13420 |
CM0952A-IV-ii-a-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II | 15133 |
CM0952A-IV-ii-a-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III | 5535 |
CM0952A-IV-ii-a-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance | 9923 |
CM0952A-IV-ii-b-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE | 15573 |
CM0952A-IV-ii-b-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I | 12110 |
CM0952A-IV-ii-b-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II | 3200 |
CM0952A-IV-ii-b-4 : Multiagent Chemotherapy + TKIs MAINTENANCE | 6410 |
CM0952A-IV-ii-b-5 : Imatinib | 1525 |
CM0952A-IV-ii-b-6 : Nilotinib | 17800 |
CM0952A-IV-ii-c : Corticosteroids + TKIs | 9035 |
CM0952A-IV-ii-d : Other Regimen | 10000 |
CM0952A-IV-iii-a-1 : GRAALL-2003 INDUCTION | 15678 |
CM0952A-IV-iii-a-2 : GRAALL-2003 SALVAGE | 28760 |
CM0952A-IV-iii-a-3 : GRAALL-2003 CONSOLIDATION | 30779 |
CM0952A-IV-iii-a-4 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in complete remission [CR] after the first induction course) | 15495 |
CM0952A-IV-iii-a-5 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in CR after salvage course) | 27210 |
CM0952A-IV-iii-a-6 : GRAALL-2003 Maintenance | 56898 |
CM0952A-IV-iii-b : CNS Therapy-Treatment of patients with initial CNS involvement: | 21155 |
CM0952A-IV-iii-v : CCG-1961 | 18310 |
CM0952A-IV-iii-vi : Other Regimen | 10000 |
CM0952A-IV-iv-a-1 : CALGB 8811 (Larson Regimen) INDUCTION | 18038 |
CM0952A-IV-iv-a-2 : CALGB 8811 (Larson Regimen) CONSOLIDATION | 16685 |
CM0952A-IV-iv-b-1 : Hyper-CVAD with or without Rituximab CYCLE 1,3,5,7 | 60970 |
CM0952A-IV-iv-b-2 : Hyper-CVAD with or without Rituximab CYCLE 2,4,6,8 | 56820 |
CM0952A-IV-iii-c : Other Regimen | 10000 |
CM0952-ii : Surgery for All Leukemias - Utilise Surgical Oncology Package if unavailable maximum payable | 45000 |
CM0953A-I-a : ABVD | 4480 |
CM0953A-I-b : Escalated BEACOPP | 7119 |
CM0953A-I-c : ABVD + Rituximab (cyled every 4 weeks) | 28480 |
CM0953A-I-d-i : ABVD + Rituximab (1 cycle - weekly rituximab 4 doses) followed by ABVD | 102480 |
CM0953A-I-d-ii : ABVD | 4480 |
CM0953A-I-e-i : CHOP + Rituximab | 26818 |
CM0953A-I-e-ii : CHOP | 2818 |
CM0953A-I-f-i : CVP +/- Rituximab | 25768 |
CM0953A-I-f-ii : CVP | 1768 |
CM0953A-I-g : Rituximab | 25500 |
CM0953A-I-h : Other Regimen | 10000 |
CM0953A-II-a : Bortezomib + dexamethasone | 68038 |
CM0953A-II-b : Cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab | 26818 |
CM0953A-II-c : Rituximab | 25500 |
CM0953A-II-d : Rituximab + cyclophosphamide + prednisone | 25738 |
CM0953A-II-e : Rituximab + cyclophosphamide + dexamethasone | 25520 |
CM0953A-II-f-i : Thalidomide with or without rituximab (Weeks 1 and 2) | 2540 |
CM0953A-II-f-ii : Thalidomide with or without rituximab (Weeks 3-50) | 6000 |
CM0953A-II-f-iii : Thalidomide with or without rituximab (Weeks 50-52) | 6000 |
CM0953A-II-f-iv : Thalidomide with or without rituximab Weeks 2-5 and 13-16 | 24000 |
CM0953A-II-g-i : Bendamustine with or without rituximab | 36500 |
CM0953A-II-g-ii : Bendamustine - rituximab | 12500 |
CM0953A-II-h-i : Cladribine with or without rituximab | 32250 |
CM0953A-II-h-ii : Cladribine - rituximab | 8250 |
CM0953A-II-i : Bendamustine | 12500 |
CM0953A-II-j : Chlorambucil | 1126 |
CM0953A-II-k : Fludarabine | 12030 |
CM0953A-II-l : Fludarabine + cyclophosphamide + rituximab (FCR) | 32398 |
CM0953A-II-m : Alemtuzumab | 2650 |
CM0953A-II-n : Other Regimen | 10000 |
CM0953A-III-i-a -1 : CALGB 10002 Cycle 1: | 8967 |
CM0953A-III-i-a-2 : CALGB 10002 Cycles 2 (beginning Day 8), 4, and 6: | 66113 |
CM0953A-III-i-a-3 : CALGB 10002 Cycles 3, 5, and 7: | 33108 |
CM0953A-III-i-a-4 : CALGB 10002 Cycles 4, and 6: | 36413 |
CM0953A-III-i-b : CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine with intrathecal MTX + cytarabine, followed by systemic MTX and cytarabine) with or without Rituximab | 46780 |
CM0953A-III-i-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1 & 2) | 32972 |
CM0953A-III-i-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) | 32572 |
CM0953A-III-i-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | 59429 |
CM0953A-III-i-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | 61880 |
CM0953A-III-i-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | 10969 |
CM0953A-III-i-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | 12920 |
CM0953A-III-i-e-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab | 46780 |
CM0953A-III-i-e-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab | 42847 |
CM0953A-III-i-f : RICE (rituximab + ifosfamide + carboplatin + etoposide) | 32994 |
CM0953A-III-i-g : RIVAC (rituximab + ifosfamide + cytarabine + etoposide) | 43894 |
CM0953A-III-i-h : RGDP (rituximab + gemcitabine + dexamethasone + cisplatin) | 32255 |
CM0953A-III-i-i : HDAC + Rituximab | 27800 |
CM0953A-III-i-ii : Other Regimen | 10000 |
CM0953A-III-ii-a-1 : Zidovudine + alpha-interferon (induction) | 4580 |
CM0953A-III-ii-a-2 : Zidovudine + alpha-interferon (Maintenance Therapy) | 2100 |
CM0953A-III-ii-b : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | 2818 |
CM0953A-III-ii-c : CHOEP | 8640 |
CM0953A-III-ii-d : Dose-adjusted EPOCH(etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) | 6892 |
CM0953A-III-ii-e : Other Regimen | 10000 |
CM0953A-III-iii-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab | 2500 |
CM0953A-III-iii-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | 46780 |
CM0953A-III-iii-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | 42847 |
CM0953A-III-iii-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) | 32972 |
CM0953A-III-iii-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) | 32572 |
CM0953A-III-iii-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | 59429 |
CM0953A-III-iii-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | 61880 |
CM0953A-III-iii-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | 10969 |
CM0953A-III-iii-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | 12920 |
CM0953A-III-iii-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) Rituximab | 26818 |
CM0953A-III-iii-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | 2818 |
CM0953A-III-iii-f : Other Regimen | 10000 |
CM0953A-III-iv-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab | 2500 |
CM0953A-III-iv-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | 46780 |
CM0953A-III-iv-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | 42847 |
CM0953A-III-iv-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) | 32972 |
CM0953A-III-iv-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) | 32572 |
CM0953A-III-iv-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | 59429 |
CM0953A-III-iv-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | 61880 |
CM0953A-III-iv-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | 10969 |
CM0953A-III-iv-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | 12920 |
CM0953A-III-iv-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab | 26818 |
CM0953A-III-iv-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | 2818 |
CM0953A-III-iv-f : Other Regimen | 10000 |
CM0953A-III-v-a-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab | 26818 |
CM0953A-III-v-a-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | 2818 |
CM0953A-III-v-b : Rituximab | 25500 |
CM0953A-III-v-c : Other Regimen | 10000 |
CM0953A-III-vi-a-1 : Bendamustine with or without rituximab | 36500 |
CM0953A-III-vi-a-2 : Bendamustine (-) rituximab | 12500 |
CM0953A-III-vi-b-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab | 26818 |
CM0953A-III-vi-b-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | 2818 |
CM0953A-III-vi-c : Cyclophosphamide + Vincristine + Prednisone + Rituximab (RCVP) | 25768 |
CM0953A-III-vi-d : Rituximab | 25500 |
CM0953A-III-vi-e : Lenalidomide + Rituximab | 4940 |
CM0953A-III-vi-f : Other Regimen | 10000 |
CM0953A-III-vii-a : SMILE | 27483 |
CM0953A-III-vii-b : DeVIC +RT | 9163 |
CM0953A-III-vii-c : VIPID | 6619 |
CM0953A-III-vii-d : Other Regimen | 10000 |
CM0953-ii : Surgery for All Lymphomas - Utilise Surgical Oncology Package if unavailable maximum payable | 45000 |
CM0954-i-a : Lenalidomide | 2575 |
CM0954-ii-a-1 : rHu-Epo with or without G-CSF | 26080 |
CM0954-ii-a-2 : rHu-Epo (-) G-CSF | 25750 |
CM0954-ii-b-1 : Darbepoetin alfa with or without G-CSF | 9330 |
CM0954-ii-b-2 : Darbepoetin alfa (-) G-CSF | 9000 |
CM0954-iii-a-1 : Decitabine (15mg/m2) | 15500 |
CM0954-iii-a-2 : Decitabine (20mg/m2) | 16500 |
CM0954-iii-b : Lenalidomide | 2575 |
CM0955-a : Lenalidomide (28 days) + Dexamethasone | 6817 |
CM0955-b : Lenalidomide (21 days) + Dexamethasone | 5004 |
CM0955-c : Lenalidomide | 2575 |
CM0955-d : Bendamustine + Lenalidomide + Dexamethasone | 13639 |
CM0955-e : Bendamustine | 22000 |
CM0955-f : Cyclophosphamide + Lenalidomide + Dexamethasone | 5136 |
CM0955-g : Dexamethasone + Cyclophosphamide + Etoposide + Cisplatin (DCEP) | 5764 |
CM0955-h : Dexamethasone + Thalidomide + Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide (DT-PACE) | 7724 |
CM0955-i : High-dose Cyclophosphamide | 5140 |
CM0955-j : VAD / VAMP | 6104 |
CM0955-k : Melphalan | 3900 |
CM0955-l : Melphalan + Prednisolone | 1137 |
CM0955-m : Thalidomide + Dexamethasone | 2376 |
CM0955-n : Melphalan / Prednisolone/Thalidomide(MPT) | 2257 |
CM0959 : CYSTIC FIBROSIS | 32940 |
CM0960 : SEPTIC SHOCK (ICU MANAGEMENT) | 38745 |
CM0962-I : NEPHROTIC SYNDROME | 14486 |
CM0963-I : NEPHROTIC SYNDROME WITH COMPLICATIONS | 23396 |
CM0964-I : ACUTE DISSEMINATED ENCEPHALOMYELITIS | 45000 |
CM0967-I : TOXIC/DRUG INDUCED LIVER INJURY | 24120 |
CM0968 : MALIGNANT ASCITES | 5085 |
CM0969 : SACROSPINOUS FIXATION (VAGINAL ROUTE) | 20745 |
CM0970 : SLEEVE RESECTION CA EAR | 17550 |
CM0971 : SLEEVE RESECTION CA LUNG | 21780 |
CM0973 : ENDOSCOPIC PARATHYROIDECTOMY | 27000 |
CM0974-I : IVC FILTER REMOVAL | 27315 |
CM0976A : CT / C-ARM GUIDED DISC OZONE NUCLEOLYSIS (CERVICAL / THORACIC / LUMBAR DISC) | 14175 |
CM0976B : USG GUIDED DISC OZONE NUCLEOLYSIS (CERVICAL / THORACIC / LUMBAR DISC) | 8775 |
CM0978 : C-ARM GUIDED INTRA ARTICULAR INJECTIONS (SHOULDER / ELBOW / WRIST / HIP / KNEE / ANKLE / JOINTS OF FOOT AND HAND | 14175 |
CM0979-I : CHEMO EMBOLIZATION FOR LIVER TUMORS USING DRUG AND PVA OR DC BEADS | 63675 |
CM0979-II : CHEMO EMBOLIZATION FOR LIVER TUMORS USING DRUG AND PVA OR DC BEADS | 63675 |
CM0980-I : TRANS JUGULAR INTRAHEPATIC PORTO SYSTEMIC SHUNT (TIPSS) | 118125 |
CM0980-II : TRANS JUGULAR INTRAHEPATIC PORTO SYSTEMIC SHUNT (TIPSS) | 118125 |
CM0981 : LUDWIGS ANGINA AND OTHER NECK ABSCESS DRAINAGE | 10800 |
CM0982 : OP /ANY POISIONING - CONSERVATIVE MANAGEMENT OR WITHOUT VENTILATORY SUPPORT (ONLY WITH FIR ) | 16200 |
CM0983 : MAXILLECTOMY WITH ORBITAL EXENTERATION | 30915 |
CM0984 : MAXILLECTOMY WITH SKULL BASE RESECTION | 33975 |
CM0985 : CRANIOFACIAL RESECTION | 43515 |
CM0986A : POSTERIOR DECOMPRESSION WITHOUT STABILISATION AT ANY LEVEL (2 -3 levels) | 22500 |
CM0986B : POSTERIOR DECOMPRESSION WITH STABILISATION AT ANY LEVEL (2 -3 levels) | 40500 |
CM0987 : ACUTE SEVERE ASTHMA WITH VENTILATION | 46080 |
CM0988 : CRITICAL CARE ICU MANAGEMENT ( RESPIRATORY DISTRESS/ METABOLIC COMA/MULTIORGAN DYSFUNCTION/SEPTIC SHOCK/OTHERS WITH VENTILATION | 28350 |
CM0989A : CRITICAL CARE ICU MANAGEMENT -CRITICAL LIMB ISCHEMIA (heparinisation) | 18000 |
CM0989B : CRITICAL CARE ICU MANAGEMENT -CRITICAL LIMB ISCHEMIA (SK) | 22500 |
CM0989C : CRITICAL CARE ICU MANAGEMENT -CRITICAL LIMB ISCHEMIA (rTPA) | 67500 |
FUP0046A : OESOPHAGECTOMY WITH TWO FIELD LYMPADENECTOMY / THREE FIELD LYMPADENECTOMY - First Qtr | 400 |
FUP0046B : OESOPHAGECTOMY WITH TWO FIELD LYMPADENECTOMY / THREE FIELD LYMPADENECTOMY - Next 3 Qtrs | 400 |
FUP0047A : ALL - First Qtr | 1000 |
FUP0047B : ALL - Next 3 Qtrs | 750 |
FUP0048A : CML - First Qtr | 1000 |
FUP0048B : CML - Next 3 Qtrs | 750 |
FUP0049A : CLL - First Qtr | 1000 |
FUP0049B : CLL - Next 3 Qtrs | 750 |
FUP0050A : MYELODYSPLASTIC SYNDROME - First Qtr | 1000 |
FUP0050B : MYELODYSPLASTIC SYNDROME - Next 3 Qtrs | 750 |
FUP0051A : LYMPHOMA HODGKIN DISEASE - First Qtr | 1000 |
FUP0051B : LYMPHOMA HODGKIN DISEASE - Next 3 Qtrs | 750 |
FUP0052A : LYMPHOMA NON HODGKINS DISEASES - First Qtr | 1000 |
FUP0052B : LYMPHOMA NON HODGKINS DISEASES - Next 3 Qtrs | 750 |
FUP0060A : UPTO-60% WITH SCALDS (CONSERVATIVE) - First Qtr | 750 |
FUP0060B : UPTO-60% WITH SCALDS (CONSERVATIVE) - Next 3 Qtrs | 500 |
FUP0061A : UP TO-60% MIXED BURNS (WITH SURGERIES) - First Qtr | 750 |
FUP0061B : UP TO-60% MIXED BURNS (WITH SURGERIES) - Next 3 Qtrs | 500 |
FUP0062A : ABOVE 60% MIXED BURNS (WITH SURGERIES) - First Qtr | 750 |
FUP0062B : ABOVE 60% MIXED BURNS (WITH SURGERIES) - Next 3 Qtrs | 500 |
FUP0065A : TOTAL HIP REPLACEMENT - First Qtr | 500 |
FUP0065B : TOTAL HIP REPLACEMENT - Next 3 Qtrs | 500 |
FUP0066A : REVISION HIP REPLACEMENT SURGERY (ONLY WITH SPECIFIC APPROVAL) - First Qtr | 500 |
FUP0066B : REVISION HIP REPLACEMENT SURGERY (ONLY WITH SPECIFIC APPROVAL) - Next 3 Qtrs | 500 |
FUP0067A : REVISION KNEE REPLACEMENT SURGERY ( ONLY WITH SPECIFIC APPROVAL) - First Qtr | 500 |
FUP0067B : REVISION KNEE REPLACEMENT SURGERY ( ONLY WITH SPECIFIC APPROVAL) - Next 3 Qtrs | 500 |
FUP0068A : TOTAL KNEE REPLACEMENT - First Qtr | 500 |
FUP0068B : TOTAL KNEE REPLACEMENT - Next 3 Qtrs | 500 |
FUP0076A : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - First Qtr | 1800 |
FUP0076B : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - Next 3 Qtrs | 1000 |
FUP0077A : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - First Qtr | 1800 |
FUP0077B : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - Next 3 Qtrs | 1000 |
FUP0080A : EXCISION OF BRAIN TUMORS - [PRIMARY /BENIGN ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - First Qtr | 2000 |
FUP0080B : EXCISION OF BRAIN TUMORS - [PRIMARY /BENIGN ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - Next 3 Qtrs | 1000 |
FUP0081A : EXCISION OF BRAIN TUMORS - [MALIGNANT ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - First Qtr | 2000 |
FUP0081B : EXCISION OF BRAIN TUMORS - [MALIGNANT ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - Next 3 Qtrs | 1000 |
FUP0082A : EXCISION OF BRAIN TUMORS - [SECONDARIES ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - First Qtr | 2000 |
FUP0082B : EXCISION OF BRAIN TUMORS - [SECONDARIES ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - Next 3 Qtrs | 1000 |
FUP0083A : ANEURYSM CLIPPING - First Qtr | 2000 |
FUP0083B : ANEURYSM CLIPPING - Next 3 Qtrs | 1000 |
FUP0084A : STEREOTACTIC PROCEDURES- SURGICAL PROCEDURE - First Qtr | 2000 |
FUP0084B : STEREOTACTIC PROCEDURES- SURGICAL PROCEDURE - Next 3 Qtrs | 1000 |
FUP0085A : TRANS SPHENOIDAL SURGERY (SELLAR/SUPRASELLAR/SKULL BASAL LESION) - First Qtr | 2000 |
FUP0085B : TRANS SPHENOIDAL SURGERY (SELLAR/SUPRASELLAR/SKULL BASAL LESION) - Next 3 Qtrs | 1000 |
FUP0086A : TRANS ORAL SURGERY - First Qtr | 2000 |
FUP0086B : TRANS ORAL SURGERY - Next 3 Qtrs | 1000 |
FUP0087A : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - First Qtr | 1500 |
FUP0087B : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - Next 3 Qtrs | 1000 |
FUP0088A : CORPECTOMY (ANTERIOR /ANTEROLATERAL) AT ALL SPINAL LEVELS - First Qtr | 2000 |
FUP0088B : CORPECTOMY (ANTERIOR /ANTEROLATERAL) AT ALL SPINAL LEVELS - Next 3 Qtrs | 1000 |
FUP0089A : SPINAL FIXATION RODS ,SCREWS,PLATES, ARTIFICIAL DISCS - First Qtr | 2000 |
FUP0089B : SPINAL FIXATION RODS ,SCREWS,PLATES, ARTIFICIAL DISCS - Next 3 Qtrs | 1000 |
FUP0090A : EMBOLISATION OF ANEURYSM/ ANEURYSM COILING BALLOON ASSISTED - First Qtr | 2500 |
FUP0090B : EMBOLISATION OF ANEURYSM/ ANEURYSM COILING BALLOON ASSISTED - Next 3 Qtrs | 1500 |
FUP0091A : DEEP BRAIN STIMULATION - First Qtr | 3000 |
FUP0091B : DEEP BRAIN STIMULATION - Next 3 Qtrs | 1500 |
FUP0101A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - First Qtr | 1000 |
FUP0101B : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - Next 3 Qtrs | 500 |
FUP0102A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - First Qtr | 2500 |
FUP0102B : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - Next 3 Qtrs | 1000 |
FUP0103A : THALASSEMIA MAJOR/HAEMOGLOBINOPATHIES/ CHELATION THERAPY/SICKLE CELL ANAEMIA - First Qtr | 2500 |
FUP0103B : THALASSEMIA MAJOR/HAEMOGLOBINOPATHIES/ CHELATION THERAPY/SICKLE CELL ANAEMIA - Next 3 Qtrs | 2500 |
FUP0106A : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS - First Qtr | 2500 |
FUP0106B : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS - Next 3 Qtrs | 1500 |
FUP0107A : ACUTE MI REQUIRING IABP PUMP - First Qtr | 4000 |
FUP0107B : ACUTE MI REQUIRING IABP PUMP - Next 3 Qtrs | 2000 |
FUP0108A : IMMUNOGLOBULIN THERAPY - HEREDITARY MOTOR SENSORY NEUROPATHIES/HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY/PLEXOPATHY (LUMBOSACRAL/ BRACHIAL)/PERIPHERAL NEUROPATHY (WITH NERVE BIOPSY) (HANSEN, NUTRITIONAL, TOXIC, INFECTIVE, IMMUNE)/CARPAL TUNNEL SYNDROME/ACUTE ENTRAPMENT/ COMPRESSIVE NEUROPATHY / GBS/DOG BITE CATEGORY III/OTHERS - First Qtr | 4000 |
FUP0108B : IMMUNOGLOBULIN THERAPY - HEREDITARY MOTOR SENSORY NEUROPATHIES/HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY/PLEXOPATHY (LUMBOSACRAL/ BRACHIAL)/PERIPHERAL NEUROPATHY (WITH NERVE BIOPSY) (HANSEN, NUTRITIONAL, TOXIC, INFECTIVE, IMMUNE)/CARPAL TUNNEL SYNDROME/ACUTE ENTRAPMENT/ COMPRESSIVE NEUROPATHY / GBS/DOG BITE CATEGORY III/OTHERS - Next 3 Qtrs | 2000 |
FUP0111A : RT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - First Qtr | 2200 |
FUP0111B : RT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - Next 3 Qtrs | 1200 |
FUP0112A : LT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - First Qtr | 2200 |
FUP0112B : LT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - Next 3 Qtrs | 1200 |
FUP0113A : PORTOCAVAL ANASTOMOSIS - First Qtr | 4000 |
FUP0113B : PORTOCAVAL ANASTOMOSIS - Next 3 Qtrs | 2000 |
FUP0116A : DEVASCULARISATION WITH OESOPHAGEAL TRANSECTION - First Qtr | 5000 |
FUP0116B : DEVASCULARISATION WITH OESOPHAGEAL TRANSECTION - Next 3 Qtrs | 1500 |
FUP0121A : INFERIOR VENA CAVA STENTING SINGLE STENT - First Qtr | 2000 |
FUP0121B : INFERIOR VENA CAVA STENTING SINGLE STENT - Next 3 Qtrs | 1000 |
FUP0122A : ACUTE STROKE THROMBOLYSIS (R TPA ) - First Qtr | 2000 |
FUP0122B : ACUTE STROKE THROMBOLYSIS (R TPA ) - Next 3 Qtrs | 1000 |
FUP0123A : RENAL ARTERY EMBOLIZATION WITH MULTIPLE COILS AND MICRO CATHETER - First Qtr | 2500 |
FUP0123B : RENAL ARTERY EMBOLIZATION WITH MULTIPLE COILS AND MICRO CATHETER - Next 3 Qtrs | 1000 |
FUP0124A : CORTICAL VENOUS SINUS THROMBOLYSIS - First Qtr | 2500 |
FUP0124B : CORTICAL VENOUS SINUS THROMBOLYSIS - Next 3 Qtrs | 1000 |
FUP0125A : INFERIOR VENA CAVA FILTER PLACEMENT - First Qtr | 3000 |
FUP0125B : INFERIOR VENA CAVA FILTER PLACEMENT - Next 3 Qtrs | 1500 |
FUP0126A : SUBCLAVIAN, ILIAC, SUPERFICIAL FEMORAL ARTERY STENTING EACH WITH ONE STENT - First Qtr | 2500 |
FUP0126B : SUBCLAVIAN, ILIAC, SUPERFICIAL FEMORAL ARTERY STENTING EACH WITH ONE STENT - Next 3 Qtrs | 1200 |
FUP0127A : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - First Qtr | 2500 |
FUP0127B : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - Next 3 Qtrs | 1200 |
FUP0128A : MESENTERIC ARTERY ANGIOPLASTY & STENTING IN ACUTE & CHRONIC MESENTERIC ISCHEMIA - SINGLE STENT - First Qtr | 2500 |
FUP0128B : MESENTERIC ARTERY ANGIOPLASTY & STENTING IN ACUTE & CHRONIC MESENTERIC ISCHEMIA - SINGLE STENT - Next 3 Qtrs | 1200 |
FUP0129A : BILIARY DRAINAGE PROCEDURES/ERCP - EXTERNAL DRAINAGE AND STENT PLACEMENT - METALLIC BILIARY STENT / POST OP BILIARY STRICTURE/LEAK/CHOLANGITIS/BILIARY PANCREATITIS/CHOLEDOCHAL CYST/BILE DUCT STONES - First Qtr | 2000 |
FUP0129B : BILIARY DRAINAGE PROCEDURES/ERCP - EXTERNAL DRAINAGE AND STENT PLACEMENT - METALLIC BILIARY STENT / POST OP BILIARY STRICTURE/LEAK/CHOLANGITIS/BILIARY PANCREATITIS/CHOLEDOCHAL CYST/BILE DUCT STONES - Next 3 Qtrs | 1000 |
FUP0130A : INTRA-ARTERIAL THROMBOLYSIS FOR ACUTE ISCHEMIC LIMBS - First Qtr | 2000 |
FUP0130B : INTRA-ARTERIAL THROMBOLYSIS FOR ACUTE ISCHEMIC LIMBS - Next 3 Qtrs | 1000 |
FUP0131A : CENTRAL VENOUS STENTING FOR CENTRAL VENOUS OCCLUSION (BRACHIOCEPHALIC, SUBCLAVIAN VEIN AND SUP VENA CAVA) SINGLE METALLIC STENT - First Qtr | 2500 |
FUP0131B : CENTRAL VENOUS STENTING FOR CENTRAL VENOUS OCCLUSION (BRACHIOCEPHALIC, SUBCLAVIAN VEIN AND SUP VENA CAVA) SINGLE METALLIC STENT - Next 3 Qtrs | 1200 |
FUP0132A : ENDOVASCULAR INTERVENTION FOR SALVAGING HEMODIALYSIS AV FISTULA - First Qtr | 2000 |
FUP0132B : ENDOVASCULAR INTERVENTION FOR SALVAGING HEMODIALYSIS AV FISTULA - Next 3 Qtrs | 1000 |
FUP0133A : BALLOON RETROGRADE TRANSVENOUS OBLITERATION OF BLEEDING GASTRIC VARICES (BRTO) - First Qtr | 3500 |
FUP0133B : BALLOON RETROGRADE TRANSVENOUS OBLITERATION OF BLEEDING GASTRIC VARICES (BRTO) - Next 3 Qtrs | 1500 |
FUP0134A : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS - First Qtr | 2000 |
FUP0134B : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS - Next 3 Qtrs | 1000 |
FUP0135A : CHEMO EMBOLIZATION FOR LIVER TUMORS USING DRUG AND PVA OR DC BEADS - First Qtr | 2000 |
FUP0135B : CHEMO EMBOLIZATION FOR LIVER TUMORS USING DRUG AND PVA OR DC BEADS - Next 3 Qtrs | 1000 |
FUP0136A : TRANS JUGULAR INTRAHEPATIC PORTO SYSTEMIC SHUNT (TIPSS) - First Qtr | 3500 |
FUP0136B : TRANS JUGULAR INTRAHEPATIC PORTO SYSTEMIC SHUNT (TIPSS) - Next 3 Qtrs | 1500 |
FUP0137A : EMBOLIZATION OF PULMONARY AV MALFORMATION - First Qtr | 2500 |
FUP0137B : EMBOLIZATION OF PULMONARY AV MALFORMATION - Next 3 Qtrs | 1000 |
FUP0138A : PREOPERATIVE PROPHYLACTIC TUMOR EMBOLISATION - First Qtr | 2000 |
FUP0138B : PREOPERATIVE PROPHYLACTIC TUMOR EMBOLISATION - Next 3 Qtrs | 1000 |
FUP0139A : EMBOLIZATION OF AV MALFORMATION OF BRAIN PER SITTING WITH ONYX - First Qtr | 6000 |
FUP0139B : EMBOLIZATION OF AV MALFORMATION OF BRAIN PER SITTING WITH ONYX - Next 3 Qtrs | 1000 |
FUP0140A : CAROTID STENTING SINGLE STENT WITH EMBOLIC PROTECTION DEVICE - First Qtr | 2000 |
FUP0140B : CAROTID STENTING SINGLE STENT WITH EMBOLIC PROTECTION DEVICE - Next 3 Qtrs | 1000 |
FUP0141A : INTRACRANIAL VENOUS STENTING - First Qtr | 6000 |
FUP0141B : INTRACRANIAL VENOUS STENTING - Next 3 Qtrs | 1000 |
FUP0142A : INTRACRANIAL ARTERIAL STENTING - First Qtr | 6000 |
FUP0142B : INTRACRANIAL ARTERIAL STENTING - Next 3 Qtrs | 1000 |
FUP0143A : PERIPHERAL STENT GRAFT FOR PERIPHERAL ANEURYSMS AND AV FISTULA - First Qtr | 2500 |
FUP0143B : PERIPHERAL STENT GRAFT FOR PERIPHERAL ANEURYSMS AND AV FISTULA - Next 3 Qtrs | 1200 |
FUP0144A : EMBOLIZATION OF CARATICO-CAVERNOUS FISTULA - First Qtr | 6000 |
FUP0144B : EMBOLIZATION OF CARATICO-CAVERNOUS FISTULA - Next 3 Qtrs | 1000 |
FUP0145A : PLAIN SIMPLE COILING OF ANEURYSM - First Qtr | 2500 |
FUP0145B : PLAIN SIMPLE COILING OF ANEURYSM - Next 3 Qtrs | 1500 |
FUP0146A : ILIAC / IVC STENTING / HIGH END VASCULAR REVASCULARISATION PROCEDURE - First Qtr | 2500 |
FUP0146B : ILIAC / IVC STENTING / HIGH END VASCULAR REVASCULARISATION PROCEDURE - Next 3 Qtrs | 1200 |
FUP0147A : VENOUS / POLY TETRA FLUORO ETHYLENE PATCH ANGIOPLASTY - First Qtr | 2500 |
FUP0147B : VENOUS / POLY TETRA FLUORO ETHYLENE PATCH ANGIOPLASTY - Next 3 Qtrs | 1200 |
FUP0148A : HEPATIC VEIN ANGIOPLASTY AND STENTING - First Qtr | 3000 |
FUP0148B : HEPATIC VEIN ANGIOPLASTY AND STENTING - Next 3 Qtrs | 1500 |
FUP0151A : MULTI ORGAN RESECTION FOR ANY GI CANCERS - First Qtr | 1500 |
FUP0151B : MULTI ORGAN RESECTION FOR ANY GI CANCERS - Next 3 Qtrs | 1000 |
CM0494A : ARRYTHMIAS (SUPRAVENTRICULLAR / VENTRICULAR) - INVASIVE MANAGEMENT (without 3D mapping) | 55000 |
CM0100-N : BREAST CANCER - TAMOXIFEN | 100 |
CM0100-O : BREAST CANCER - AROMATASE INHIBITORS | 1000 |
CM0100-P : BREAST CANCER - Zoledronic Acid for skeletal metastasis | 2700 |
CM0124-c : PROSTATE CANCER - Zoledronic Acid for skeletal metastasis | 2700 |
CM0955-O : Multiple Myeloma - Zoledronic Acid | 2700 |
CM0100-a-III : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 21 days for 4 cycles | 7000 |
CM0100-a-IV : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 80mg/m2) Repeat cycle - weekly for 12 cycles | 3500 |
CM0101-a-IV : BLADDER CANCER - Radiosensitizing - Cisplatinc + 5-FU ; Days 1, 2, 3, 15, 16, and 17: IV hydration at a rate of 500mL/hour; followed by 5-FU 400mg/m2 IV push; followed by cisplatin 15mg/m2 IV over 1 hour as induction and consolidation therapy | 9800 |
CM0101-a-V : BLADDER CANCER -Radiosensitizing - Cisplatin + paclitaxel ; Days 1, 8, and 15: Paclitaxel 50mg/m2 ; Day 1-3, 8-10, 15-17: Cisplatin 15mg/m2; followed by twice-daily radiotherapy for 8 days | 18400 |
CM0101-a-VI : BLADDER CANCER -Radiosensitizing - 5-FU + mitomycin32 ; Day 1 of radiotherapy: Mitomycin 12mg/m2 IV bolus, plus ; Week 1 (fractions 1-5) and Week 4 (fractions 16-20) of radiotherapy: 5-FU 500mg/m2 continuous IV infusion (10 days total) | 15100 |
CM0101-c : BLADDER CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles | 1800 |
CM0103-v: ESOPHAGEAL CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles | 1800 |
CM0106-vi : Other bone tumors - Mesenchymal Chordosarcoma VIDE (vincristine + ifosfamide + doxorubicin + etoposide) ; Day 1: Vincristine 1.4mg/m2 (max 2mg), ; Days 1-3: Doxorubicin 20mg/m2 IV + ifosfamide 3mg/m2 IV + mesna 3g/m2 + etoposide 150mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. | 9200 |
CM0114-i-b-1 : EWINGS SARCOMA - Induction Treatment - VAC/IE - VAC ; Day 1: Vincristine 2mg/m2 (max 2mg) IV, doxorubicin 75mg/m2 IV bolus, cyclophosphamide 1,200mg/m2 IV, mesna. ; Dactinomycin 1.25mg/m2 IV can be substituted for doxorubicin when a total doxorubicin dose of 375mg/m2 is reached. | 4600 |
CM0114-i-b-2 : EWINGS SARCOMA - Induction Treatment - VAC/IE - IE ; IE cycles ; Days 1-5: Ifosfamide 1,800mg/m2 IV + mesna + etoposide 100mg/m2 IV. ; Repeat each cycle every 3 weeks for 17 cycles. | 6000 |
CM0114-i-e : EWINGS SARCOMA - Induction Treatment - VACA ; Day 1: Vincristine 1.5mg/m2 IV + cyclophosphamide 1,200mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 10 cycles. | 4600 |
CM0117-e : VULVAL CANCER - Cisplatin + 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV | 11100 |
CM0128-ii-c-1 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) | 7200 |
CM0128-ii-c-2 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - adjuvant temozolomide - preceeded by Concurrent Temozolomide (with RT) ; Temozolomide 150-200mg/m2/day for 5 days. ; Repeat cycle every 28 days for 6 cycles | 2100 |
CM0130 I a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily | 19250 |
CM0130 I b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. | 29250 |
CM0130 I c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Bevacizumab + IFN-alpha ; Bevacizumab 10mg/kg IV every 2 weeks + IFN-alpha. | 66750 |
CM0130 I d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily | 3650 |
CM0130 II a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Everolimus ; Everolimus 10mg orally once daily | 37250 |
CM0130 II b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Pazopanib ; Pazopanib 800mg orally once daily | 19250 |
CM0130 II c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sorafenib ; Sorafenib 400mg orally twice daily | 3650 |
CM0130 II d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. | 29250 |
CM0130 II e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. | 66250 |
CM0130 III a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. | 29250 |
CM0130 III b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. | 66250 |
CM0130 III c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Everolimus ; Everolimus 10mg orally once daily | 37250 |
CM0130 III d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Erlotinib ; Erlotinib 150mg orally once daily | 3400 |
CM0130 III e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily | 19250 |
CM0130 III f : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily | 3650 |
CM0130 IV: RENAL CELL CARCINOMARENAL CELL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | 10000 |
CM0131-i-g : UNKNOWN PRIMARY - Adenocarcinoma - mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles | 8000 |
CM0131-i-h : UNKNOWN PRIMARY - Adenocarcinoma - CapeOX ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Day 1-14: Capecitabine 850-1000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 16 cycles. | 6500 |
CM0131-i-i : UNKNOWN PRIMARY - Adenocarcinoma - Irinotecan + carboplatin ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for up to 6 cycles | 7700 |
CM0131-ii-c : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + carboplatin ; Day 1: Carboplatin AUC 6mg per min/mL IV over 30 minutes + paclitaxel 200mg/m2 IV over 3 hours. ; Repeat cycle every 3 weeks for 8 cycles in responding patients and for 6 cycles maximum in patients with stable disease | 7200 |
CM0131-ii-d : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + gemcitabine ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. | 5250 |
CM0131-ii-e : UNKNOWN PRIMARY - Squamous cell carcinoma -mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles. | 8000 |
CM0131-ii-f : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + cisplatin ; Day 1: Paclitaxel 175mg/m2 IV + cisplatin 60mg/m2 IV. ; Repeat cycle every 3 weeks. | 6450 |
CM0131-ii-g : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + carboplatin ; Day 1: Docetaxel 75mg/m2 IV over 30 minutes + carboplatin AUC 5mg per min/mL IV over 30 minutes. ; Repeat cycle every 3 weeks for 8 cycles | 8700 |
CM0131-ii-h : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 60mg/m2 IV + cisplatin 80mg/m2 IV. ; Repeat cycle every 3 weeks for 2 cycles and an additional 4 cycles until disease progression is demonstrated | 5040 |
CM0131-ii-i : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. | 3820 |
CM0131-ii-j : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + fluorouracil ; Days 1-5: Cisplatin 20mg/m2 IV ; Days 1-5: Fluorouracil 700mg/m2/day IV via continuous infusion over 24 hours. ; Repeat cycle every 4 weeks for 3 cycles. | 7050 |
CM0694-II-d : ERCP and Stent (plastic) | 22500 |
CM0694-II-e : ERCP and Stent (SEMS) | 49500 |
CM0694-II-f : POST OP BILIARY STRICTURE | 31500 |
CM0707-I-A : ACUTE MILD PANCREATITIS - CONSERVATIVE MANAGEMENT | 27000 |
CM0707-I-B : ACUTE MODERATE PANCREATITIS - CONSERVATIVE MANAGEMENT | 36000 |
CM0707-I-C : ACUTE SEVERE PANCREATITIS - CONSERVATIVE MANAGEMENT | 50355 |
CM0630 B -II-c : MIXED CONNECTIVE TISSUE DISEASE - WITH GANGRENE ON IV PROSTACYCLIN | 6300 |
CM0630 B -II-d : MIXED CONNECTIVE TISSUE DISEASE - PNEUMOCOCCAL VACCINATION | 4500 |
CM0631A-II -a : VASCULITIS - PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE | 2700 |
CM0631A-II -b : VASCULITIS - PULSE CYCLOPHOSPHAMIDE THERAPY | 2700 |
CM0630 A-I-a-ii : MIXED CONNECTIVE TISSUE DISEASE- PULSE CYCLOPHOSPHAMIDE THERAPY | 2700 |
CM0630 A-I-b-ii :MIXED CONNECTIVE TISSUE DISEASE-METHOTREXATE OR AZATHIOPRINE OR HYDROXY CHLOROQUINE | 2700 |
CM0630 B -II-a : MYCOPHENOLATE MOFETIL INDUCTION | 5400 |
CM0630 B -II-b : MYCOPHENOLATE MOFETIL MAINTENANCE | 2700 |
CM0630 B -II-e : MIXED CONNECTIVE TISSUE DISEASE-(METHOTREXATE OR AZATHIOPRINE OR HYDROXY CHLOROQUINE/ PULSE CYCLOPHOSPHAMIDE THERAPY/ MYCOPHENOLATE MOFETIL INDUCTION/MYCOPHENOLATE MOFETIL MAINTENANCE/ WITH GANGRENE ON IV PROSTACYCLIN/ PNEUMOCOCCAL VACCIN | 27000 |
CM0631A-II-c : VASCULITIS (PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE/ PULSE CYCLOPHOSPHAMIDE THERAPY )(including Diagnostic evaluation - 1st time) | 10800 |
CM0707-II-A : ACUTE MILD PANCREATITIS - CONSERVATIVE MANAGEMENT | 27000 |
CM0707-II-B : ACUTE MODERATE PANCREATITIS - CONSERVATIVE MANAGEMENT | 36000 |
CM0707-II-C : ACUTE SEVERE PANCREATITIS - CONSERVATIVE MANAGEMENT | 50355 |
CM0881 A-I-a : THALASSEMIA MAJOR (upto) | 6300 |
CM0931-I-B : MANAGEMENT CHRONIC HEPATITIS B / C - ENTECAVIR 1 MG 30 TABS | 1800 |
CM0931-I-C : MANAGEMENT CHRONIC HEPATITIS B / C - ENTECAVIR 0.5MG 30 TABS | 3500 |
CM0931-I-F : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS | 2000 |
CM0931-I-H : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS + VELPATASVIR 100 28 TABS | 6000 |
CM0931-II-B : MANAGEMENT CHRONIC HEPATITIS B / C - ENTECAVIR 1 MG 30 TABS | 4500 |
CM0931-II-D : MANAGEMENT CHRONIC HEPATITIS B / C - TELBUVUDINE 600MG 30 TABS | 16000 |
CM0931-II-F : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS | 11000 |
CM0931-I-ii : INVESTIGATION OF CHRONIC HEPATITIS B / C (VIRAL LOAD) | 10000 |
CM0931-II-I : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS + LEDIPASVIR 90 28 TABS | 15000 |
CM0931-II-i i: INVESTIGATION OF CHRONIC HEPATITIS B / C (VIRAL LOAD) | 10000 |
CM0931-I-J : MANAGEMENT CHRONIC HEPATITIS B / C INTERFERON WILL BE APPROVED BASED ON DOSAGE) | 1000 |
CM0879-I-a :LAPAROSCOPIC - ECTOPIC RESECTION | 19215 |
CM0629-II-a : OBSCURE BLEED - Conservative management including Capsule endoscopy | 27000 |
CM0629-II-b : OBSCURE BLEED - Conservative | 9000 |
CM0629-II-c : NON VARICEAL BLEED - CLIPPING | 27000 |
CM0629-II-d : NON VARICEAL BLEED - ARGON PLASMA COAGULATION | 41535 |
CM0629-II-e : NON VARICEAL BLEED - CONSERVATIVE | 9000 |
CM0774 A : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY | 18045 |
CM0820-I-A : Amputation of AK / BK | 27000 |
CM0820-I-B : Amputation of AE / BE | 22500 |
CM0820-I-C : Amputation of Fore-Foot | 13500 |
CM0820-I-E : Amputation of Toes | 6300 |
CM0820-I-F : Amputation of Fingers | 9000 |
CM0820-I-G : Trans Meta-Tarsal Amputation | 13500 |
CM0879-I-b :LAPROTOMY - ECTOPIC RESECTION | 10800 |
CM0898 A : COLONIC PULL THROW | 45000 |
CM0898 B : COLOPLASTY | 27000 |
CM0898 C : ABDOMINAL RESECTION | 36000 |
CM0905-IA : CYST EXCISION WITH HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE | 40500 |
CM0905-IB : CYST EXCISION WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE | 31500 |
CM0774 B : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY | 18045 |
CM0642D-II : USG GUIDED MINOR PROCEDURES (TAPPING) - Endoscopic Ultrasound Guided procedure | 2700 |
CM0647-IA : EMBOLIZATION OF POSTOPERATIVE/ POST TRAUMATIC BLEEDING - Large vessels | 73575 |
CM0647-IB :EMBOLIZATION OF POSTOPERATIVE/ POST TRAUMATIC BLEEDING - Medium vessels | 47475 |
CM0647-IC : EMBOLIZATION OF POSTOPERATIVE/ POST TRAUMATIC BLEEDING - Small vessels | 40500 |
CM0674-I-a : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - Balloon plasty | 52425 |
CM0674-I-b : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - Stenting | 83925 |
CM0692-I-A : ACUTE STROKE THROMBOLYSIS (R TPA ) (Cathter Directed) | 67725 |
CM0952A-I-iii-j : Chronic Myeloid Leukemia (CML) - Other Regimen | 10000 |
CM0952A-II-z : Acute Myeloid Leukemia (AML) - Other Regimen | 10000 |
CM0183a : Neck/ Shaft Of Femur ORIF | 20025 |
CM0183b : IM Nailing | 13500 |
CM0183c : Shaft of Other Long Bones (Humerus) | 15300 |
CM0183d : Tibia | 13500 |
CM0183e : Radius, Fibula, Ulna (ORIF) | 13500 |
CM0183f : Clavicle ( CRIF) (Displaced) | 7200 |
CM0183g : Clavicel (ORIF) (Displaced) | 10800 |
CM0183h : Both Bones of Forearm, Both Bones of Leg (Fixation of both bones) | 20025 |
CM0183i : Bimalleolar Fracture | 13500 |
CM0183j : Closed Reduction and Proximal Femoral nailing / Screw Fixation | 13500 |
CM0183k : Closed Reduction and Pinning / Tens Nail | 10800 |
CM0183l : Closed Reduction and Internal Fixation with K wire | 5400 |
CM0183m : Tension Band wiring | 10800 |
CM0184a : Neck/ Shaft Of Femur ORIF | 20025 |
CM0184b : IM Nailing | 13500 |
CM0184c : Shaft of Other Long Bones (Humerus) | 15300 |
CM0184d : Tibia | 13500 |
CM0184e : Radius, Fibula, Ulna (ORIF) | 13500 |
CM0184f : Clavicle ( CRIF) (Displaced) | 7200 |
CM0184g : Clavicel (ORIF) (Displaced) | 10800 |
CM0184h : Both Bones of Forearm, Both Bones of Leg (Fixation of both bones) | 20025 |
CM0184i : Bimalleolar Fracture | 13500 |
CM0184j : Closed Reduction and Proximal Femoral nailing / Screw Fixation | 13500 |
CM0184k : Closed Reduction and Pinning / Tens Nail | 10800 |
CM0184l : Closed Reduction and Internal Fixation with K wire | 5400 |
CM0184m : Tension Band wiring | 10800 |
CM0186A-i : IMPLANT EXIT- K-WIRES - Single | 1350 |
CM0186A-ii : IMPLANT EXIT- K-WIRES - Multiple | 2250 |
CM0186A-iii : IMPLANT EXIT- SCREWS - single (Open) | 3600 |
CM0186A-iv : IMPLANT EXIT- SCREWS - Multiple (Open) | 6750 |
CM0186A-v : IMPLANT EXIT- SCREWS - single (Closed) | 1800 |
CM0186A-vi : IMPLANT EXIT- SCREWS - Multiple (Closed) | 2700 |
CM0186A-vii : IMPLANT EXIT- OTHER MINOR IMPLANTS (TENS, TBW, etc) - Solitary | 4500 |
CM0186A-viii : IMPLANT EXIT- OTHER MINOR IMPLANTS (Pins / TENS, TBW, etc) - Multiple | 6975 |
CM0186B-i : IMPLANT EXIT- PLATES (Open) | 11250 |
CM0186B-ii : IMPLANT EXIT- Femoral Screws / IM Nails / Rush Nail (Open) | 9000 |
CM0186B-iii : IMPLANT EXIT- SPINE IMPLANTS - upto 2 levels(complete exit) (eg- L2-L3, L3-L4) | 15750 |
CM0186B-iv : IMPLANT EXIT- SPINE IMPLANTS - upto 2 levels(partial exit) (eg- L2-L3, L3-L4) | 13500 |
CM0186B-v : IMPLANT EXIT- SPINE IMPLANTS - > 2 levels(complete exit) (eg- L2-L3, L3-L4, L4-L5) | 18450 |
CM0186B-vi : IMPLANT EXIT- SPINE IMPLANTS - > 2 levels(partial exit) (eg- L2-L3, L3-L4, L4-L5) | 15750 |
CM0186B-vii : IMPLANT EXIT- Bipolar, etc | 13500 |
CM0186B-viii : IMPLANT EXIT - Other Major implants | 11250 |
CM0187a : ARTHRODESIS OF JOINTS - HIP | 24300 |
CM0187b : ARTHRODESIS OF JOINTS - SHOULDER / KNEE | 18000 |
CM0187c : ARTHRODESIS OF JOINTS - ELBOW/ ANKLE / WRIST | 13500 |
CM0187d : ARTHRODESIS OF JOINTS - ANKLE - Triple Arthrodesis | 14400 |
CM0187e : ARTHRODESIS OF JOINTS - HAND / FOOT | 9000 |
CM0192-A : ILIZAROV RING FIXATOR APPLICATION-FEMUR - DEFORMITY CORRECTION / LIMB LENGTHENING | 22500 |
CM0192-B : ILIZAROV RING FIXATOR APPLICATION- TIBIA - DEFORMITY CORRECTION / LIMB LENGTHENING | 16200 |
CM0193-A : SURGERY FOR NEGLECTED CTEV/RECURRENT CTEV/RESISTANT CTEV BY JESS FIXATION | 40275 |
CM0195-A : KNEE LIGAMENT RECONSTRUCTION-ACL RECONSTRUCTION/PCL RECONSTRUCTION | 27000 |
CM0195-B : KNEE LIGAMENT RECONSTRUCTION-MPFL RECONSTRUCTION | 22500 |
CM0204- b : ACETABULAR FRACTURES | 26550 |
CM0204-a : CORRECTION SACRO ILLIAC JOINT | 18000 |
CM0625-II A : AMPUTATIONS - FORE QUARTER | 36000 |
CM0625-II B : AMPUTATIONS - HIND QUARTER / Internal Hemipelvectomy | 36000 |
CM0625-II C : AMPUTATIONS - HIND QUARTER / External Hemipelvectomy | 36000 |
CM0722-II-A : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MAXILLA | 9023 |
CM0722-II-B : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE | 9023 |
CM0722-II-C : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE, MAXILLA- INTERDENTAL WIRING | 4500 |
CM0807-a - I : Cementing (only as Addon) | 4500 |
CM0807-a : BONE RESECTION | 22500 |
CM0807-b - I : Cementing (only as Add on) | 4500 |
CM0807-b : BONE Curettage | 13500 |
CM0820-II-A : Amputation of AK / BK | 27000 |
CM0820-II-B : Amputation of AE / BE | 22500 |
CM0820-II-C : Amputation of Fore-Foot | 13500 |
CM0820-II-E : Amputation of Toes | 6300 |
CM0820-II-F : Amputation of Fingers | 9000 |
CM0820-II-G : Trans Meta-Tarsal Amputation | 13500 |
CM0820-III-a : Amputation of great toe | 6300 |
CM0820-III-b : Amputation toe- single | 4500 |
CM0820-III-c : Amputation toe- Multiple | 6300 |
CM0820-III-d : Amputation of Finger - single | 6300 |
CM0820-III-e : Amputation of Finger - Multiple | 9000 |
CM0820-III-f : Transmetatarsal Amputation | 9000 |
CM0861-II-A : POSTERIOR DISCECTOMY WITH SPACER/IMPLANT/VERTEBROPLASTY (open) | 38700 |
CM0861-II-B : POSTERIOR DISCECTOMY WITH BONE GRAFT | 29700 |
CM0861-II-C : POSTERIOR DISCECTOMY WITHOUT BONE GRAFT/SPACER/IMPLANT/VERTEBROPLASTY | 22500 |
CM0715A : CLEFT LIP - Unilateral | 9000 |
CM0715B : CLEFT LIP - Bilateral | 14490 |
CM0718A-II : MICROTIA/ANOTIA - STAGE 1 | 9000 |
CM0718A-IV : MICROTIA/ANOTIA - STAGE 1 (with artificial Implant) | 22860 |
CM0158- a : Medical management only (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) upto | 4500 |
CM0158- b : 10 to 20% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application | 9000 |
CM0158- c : 20 to 30% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application | 17100 |
CM0158- d : 30 to 40% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application including ICU stay | 25200 |
CM0158- e : upto 10% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application including ICU stay | 6300 |
CM0159 - b : 20 to 30% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG | 27000 |
CM0159- a : UPTO 20% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG | 18000 |
CM0159- c : 30 to 40% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG including ICU stay | 36000 |
CM0160A : 40 TO 50% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application | 44820 |
CM0161A : 40 to 50% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG | 54900 |
CM0162A : 50 TO 60% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application including ICU stay | 67320 |
CM0163- a : 50 TO 60% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG including ICU stay | 72900 |
CM0164-a : ABOVE 60% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG including ICU stay | 90000 |
CM0165a : Fingers | 3600 |
CM0165b : Neck - MILD (LESS THAN 1/3RD) - Flexion and extension videos to be uploaded | 13500 |
CM0165c : Others (elbow, thigh, etc) | 9000 |
CM0165d : Pressure Garments and Physiotherapy (2 weeks) - only as an addon | 5400 |
CM0166a : Fingers | 5400 |
CM0166b : Neck - MODERATE (1/3RD TO 2/3RD) - Flexion and extension videos to be uploaded | 22500 |
CM0166c : Others (elbow, thigh, etc) | 13500 |
CM0166d : Pressure Garments and Physiotherapy (2 weeks) - only as an addon | 5400 |
CM0167a : Fingers | 7200 |
CM0167b : Neck - SEVERE (> 2/3RD) - Flexion and extension videos to be uploaded | 29700 |
CM0167c : Others (elbow, thigh, etc) | 18000 |
CM0167d : Pressure Garments and Physiotherapy (2 weeks) - only as an addon | 5400 |
CM0168a : PTOSIS Single | 13500 |
CM0168b : PTOSIS Bilateral | 22050 |
CM0175a : Polydactyly - Simple | 4500 |
CM0175b : Polydactyly - Bone and neurovascular bundle | 9000 |
CM0175c : Simple syndactyly (per finger) | 5400 |
CM0175d : Complex syndactyly (per finger) | 9000 |
CM0175e : Radial clubhand | 13500 |
CM0175f : Ulnar clubhand | 13500 |
CM0175g : Macrodactyly | 15750 |
CM0175h : Others minor (will be paid as per procedure) Upto | 9000 |
CM0175i : Others major (will be paid as per procedure) Upto | 23940 |
CM0176a : PRESSURE SORE RECONSTRUCTIVE SURGERY - SSG - per 10 sq CM (upto) | 10800 |
CM0176b : PRESSURE SORE RECONSTRUCTIVE SURGERY - Single Rotation FLAP - per 10 sq CM (upto) - per 10 sq CM (upto) | 13500 |
CM0176c : PRESSURE SORE RECONSTRUCTIVE SURGERY - Bilateral FLAP - per 10 sq CM (upto) | 18000 |
CM0176d : PRESSURE SORE RECONSTRUCTIVE SURGERY - Musculocutaneous flap - per 10 sq CM (upto) | 27000 |
CM0176e : PRESSURE SORE RECONSTRUCTIVE SURGERY - Fasciocutaneous flap - per 10 sq CM (upto) | 22500 |
CM0176f : PRESSURE SORE RECONSTRUCTIVE SURGERY - Tensor fascia lata flap - per 10 sq CM (upto) | 39510 |
CM0176g : others (payable based on the procedure carried out) (upto) | 39510 |
CM0177a : single closure | 18000 |
CM0177b : Fascia Lata Graft | 31500 |
CM0177c : Mesh Closure | 22500 |
CM0177d : Local Flaps | 18000 |
CM0177e : Myocutaneous Transposition | 31500 |
CM0177f : TRAM | 39510 |
CM0178a : Unilateral | 9000 |
CM0178b : Bilateral | 14400 |
CM0716A : CLEFT PALATE - Partial | 13500 |
CM0716B : CLEFT PALATE - Complete | 18090 |
CM0716C : CLEFT PALATE - Sub mucous (before 1.5 years of age) | 18090 |
CM0717A : Simple syndactyly (Per finger) | 5400 |
CM0717B : Complex Syndactyly (Per finger) | 9000 |
CM0717C : Simple syndactyly (Per finger) | 13500 |
CM0717D : Complex Syndactyly (Per hand) | 23940 |
CM0718A-I : MICROTIA/ANOTIA - STAGE 1 | 22860 |
CM0718A-III : MICROTIA/ANOTIA - STAGE 1 (with cartilage autograft) | 13500 |
CM0722-III-A : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MAXILLA | 9023 |
CM0722-III-B : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE | 9023 |
CM0722-III-C : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE, MAXILLA- INTERDENTAL WIRING / Archbar | 4500 |
CM0814-II-a : VASCULAR MALFORMATIONS- Sclerotherapy | 11700 |
CM0814-II-b : VASCULAR MALFORMATIONS- Sclerotherapy and Excision | 23625 |
CM0816A-i : FLAP SURGERIES CUTANEOUS- UPPER LIMB | 18000 |
CM0816A-ii : FLAP SURGERIES CUTANEOUS- LOWER LIMB | 10800 |
CM0861-I-A : POSTERIOR DISCECTOMY WITH SPACER/IMPLANT/VERTEBROPLASTY (open) | 38700 |
CM0861-I-B : POSTERIOR DISCECTOMY WITH BONE GRAFT | 29700 |
CM0861-I-C : POSTERIOR DISCECTOMY WITHOUT BONE GRAFT/SPACER/IMPLANT/VERTEBROPLASTY | 22500 |
CM0862A : ANTERIOR DISCECTOMY WITHOUT IMPLANTS | 27000 |
CM0862B : ANTERIOR DISCECTOMY WITH IMPLANTS | 38835 |
CM0947 A : SPINAL DEFORMITY STABILISATION/CORRECTION PROCEDURES ( MORE THAN 4 LEVELS) | 67500 |
CM0947 B : SPINAL DEFORMITY STABILISATION/CORRECTION PROCEDURES LESS THAN 4 LEVELS) | 45000 |
CM0947C : SPINAL DEFORMITY STABILISATION/CORRECTION PROCEDURES WITH VERTERBROPLASTY | 40500 |
CM0629-I-a : OBSCURE BLEED - Conservative management including Capsule endoscopy | 27000 |
CM0629-I-b : OBSCURE BLEED - Conservative | 9000 |
CM0629-I-c : NON VARICEAL BLEED - CLIPPING | 27000 |
CM0629-I-d : NON VARICEAL BLEED - ARGON PLASMA COAGULATION | 41535 |
CM0629-I-e : NON VARICEAL BLEED - CONSERVATIVE | 9000 |
CM0694-I-a : BILIARY DRAINAGE PROCEDURES - T- Tube | 18000 |
CM0694-I-b : BILIARY DRAINAGE PROCEDURES - Choledocojejunostomy | 31500 |
CM0694-I-c : BILIARY DRAINAGE PROCEDURES - Hepaticojejunostomy | 40500 |
CM0694-I-d : ERCP and Stent (plastic) | 22500 |
CM0694-I-e : ERCP and Stent (SEMS) | 49500 |
CM0694-I-f : POST OP BILIARY STRICTURE | 31500 |
CM0905-IBI : CYST EXCISION WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE | 31500 |
CM0905-IIA : CYST EXCISION WITH HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE | 40500 |
CM0775-I-a : SALPINGO OOPHORECTOMY B/L- FOR CA | 22815 |
CM0775-I-b : SALPINGO OOPHORECTOMY U/L FOR CA | 16200 |
CM0625-I A : AMPUTATIONS - FORE QUARTER | 36000 |
CM0625-I B : AMPUTATIONS - HIND QUARTER / Internal Hemipelvectomy | 36000 |
CM0625-I C : AMPUTATIONS - HIND QUARTER / External Hemipelvectomy | 36000 |
CM0765A : GLOSSECTOMY (HEMI/PARTIAL) WITH RECONSTRUCTION- FOR CANCER | 27000 |
CM0765B : GLOSSECTOMY (TOTAL) WITH RECONSTRUCTION- FOR CANCER | 35865 |
CM1038 : Drainage of Subdiaphramatic Abscess | 9000 |
CM1046 : Excision Benign Tumor -Small intestine | 13500 |
CM1067 : IlieoSigmoidostomy | 15300 |
CM1076 : Repair of Common Bile Duct | 13500 |
CM1083 : Pharyngectomy& Reconstruction - Total | 18000 |
CM1084 : Tracheoplasty (Throat) | 13500 |
CM1088 : Estlander Operation (lip) | 6300 |
CM1093 : Operation for carcinoma lip- cheek advancement | 10800 |
CM1096 : Resection Enucleation of Adenoma (lung) | 9000 |
CM1099 : Thoracoplasty | 18000 |
CM1100 : Thoracoscopic Segmental Resection | 22500 |
CM1101 : Thoracoscopic Sympathectomy | 13500 |
CM1191 : Abdominal Perineal neo construction Cx + Uteria + Vagina | 18000 |
CM1198 : Brust abdomen repair | 12600 |
CM1212 : Intrauterine transfusions | 9000 |
CM1220 : Fixator with Joint Arthrolysis | 18000 |
CM1223 : Pelvic Osteotomy with fixation with plaster | 27000 |
CM1231 : Endopyelotomy (retrograde with laser/bugbee) | 22500 |
CM1232 : Endopyelotomy (antegrade with laser/bugbee) | 25200 |
CM1233 : Ureterocalycostomy Open | 22500 |
CM1234 : Ureterocalycostomy Laparoscopic | 27000 |
CM1235 : Uretero-ureterostomy Open | 22500 |
CM1236 : Uretero-ureterostomy Laparoscopic | 31500 |
CM1252 : Holmium Laser Prostatectomy | 36000 |
CM1276 : Duroplasty - Endogenous | 11250 |
CM1277 : Duroplasty - Exogenous | 36225 |
CM1279 : Micro discectomy - Cervical | 36000 |
CM1283 : Cranial Nerve Anastomosis | 28800 |
CM1286 : Additonal clip for Aneurysm Clipping | 13500 |
CM1288 : Superficial Temporal Artery (STA): middle cerebral artery (MCA) or (other EC - IC) Bypass procedure | 54000 |
CM1289 : Additional coil for coil embolization for aneurysms | 24000 |
CM1290 : Parent vessel occlusion - Basic | 30000 |
CM1291 : Additonal coil for Parent Vessel Occlusion | 24000 |
CM1292 : Additonal balloon for Parent Vessel Occlusion | 11000 |
CM1293 : Balloon test occlusion | 70000 |
CM1323 : Microvascular reconstruction | 40500 |
CM1325 : Axillary dissection | 13500 |
CM1326 : Enucleation of pancreatic neoplasm | 22500 |
CM1419 A : Acute lymphoblastic leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | 20000 |
CM1420 A : Acute myeloid leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage | 30000 |
CM1421 A : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | 15000 |
CM1422 A : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | 25000 |
CM1423 A : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | 50000 |
CM1429 A : Chronic Myeloid Leukemia : supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | 20000 |
CM1430 A : Terminally Ill - Pain management (Opioid therapy / Neural Blocks / epidural or Intrathecal infusions / Antero-lateral spinal cordotomy (tractotomy) by RFA) / TPN - Per month | 3000 |
CM0692-I-B-i : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 50 mg) | 30300 |
CM0692-I-B-ii : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 70mg) | 48300 |
CM0692-III : ACUTE STROKE THROMBOLYSIS (R TPA ) | 67725 |
CM0692-III-B-i : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 50 mg) | 30300 |
CM0692-III-B-ii : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 70mg) | 48300 |